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ABSTRACT 
Proteins mediate many essential functions in cells, and methods to profile cellular proteins are of 
great interest for biological discovery. Whereas all of the cells in an organism share the same 
genome, the landscape of proteins (the proteome) varies between different cell types and over the 
lifetime of the organism. Rapid progress in mass spectrometers is enabling the detailed analysis of 
cellular proteomes. Whereas better instruments increase coverage, throughput, and measurement 
precision, new chemical reporters, metabolic tags, and synthetic biology techniques are required to 
enhance the specificity and spatiotemporal resolution of protein labeling and detection. This work 
introduces methods for cell-selective proteome analysis through the incorporation of non-canonical 
amino acids into newly synthesized proteins.  
Chapter I provides an overview of current technologies for translational profiling and proteomic 
analysis in cells. Strategies for the residue-specific incorporation of non-canonical amino acids and 
bioorthogonal non-canonical amino acid tagging are discussed. Chapter II introduces a new 
approach for the identification of secreted bacterial proteins from infected host cells using non-
canonical amino acid labeling. This work demonstrates an application of cell-selective proteome 
labeling. Selectivity is achieved through controlled expression of a mutant aminoacyl tRNA 
synthetase (aaRS) enzyme that enables the metabolic incorporation of a non-canonical amino acid.  
Ideally, the activity of multiple genes should be used to genetically control the extent of proteome 
labeling in cells. This is useful because many cell states are characterized by the activity of multiple 
genes and identified based on the expression of several proteins. Therefore chapter III introduces a 
novel approach to control proteome labeling as a function of multiple promoters using a genetically 
encoded AND gate based on a bisected methionyl-tRNA synthetase, a class I aaRS. Cellular protein 
labeling occurs only upon activation of two different promoters that drive expression of the N- and 
C-terminal fragments of this bisected aaRS. The utility of this tool is demonstrated by the selective 
labeling of proteins in subpopulations of bacterial cells in a laminar-flow microfluidic channel.  
Chapter IV extends the cell-selective incorporation of non-canonical amino acids from bacterial 
systems to mammalian cells by introducing a mutant mammalian methionyl-tRNA synthetase for 
cell-targeted proteome labeling. This enzyme is genetically encoded and can be conditionally 
activated for time-resolved and cell-targeted proteome analysis in a variety of different mammalian 
cell types. Chapter V uses this enzyme for lineage-specific proteomic analysis of mouse embryonic 
stem cells during differentiation to cardiac and mesoderm lineages. This approach for lineage-
 vii 
specific protein labeling enables the unbiased and comprehensive analysis of proteomic changes 
that occur during stem cell differentiation and cell-fate commitment.    
Appendices A-G provide brief summaries of publications and research efforts during my PhD that 
are not directly related to this thesis. These publications are the result of a number of collaborations 
that I have been fortunate to be involved with during my graduate research. 
The technologies and methods introduced in this thesis provide versatile tools for the 
comprehensive and unbiased detection and identification of newly synthesized proteins in complex 
multicellular systems. Time-resolved, genetically encoded, and spatially defined non-canonical 
amino acid incorporation enables the identification of proteins involved in cell-cell interactions and 
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Targeted Approaches for Comprehensive Profiling of Newly 




Technological developments in DNA sequencers and mass spectrometers have enabled the study 
of cellular functions with unprecedented coverage, throughput, and precision. Cells have evolved 
sophisticated machinery to accurately control protein synthesis, and oftentimes mRNA levels are 
an inadequate proxy for protein production. Therefore, comprehensive methods to analyze protein 
synthesis are being developed. In this review, we present an overview of these approaches, 
focusing specifically on the subset of methods that enable the investigation of protein synthesis in 
a cell-selective manner. We provide examples of how these tools are being used to answer 







Proteins mediate many essential functions in cells, and methods to profile cellular proteins are of 
great interest for biological discovery. Whereas all of the cells in an organism share the same 
genome, the landscape of proteins (i.e, the proteome) varies between different cell types and over 
the lifetime of the organism. Therefore, proteome dynamics are often cell type specific and 
spatially and temporally regulated. As such, measures of protein synthesis in various cell types 
can be very useful for biological discovery and inform new approaches towards understanding 
and engineering the regulation of cellular functions. Understanding cellular regulatory 
mechanisms is also important because disruption in protein homeostasis is often the root cause of 





developmental abnormalities, and inherited disorders.
5
  
Transcriptomics, the identification and quantitation of mRNAs, provides a readout of actively 
transcribed genes and is often used as a proxy for protein synthesis. Analysis of mRNA levels has 
enabled investigators to develop a global perspective of gene activity in different cells and to 
monitor the induction of different genes in response to various stimuli. Modified transcriptional 
profiling methods, such as tagging mRNAs with thiouracil (TU-tagging), enable the cell specific 
profiling of actively transcribed genes
6
. However, a more sophisticated understanding of 
proteomic changes in cells requires post-transcriptomic approaches that measure translation 
products and track protein synthesis rather than mRNA levels. Notably, various control 
mechanisms influence translation of mRNAs to the extent that mRNA levels poorly correspond to 
protein levels
7-9
. Moreover, tracking mRNAs provides little information about proteomic changes 
resulting from localization (i.e., sites of protein synthesis), transport, and post-translational 
modifications. Indeed, these mechanisms have profound effects on protein function and are 
increasingly the targets of new molecular therapies
10,11
. Therefore, methods are needed to 
accurately detect and measure protein synthesis rather than transcripts. Traditional techniques 
such as genetic screens and custom assays to assess small libraries of candidate proteins can be 
laborious and non-comprehensive. Advances in DNA sequencers and mass spectrometers are 
rapidly changing the way protein synthesis is being studied. The comprehensive analysis of 
thousands of proteins in biological samples is becoming the norm rather than the exception. 
Technological advances in instrumentation are an important enabling factor for these approaches. 
For example, high-resolution liquid chromatography tandem mass spectrometry (LC-MS/MS) 
instruments can routinely identify thousands of proteins in a given sample and provide high-
quality information about co- or post-translational modifications to those proteins. These 
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approaches provide unbiased and comprehensive datasets that are ideally suited to machine-
learning and data-analytics techniques that are being increasingly used in the biological sciences.  
Proteomics platforms have rapidly advanced in the last decade.  Advances in sequencing and 
proteomics have and will continue to beat Moore’s law in the years to come.12-14 These 
improvements are complemented by the development of new chemical and synthetic biology 
tools that are specifically designed to leverage and utilize the capabilities of new instruments. 
Whereas instrumentation advances have enabled increased coverage, throughput, and precision, 
better chemical reporters and metabolic tags have enhanced the specificity and spatiotemporal 
resolution of labeling and detection. Here we provide an overview of new approaches to profile 
protein synthesis in cells. We also highlight a selective subset of chemical and synthetic 
techniques that enable the identification and quantitation of newly made proteins in different cell 
types. Notably, these techniques enable study of protein synthesis with varied spatial and 
temporal resolution in multicellular contexts as well as sub-cellular scales. We first review recent 
advances in translational profiling approaches that enable cell targeted and organelle-specific 
profiling. We then provide an overview of amino acid metabolic labeling methods to analyze 
newly synthesized proteins and highlight the use of bio-orthogonal chemistries to develop 
chemical reporters and improve quantitative proteomics capabilities. We close by providing an 
outlook on future directions to enhance the labeling, detection, and quantitation of proteome 
dynamics in cells that will ultimately facilitate biological discovery and inform subsequent 
engineering efforts.  
Translational Profiling Approaches  
mRNA translation often occurs in polyribosomes (often referred to as polysomes), the centers of 
protein production in cells.
15
 Polysomes consist of mRNA-bound ribosomes and RNA-binding 
proteins that repress or activate translation and influence levels of protein synthesis. Polysome 
complexes are associated with mRNA sequences that are being translated at any given time in the 
cell. Sequencing RNA-bound polysomes enables the identification of proteins that are actively 
being synthesized. Translation profiling has been used in a series of techniques to study protein 
synthesis in vitro and in vivo.
16
    
Polysome Profiling 
Polysome profiling involves separating mRNAs based on the degree of ribosome loading. In this 
technique, mRNAs are fractionated based on the density of bound ribosomes, converted to 
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cDNAs and then sequenced (Figure 1.1A).
17
 Polysome profiling has been applied to a variety of 




 and bacterial cells.
20
  Polysome profiling 
provided some of the early examples of how genome-wide and comprehensive translation 
analysis can provide mechanistic insight that would otherwise not be obtained from single-
transcript studies. For example, analysis of L. lactis demonstrated that transcript-specific 
translation changes occur during exponential growth 
20
. Gilbert and coworkers studied the effects 
of environmental stress on protein translation in yeast, showing that glucose starvation leads to 
the removal of mRNAs from polysomes and into P-bodies. They further showed that reactivation 
of translation upon glucose addition only occurs in a selective subset of transcripts, wherein 
transcripts whose translation is rate-limiting become transiently paused in rapidly changing cell 
environments.
21
 Notably, however, polysome profiling is not cell-selective. Moreover, it is 




Translating Ribosome Affinity Purification 
Whereas polysome profiling enables actively translating mRNAs to be tracked, the technique 
lacks cell-specificity. Although cell sorting can be combined with polysome profiling to achieve 
cell selectivity, manipulation of cells during sorting may influence cellular functions or alter the 
transient profile of actively translating mRNAs
23-25
. Therefore, a logical extension of polysome 
profiling has been the use of genetically encoded and epitope-tagged ribosomes for affinity 
purification.
26
 Tagging ribosomes with epitopes in cells of interest enables the selective isolation 
of polysomes from those cells. Translating ribosome affinity purification (TRAP)
27
 is a method in 
which ribosomal protein L10a, a component of the 60S ribosomal unit, is fused to EGFP (Figure 
1.1B). Heintz and coworkers used tissue-selective expression of this construct from bacterial 
artificial chromosomes to restrict labeling to specific neuronal subpopulations in the mouse brain. 
They affinity purified the tagged polysomes using an anti-GFP antibody to show that different 
subpopulations of neurons have different translation profiles. In addition to its use in the 
translation profiling of neurons
28
 and other tissues in the mouse
29,30







 and was also modified for cre-lox conditional 
activation in mice.
24
 A similar strategy called in vivo ribosome tagging (Ribo-Tag) uses epitope-
tagged ribosomal subunits. In Ribo-Tag, a mouse model was developed that expresses a Cre-
activated hemagglutinin-tagged ribosomal protein L22 for tissue-selective expression and affinity 
purification of epitope-tagged polysomes.
37,38
 Although both TRAP and Ribo-Tag can be used for 
cell-selective translation profiling, these techniques do not provide information regarding the 
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positions of ribosomes on the mRNA transcripts or the number of ribosomes on each transcript. 
Ribosome stalling confounds these results and requires that other techniques be developed to 
determine the positions of ribosomes on active mRNA transcripts.   
Ribosome Profiling 
Weissman and coworkers developed ribosome profiling by digesting mRNA transcripts with 
nucleases, which results in ribosome-protected mRNA fragments that delineate the precise 
positioning of ribosomes along the mRNA sequence (Figure 1.1c).
39
 High-throughput sequencing 
of ribosome-protected mRNA fragments provides a measure of ribosome density for each 
mRNA, which corresponds to the overall rate of translation. Because ribosome profiling provides 
nucleotide resolution of ribosomal positioning, this technique has enabled the identification of 
many upstream open reading frames, non-AUG start sites, and stop-codon read-throughs.
40
 This 
approach has been used to determine ribosome pausing and biased codon usage.
41
 The strategy 
was used for a pulse-chase type of analysis and applied to mouse embryonic stem cells to identify 
ribosome pause sites and a class of short polycistronic  ribosome-associated coding RNAs that 
encode small proteins.
42







 and translation in subcellular compartments.
48
 Enhanced subcellular 
translation profiling was recently achieved by proximity-specific ribosome profiling, which 
utilizes an encoded Avi-tagged ribosomal subunit and an organelle-targeted and spatially-
localized biotin ligase, BirA, to tag organelle-associated ribosomes. This technique ultimately 
permits the subcellular identification of spatially defined protein synthesis in cells.
49,50
 Ribosome 
footprints provide a detailed view of translation in cells. Proximity-specific ribosome profiling 
provides a valuable tool in the study of localized protein synthesis. Notably, ribosome profiling 
amplifies transcripts, provides excellent coverage, and enables the detection of low abundance 
transcripts. However, as with any technique, certain applications require workarounds due to the 
inherent limitations of the method. For example, restricting the labeling time is important in 
identifying newly synthesized proteins with good temporal resolution. In most ribosome profiling 
applications translation inhibitors such as harringtonine and cycloheximide are used. However, 
the ability to deliver such chemicals to cells, particularly for in vivo applications, may limit the 
temporal resolution of such analyses. Moreover, analysis of mRNA fragments does not directly 
tag newly made polypeptides and therefore cannot be used to identify and quantitate proteins that 
are transported between cellular compartments or between different cell types and tissues. 
Additionally, translation profiling cannot be used to track newly made proteins that may undergo 
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various post-translational modifications. For these types of analysis, methods are needed to 
directly detect newly synthesized proteins and nascent polypeptides chains.  
Protein Synthesis Detection Strategies 
Labeling and detecting newly synthesized proteins requires chemical reporters that are 
metabolically incorporated into the protein sequence. For example, modified amino acids that can 
be incorporated into proteins are ideally suited for this type of analysis. Isotopically labeled 
amino acids provided one of the first examples of metabolic protein labeling in cells.
51,52
 
Substrate mimics that are incorporated into polypeptide chains can also serve as protein synthesis 
reporters. Advances in bio-orthogonal chemistries- chemical reactions that can be carried out in 
cellular environments with specificity and selectivity- have enabled the development of chemical 
biology based probes that can be used to investigate protein synthesis in cells (Figure 1.2). In 
particular, click chemistry has enabled the development of a large number of bio-conjugations 
that can be deployed in various chemical biology applications. For a review of bio-orthogonal 







 groups. Here we focus on labeling strategies that are specifically designed for the 
analysis of protein synthesis.  
Labeling Nascent Polypeptide Chains 
Inhibitors of protein synthesis constitute a class of chemical reporters that are used to detect 
nascent polypeptide chains. For example, labeling with puromycin, an inhibitor of protein 
synthesis that can be incorporated into nascent polypeptide chains, yields truncated proteins that 
can be detected and identified.
58,59
 Puromycin is an aminonucleoside antibiotic that resembles the 
3’tail of a charged (aminoacylated) tRNA; the ribosome incorporates puromycin into the C-
terminus of a growing polypeptide chain where it stops translation.
60
 Several different approaches 
have been devised based on affinity tagging with puromycin in order to detect and identify 
translation products . For example, Roberts and coworkers developed puromycin variants 
containing fluorescent and biotin conjugates to detect nascent polypeptide chains.
61
 In a similar 
manner, Pierre and coworkers developed a method called surface sensing of translation 
(SunSET), which relies upon the immunodetection of puromycin (Figure 1.3A).
62
 Stein and 
colleagues developed a method called puromycin-associated nascent chain proteomics (PUNCH-
P) (Figure 1.3B), where they deploy biotin-conjugated puromycin for affinity enrichment and 
subsequently use mass spectrometry to identify nascent polypeptides.
63
 Salic and coworkers 
developed an alkyne analogue of puromycin (Figure 1.2, structure 1) that enables the 
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chemoselective and bioorthogonal tagging of nascent polypeptides with affinity tags (Figure 
1.3C).
64
 Although puromycin-based detection is not a cell-selective technique, these methods 
represent an important class of chemical strategies that can be used to detect protein synthesis. 
Utilizing an inhibitor of protein synthesis to profile translation may seem counter-intuitive; 
however the advent of this approach highlights the importance of developing good chemical 
biology tools and comprehensive methods to analyze newly made proteins.   
Isotopically Labeled Amino Acids for Proteomics 
Isotopically labeled amino acids, particularly 
35
S-methionine and cysteine, have enabled the 
detection of protein synthesis in cells. Based on this concept, Mann and coworkers developed a 
method titled stable isotope labeled amino acids in cell culture (SILAC) by utilizing heavy 
arginine and lysine.
65
 SILAC differs from radiolabeling in that it enables relative quantitation of 
proteins between samples. SILAC is among the first chemical reporter technologies specifically 
designed for use with modern mass spectrometers. Other notable quantitative proteomics 




 However, in contrast to iTRAQ and 
ICAT, which use isotopically labeled tags that react with the side chains of amino acids, SILAC 
metabolically incorporates isotopically labeled amino acids into nascent proteins. In SILAC, cells 
grown in normal amino acids and under one set of conditions are compared with cells grown in 
the presence of a heavy amino acid (often arginine and lysine) and under a different set of 
conditions. The mass shift associated with isotope labeling between samples is detected on a mass 
spectrometer and used to provide relative quantification between protein levels in samples (Figure 
1.3D). Similarly, pulsing in heavy amino acids and subsequently analyzing the samples by mass 
spectrometry can be used to identify newly made proteins.
68
 Pulsed-SILAC (pSILAC), a modified 
version of SILAC, utilizes a pulse with isotopically labeled amino acids,
69
 which obviates the 
need to continuously culture cells in heavy amino acids. Importantly, pSILAC can be used to 
detect proteins synthesized in response to different stimuli. SILAC has been applied to a variety 






 and C. elegans.
73
 SILAC has also been 
used to label whole mice for quantitative proteomics.
74,75
 SILAC has been modified to study cell-
cell interactions (trans-SILAC)
76
 and to identify secreted proteins in an approach called 
secretome-derived isotope tags (SDIT).
77
 SILAC can also be combined with various chemical 
biology-based labeling approaches that are discussed below. Notably, even though SILAC can be 
combined with fractionation techniques for subcellular proteomics,
78
 this approach does not label 
newly made proteins in a cell-selective fashion. Moreover, the affinity enrichment of low 
abundance, newly synthesized, proteins is not possible through this method because isotopically 
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labeled amino acids do not contain orthogonal chemical handles. However, several new 
techniques have been devised recently to address the lack of cell-specificity in current proteomic 
analyses. For example, a method titled isolation of nuclei tagged in specific cell types 
(INTACT)
79
 has been devised for cell-specific proteomic analysis using purified nuclei labeled in 
vivo with biotin.
80
 Miller and coworkers developed cell type-specific labeling using amino acid 
precursors (CTAP),
81
 a method that utilizes genetically encoded enzymes that convert isotopically 
labeled lysine precursors to uncaged lysine, which can be incorporated in cells expressing these 
enzymes (Figure 1.3E).
81
 Only cells expressing these enzymes are able to uncage the lysine 
precursors. Therefore, the controlled expression of this enzyme enables the cell-selective labeling 
of proteins with isotopically labeled lysine. This technique was used to investigate cell-cell 
interactions in continuous culture.
81,82
 Although such approaches confer cell selectively for 
proteomic analyses, the ability to detect newly synthesized proteins of low abundance proteins in 
complex cellular mixtures is limited by the lack of suitable enrichment tags. Additional methods 
are needed to address these limitations.  
Non-Canonical Amino Acids and Chemical Biology-Inspired Methods 
Whereas isoptopically labeled amino acids provide mass signatures that can be detected for 
proteomic identification and quantitation, non-canonical amino acids (ncAAs) provide chemical 
handles that can be selectively tagged for the detection and affinity purification of newly 
synthesized proteins. Enrichment simplifies subsequent analyses by enabling the separation of 
newly synthesized proteins from abundant pre-existing proteins, thereby greatly reducing sample 
complexity. Non-canonical amino acids are ideal for tracking protein dynamics because they are 
readily taken up by cells through amino acid transporters, their small size diminishes interference 
with protein function, and they can be covalently tagged, which permits more stringent affinity 
purification. Taking advantage of these desirable characteristics, bioorthogonal non-canonical 
amino acid tagging (BONCAT) was developed to label, detect, and identify newly synthesized 
proteins.
83
 BONCAT utilizes residue-specific incorporation of non-canonical amino acids. 
Specifically, a proteogenic amino acid, such as methionine, is replaced by its non-canonical 
counterpart throughout the proteome during protein synthesis. Labeling is achieved without a 
priori knowledge of protein identity, and the concentration of the non-canonical amino acid can 
be used to control the extent of incorporation. The first example of BONCAT utilized the non-
canonical amino acid Aha (Figure 1.2A, 2), a methionine surrogate, to label newly synthesized 
proteins. Aha incorporation does not alter the proteome.
84
 Moreover, the azide side chain of Aha 





separation of newly synthesized proteins from pre-existing proteins by affinity chromatography 
(Figure 1.3F). After separation, proteins are identified by tandem mass spectrometry (MS). 
Temporal control of labeling is achieved though addition of Aha to the growth medium (Figure 
1.4A). However, because all cells incorporate this non-canonical amino acid, it is not ideally 
suited for cell-selective proteomics. Cell-selective BONCAT was developed by deploying non-
canonical amino acids that require a mutant enzyme [aminoacyl tRNA synthetase (aaRS)] to be 
charged to an endogenous tRNA. The controlled expression of the mutant aaRS enables selective 
incorporation of non-canonical amino acids into cells of interest (Figure 1.4B).  
Initial examples of cell-selective BONCAT were demonstrated using the azide-functionalized 
methionine surrogate Anl,
86
 and it was later also performed with ncAAs containing an alkyne 
functionality (Figure 1.2B, 5-6).
87
 In principle, the same approach can be used with non-
methionine surrogates (e.g., phenylalanine or leucine analogues) (Figure 1.2B, 7-12). Such an 
expanded set of ncAAs can be used to label multiple subpopulations of cells with distinct sets of 
reactions (Figure 1.4C). For example, two different mutant aaRSs were used to incorporate the 
non-canonical amino acids Anl (Figure 1.2A, 4) and Pra (Figure 1.2A, 5) into distinct bacterial 
subpopulations.
88
 An expanded set of ncAAs enables the use of a wide range of chemical 
reactions to tag proteins. Alkyne- and azide-functionalized ncAAs can be tagged using the 
copper-catalyzed azide-alkyne cycloaddition reaction (Figure 1.2C); azide functionalized ncAAs 
can also be tagged through copper-free reactions with alkyne or alkynyl probes (Figure 1.2D).
89-91
 
Copper-free reactions with strain-promoted cyclooctynes are particularly useful for live-cell and 
in vivo applications,
56,90,92
 and also well-suited for affinity enrichment and proteomic analysis.
93
 
ncAAs containing aryl-halides (Figure 1.2A, 9, 10) can be tagged using modified Suzuki-Miyaura 
cross-coupling reactions (Figure 1.2E).
94
 Ketone-containing ncAAs (Figure 1.2A, 11,12) can be 
reacted with hydrazide functionalized tags (Figure 1.2F).
95
 Chin and coworkers recently 
incorporated a ncAA containing 1,3 disubstituted cyclopropene, which was reacted with tetrazine 
tags using the inverse electron demand Diels-Alder reaction (Figure 1.2G).
96
 The incorporation of 
this ncAA required co-expression of a mutant aaRS and its cognate tRNA; the approach was 
titled stochastic orthogonal recoding of translation with chemoselective modification (SORT-M). 
SORT-M differs from BONCAT in that BONCAT only requires expression of a mutant aaRS in 
cells of interest. While both tetrazine-cyclopropene and strained cyclooctyne-azide reactions are 
fast enough for most proteomic applications, strained cyclooctynes and cyclopropenes may react 
with thiols and result in non-specific labeling;
97
 therefore, additional care must be taken to protect 
free thiols and reduce non-specific labeling when using these chemistries. Taken together, these 
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examples demonstrate that a variety of chemical coupling strategies have been developed for 
BONCAT, and the choice of a particular chemistry depends on the availability of reagents, ease 
of use, and the subsequent proteomic analysis. To date, Aha has been the most widely used ncAA 
for BONCAT applications (Figure 1.2A, 2). However, we anticipate that cell-selective BONCAT 
using Anl (Figure 1.2A, 4) will be increasingly used for various proteomics applications requiring 
cell selectivity and tissue specificity.  
Non-Canonical Amino Acids and Quantitative Proteomics  
One of the important advantages of BONCAT is that it can be easily interfaced with other protein 
labeling strategies, including quantitative proteomic labeling methods such as SILAC. In a 
combined BONCAT SILAC approach, proteins are simultaneously labeled with both a non-
canonical amino acid for BONCAT labeling and an isotopically labeled amino acids for SILAC 
labeling. After BONCAT enrichment and shotgun proteomics, quantitative proteomic search 
engines such as MaxQuant
98
 are used to look for SILAC pairs in the mass spectra, enabling 
quantitation of newly made proteins across different conditions (Figure 1.4D). BONCAT reduces 
sample complexity and enables the detection of low-abundance proteins.
84
 Lu et al. used this 
approach to study the effects of microRNAs on proteome dynamics in cancer cells.
99
 Krigsveld 
and coworkers used BONCAT to quantitatively analyze secreted proteins. Notably, BONCAT 
enabled them to analyze the secretome of different cell lines even in the presence of abundant 
serum proteins.
100,101
 Acuto and coworker used quantitative non-canonical amino acid tagging 
(QuaNCAT) to analyze primary cells.
102
 While all of these studies used Aha for BONCAT 
labeling, we anticipate that recent progress in cell-selective BONCAT will allow the combination 
of SILAC with cell- and tissue-targeted BONCAT for quantitative proteome and secretome 
analysis in in vitro and in vivo cell populations. BONCAT can also be combined with other 
quantitative proteomic approaches. For example, one particularly promising approach is dimethyl 
labeling, which is a peptide labeling strategy based on the reductive amination of the N-terminus 
and the ɛ-amino groups of lysines.103 Dimethyl labeling is inexpensive, commercially available, 
and easy to use. Importantly, dimethyl labeling does not require the incorporation of istopically 
labeled amino acids. We anticipate that dimethyl labeling could be easily combined with 






Non-Canonical Amino Acids for Cell-Selective and Subcellular-Specific Proteomic Labeling 
The original implementation of BONCAT utilized Aha, which allows for detection of newly 
synthesized proteins at specified time points. This protein labeling strategy has been used to study 
the kinetics of nucleosome turnover by metabolically labeling histones,
104,105
 and to visualize 









 and environmental microbes.
112
 Restricting protein labeling through the controlled 
expression of mutant aaRS enzymes has been used to achieve cell-selective BONCAT. Cell-
selective BONCAT has been used to restrict protein labeling to pathogenic microbes in the 
presence of host cells and to identify the virulence factors that bacterial pathogens secrete into 
mammalian cells. Because the host cells do not incorporate the non-canonical amino acid, only 
the pathogen proteins are labeled, permitting them to be tagged and identified even inside host 
cells.
113
 Promoter-controlled expression of mutant aaRS enzymes is another strategy by which 
selective BONCAT can be achieved. For example, a mutant methionyl tRNA synthetase was 
placed under the control of a redox sensitive promoter in the SoxRS regulon. This strategy 
enabled redox-activated labeling of proteins in bacteria (Figure 1.5A).
114
 There are also instances 
in which one would like to activate protein labeling as a function of multiple promoters for 
context-specific BONCAT. To solve this problem, a split mutant methionyl tRNA synthetase was 
developed that allows incorporation of the non-canonical amino acid Anl only when both 
fragments of the enzyme are present in cells. In this approach, labeling occurs only upon 
activation of two different promoters that drive the expression of the N- and C-terminal fragments 
of this bisected synthetase.
115
 Using multiple promoters to control proteomic labeling expands the 
possibility of questions that BONCAT can address by improving the spatiotemporal resolution of 
the technique. Additional approaches towards subcellular-specific proteome labeling are being 
developed. For example, Schuman and coworkers used BONCAT to detect dendrite localized 
protein synthesis in neurons (Figure 1.5B).
106
 Specialized methods to target protein labeling to 
specific organelles are also being developed. For example, Ting and coworkers recently 
developed a method called APEX using an engineer peroxidase to analyze proteins at the 
interface of the mitochondrial intermembrane.
116
 Selective proteome labeling methods can 
potentially be complemented with the targeted delivery of chemical reporters to cells of 
interest.
117
 Taken together, we anticipate that such approaches will increase the diversity of 
chemical toolsets available for the study of protein synthesis in specific cell types and subcellular 





Technological advancements in DNA sequencers and mass spectrometers will continue to 
increase the coverage, throughput, and precision of measurements.  In conjunction, the 
development of better chemical reporters and metabolic tags will enhance the specificity and 
spatiotemporal resolution of labeling and improve the detection of biological molecules. 
Advances in chemical reporters will continue to push the frontiers of protein detection by moving 
increasingly towards both in vivo applications and sub-cellular resolution. Elucidating the 
proteins that are synthesized in specific subcellular compartments and determining how they are 
modified will enhance our understanding of translation.
118
 As improved instruments enable the 
analysis of more complex samples, we anticipate that chemical proteomic strategies such as 
BONCAT will be increasingly deployed for in vivo applications where temporal and context-
dependent proteome profiling is required. Such strategies will also be utilized to analyze secreted 
proteins (i.e., the ‘secretome’ of various cell types). Progress towards combining quantitative 
proteomic platforms, such as multiple reaction monitoring methods (MRM),
119
 with chemical 
reporter technologies will continue to enhance our understanding of proteome dynamics by 
providing quantitative measurements of proteomic changes in various cells. Current snapshots of 
cellular protein synthesis will evolve towards time-series and comprehensive datasets that provide 











Figure 1.1. Methods for detecting and quantitating protein synthesis based on the 
translation state of cells and the sequencing of ribosome-bound mRNAs. A. Polysome 
profiling uses density separation of ribosome-bound mRNAs to identify mRNAs that are actively 
translated in cells. B. Translating Ribosome Affinity Purification (TRAP) uses epitope-tagged 
ribosomes to affinity enrich mRNAs that are being translated in cells. C. Ribosome profiling 
utilizes the nuclease digestion of ribosome-protected mRNAs to produce mRNA sequences that 
correspond to the precise position of ribosomes on the mRNA and therefore provide a snapshot of 





Figure 1.2. Chemical reporters that are incorporated into newly synthesized proteins. 
Chemically reactive functional groups and reactions discussed in this review. A. Chemical 
reporters that are incorporated into newly proteins based on puromycin addition to nascent 
polypeptide chains and incorporation of non-canonical amino acids. B. Non-canonical amino 
acids that are incorporated into newly synthesized proteins in a cell-selective manner. C. Copper-
catalyzed azide-alkyne cycloaddition between alkyne functionalized proteins and azide tags. D. 
Azide functionalized proteins can be tagged through the copper-catalyzed azide alkyne 
cycloaddition reaction (II), or through strained cyclooctynes (II, III) or alkynyl probes (IV). E. 
Aryl-halide functionalized proteins can be tagged using palladium-catalyzed modified Suzuki-
Miyaura cross-coupling reactions. F. Ketone-containing proteins can be tagged with hydrazide 
functionalized tags. G. Proteins labeled with chemical tags containing 1,3 disubstituted 






Figure 1.3. Strategies for labeling nascent polypeptides and identifying newly synthesized 
proteins. A. Surface sensing of translation (SunSET) utilizes the immunodetection of puromycin, 
which is incorporated into the C-terminus of nascent polypeptide chains. B. Puromycin-
associated nascent chain proteomics (PUNCH-P) utilizes a biotin-conjugated puromycin tag for 
the affinity enrichment of nascent polypeptides. C. O-propargyl-puromycin (OP-puro) is an 
alkyne functionalized puromycin that enables the chemoselective tagging of puromycin in 
nascent polypeptide chains. D.  Stable isotope labeled amino acids in cell culture (SILAC) uses 
the incorporation of isotope labeled amino acids for relative proteomic quantification of newly 
made proteins between samples. E. Cell-type specific labeling using amino acid precursors 
(CTAP) utilizes genetically encoded enzymes to uncage isotopically labeled lysine precursors 
that are incorporate into newly synthesized proteins. Only cells that express the enzymes can 
metabolically incorporate the lysine precursors. F. Bioorthogonal non-canonical amino acid 
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tagging method (BONCAT) uses incorporation of non-canonical amino acids for the 
bioorthogonal and chemoselective labeling, detection, and identification of newly synthesized 
proteins in cells. Cell-selective BONCAT utilizes genetically encoded enzymes for the 







Figure 1.4. Approaches for labeling, identifying, and quantifying newly synthesized proteins 
by metabolically incorporating non-canonical amino acids. A. BONCAT utilizes the cell’s 
endogenous translation machinery to incorporate non-canonical amino acids and label newly 
synthesized proteins. The addition of non-canonical amino acids at time-windows of interest 
enables temporal control over protein labeling. B. Cell-selective BONCAT utilizes a mutant aaRS 
enzyme to incorporate non-canonical amino acids. Only cells expressing the mutant aaRS 
incorporate the non-canonical amino acid; the proteome and secretome of these cells can be 
labeled and identified using mass spectrometry. C. Cell-selective BONCAT can be used to label 
distinct subsets of cells based on activation of different promoters that drive the expression of 
mutant aaRS enzymes. This approach provides spatial and temporal control of proteome labeling. 
D. Combining BONCAT with quantitative proteomic labeling methods such as SILAC or 
dimethyl labeling enables the identification and relative quantification of newly synthesized 
proteins between samples. In SILAC+BONCAT, SILAC labeling is performed at the same time 
as non-canonical amino acid labeling; BONCAT is used to chemically tag and enrich newly made 
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proteins. In the BONCAT+dimethyl labeling approach, BONCAT is used to affinity enrich newly 
made proteins; after tryptic digestion, tryptic peptides are labeled using dimethyl labeling for 







Figure 1.5. Non-canonical amino acids for the genetically encoded, cell-specific, and 
subcellular-localized labeling of newly synthesized proteins. A. State-selective BONCAT 
utilizes promoter-controlled expression of a mutant aaRS to activate the labeling of newly 
synthesized proteins with non-canonical amino acids. In this example, a SoxR promoter is 
activated in the presence of oxidizing conditions and turns on Anl incorporation in newly made 
proteins. PQ is the superoxide-generating agent paraquat. Proteome labeling was only detected in 
the presence of paraquat.
114
 B. Subcellular labeling of newly synthesized proteins in neuronal 
dendrites. Somata of neurons were perfused with different combinations of the non-canonical 
amino acid Aha, protein synthesis inhibitor anisomycin, and brain-derived neurotrophic factor 
(BDNF), which induces the protein synthesis dependent enhancement of synaptic strength and 
dendritic translation. Fluorescence confocal microscopy images at the bottom show detection of 
newly synthesized proteins in neuronal dendrites using an alkyne-functionalized dye that 
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 Identification of Secreted Bacterial Proteins by Non-
Canonical Amino Acid Tagging 
 
Abstract 
Pathogenic microbes have evolved complex secretion systems to deliver virulence factors into 
host cells. Identification of these factors is critical for understanding the infection process. We 
report a powerful and versatile approach to the selective labeling and identification of secreted 
pathogen proteins. Selective labeling of microbial proteins is accomplished via translational 
incorporation of azidonorleucine (Anl), a methionine surrogate that requires a mutant form of the 
methionyl-tRNA synthetase for activation. Secreted pathogen proteins containing Anl can be 
tagged by the azide-alkyne cycloaddition and enriched by affinity purification. Application of the 
method to analysis of the type III secretion system of the human pathogen Yersinia enterocolitica 
enabled efficient identification of secreted proteins, identified distinct secretion profiles for 
intracellular and extracellular bacteria, and allowed determination of the order of substrate 
injection into host cells. This approach should be widely useful for the identification of virulence 
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Many bacterial pathogens use elaborate secretion systems to transfer effector proteins into target 
cells.
1
  The injected proteins disrupt host-cell functions, including cytoskeletal assembly and 
cytokine production, to promote infection.
2
 An important step in understanding virulence 
mechanisms is the identification of injected and secreted bacterial proteins. Traditional methods 
have included genetic screens and candidate protein approaches, which can be laborious and non-
comprehensive. Proteome-wide labeling strategies offer the potential to rapidly identify secreted 
pathogen proteins without bias and with limited prior knowledge of host-pathogen interactions.
3
 
We have previously developed a method (designated BONCAT – bio-orthogonal non-canonical 
amino acid tagging) to incorporate azide functional groups into proteins as a general strategy for 
the enrichment of newly synthesized cellular proteins, making it possible to elucidate the spatial 
and temporal character of proteomic changes. 
4,5
 Our initial studies used the non-canonical amino 
acid azidohomoalanine (Aha) (structure 2, Fig. 2.1A), a methionine (Met) surrogate, to label 
newly synthesized proteins. 
4,5
 The azide side chain of Aha allows newly synthesized proteins to 
be tagged with alkyne-functionalized affinity reagents and separated from pre-existing proteins 
by affinity chromatography. After separation, proteins are identified by tandem mass 
spectrometry (MS). Enrichment of newly synthesized proteins reduces the complexity of the 
sample and facilitates identification of the proteins of interest.  
Recently we showed that introduction of a mutant form of the methionyl-tRNA synthetase 
(designated NLL-MetRS) into Escherichia coli enables incorporation of the non-canonical amino 
acid azidonorleucine (Anl) (structure 3, Fig. 2.1A) into the bacterial proteome. 
6
 Because Anl is 
not activated to any significant extent by any of the wild-type synthetases, 
6
 labeling is restricted 
to cells in which NLL-MetRS is expressed. 
7
 This approach has prompted recent efforts to study 
proteomic changes in pathogens during infection.
8
 At the same time, there has been considerable 
interest in protein labeling strategies to study secreted pathogen proteins, most notably through 
the use of stable-isotope labeling of amino acids in cell culture (SILAC).
9,10
 However, isotopic 
labeling does not allow enrichment of secreted pathogen proteins, and enrichment is important for 
identification of virulence factors that would otherwise be undetected among abundant host 
proteins. Here we show that non-canonical amino acid labeling enables enrichment of secreted 
virulence factors and identification of injected proteins from host cell lysates using a shotgun, 
bottom-up proteomics approach.  
31 
 
Pathogenic bacteria secrete proteins through a variety of mechanisms. Secretion via type III, type 
IV and type VI systems occurs by direct injection of proteins into host cells, while type II and 
type V secretion systems use a two-step passage through the inner and outer membranes of the 
pathogen. Secreted outer membrane vesicles also mediate export of a complex array of proteins.
11
 
We focus here on the well-characterized type III secretion system (T3SS) of Yersinia 
enterocolitica, a Gram-negative bacterium. In Yersinia, the majority of secreted proteins, 
designated Yersinia Outer Proteins (Yops), are encoded on the 70 kb virulence plasmid pYV.
2,12
 
In addition to encoding Yops, the plasmid encodes machinery consisting of needle-shaped 
structures that assemble on the bacterial surface and inject proteins into the cytoplasm of host 
cells. The T3SS is activated by a temperature shift from 26˚C to the host temperature (37˚C); 
injection is initiated upon surface contact with target cells.
13,14
 The pYV virulence plasmid also 
encodes a low calcium response (LCR) that enables secretion of T3SS substrates into the medium 
in the absence of host cells.
15
 As a control for type III secretion, we used a YscU mutant strain 
(designated T3SS-Mut), which is unable to secrete Yops.
16
 YSCU is an inner membrane protein 
required for T3SS assembly and recruitment of substrates.
17
 
In the study described here, NLL-MetRS was introduced to both wild-type and mutant Yersinia 
strains to enable selective Anl-labeling of bacterial proteins (Fig. 2.1B). Because host cells do not 
express the NLL-MetRS, host-cell proteins are not labeled with Anl. After addition of Anl to the 
infection medium, Anl-labeled proteins were tagged by copper-catalyzed cycloaddition 
18
 (Fig 
2.1C) with alkyne-functionalized dyes and detected by in-gel fluorescence or by confocal 
fluorescence imaging of infected host cells. Similarly, enrichment of Anl-labeled proteins was 
performed after attachment of a cleavable affinity tag (structure 4, Fig. 2.1A) that permits binding 
of labeled proteins to immobilized streptavidin resin and removal of unlabeled proteins. The 
small mass modification resulting from tagging of Anl residues is readily detected by MS, 
thereby facilitating identification of enriched proteins (Figs. S2.1 and 2.S2.2). In a HeLa cell 
infection model, we identified the Yersinia proteins that were secreted into the medium and 
injected into HeLa cells. In addition to identifying known Yops, we identified novel secreted 
proteins that may play important roles in Yersinia infection. An extension of this approach 
allowed us to selectively label proteins secreted by Yersinia that had invaded HeLa cells, and to 
reveal secretion of distinct subsets of virulence factors. Pulse-labeling with Anl was used to 
investigate the order of injection of type III substrates into HeLa cells, and provided a simple 
method to determine the hierarchy of injection of virulence factors. The approach described here 
32 
 
is not limited to the study of T3SS substrates; it can be used to examine the many different 
secretion systems of microbial pathogens.  
Results 
Labeling of the Yersinia Proteome and T3SS Substrates 
E. coli NLL-MetRS was constitutively expressed in Y. enterocolitica under control of its natural 
promoter to enable Anl incorporation into bacterial proteins (Fig. S2.3). Proteins secreted under 
LCR conditions were tagged with an alkyne-functionalized tetramethylrhodamine (TAMRA) dye 
(Fig. S2.4) and detected by in-gel fluorescence imaging (Fig. 2.2A). Labeling was observed only 
in samples treated with Anl (Fig. 2.2A, lane 3); nonspecific labeling in the absence of Anl was 
negligible (Fig. 2.2A, lane 1). Lack of TAMRA labeling in the absence of Anl was not due to 
absence of secreted proteins, as these proteins were detected by colloidal blue staining (Fig. 2.2B, 
lane 1). The chemoselectivity of the copper-catalyzed click reaction was confirmed by these 
results. As expected, the T3SS-Mut strain did not secrete any labeled proteins (Fig. 2.2B, lanes 2 
and 4). The similarity of the protein secretion profiles in the Met- and Anl-treated samples (Fig. 
2.2B, lanes 1 and 3), and the lack of secretion by the mutant strain (lanes 2 and 4) indicate that 
Anl incorporation does not interfere with type III secretion. Western blot analysis with antibodies 
specific for YopD and YopE confirmed Yop secretion by the T3SS-Wt strain (Fig. 2.2C). 
Analysis of Yersinia lysates showed proteome-wide incorporation of Anl into Yersinia proteins 
(Fig. 2.2D).  
Detection of Injected Proteins in Host Cells by Fluorescence Imaging 
We examined the injection of Yops into HeLa cells, a widely-used in vitro model for Yersinia 
pathogenesis.
17
 Yop injection results in a characteristic rounded HeLa cell morphology that can 
be used to track injection (Fig. S2.5).
19,20
 Infections were performed with 1 mM Anl; incubation 
of Yersinia at 37˚C prior to infection increased the efficiency of injection (Fig. S2.6). Digitonin 
was used to lyse HeLa cells selectively; it does not cause significant disruption of Yersinia 
membranes (Fig. S2.7).
19,21
 Injected T3SS substrates were labeled with alkyne-TAMRA and 
detected by in-gel fluorescence imaging. We observed distinct bands of labeled proteins 
corresponding to molecular weights of known Yops D, E, H, M, N, P, Q and LcrV (Fig. 2.3A, 
lane 1). These bands were not observed in infections with the T3SS-Mut strain (although a low 
level of background labeling was observed (Fig. 2.3A, lane 2)), and proteins injected by Yersinia 
lacking the NLL-MetRS were not labeled (Fig. 2.3A, lane 3). Cell-specific proteome-wide 
33 
 
incorporation of Anl in Yersinia was confirmed in these co-cultures (Fig. 2.3A, lanes 4 and 5). 
Injected proteins were easily detected by this chemical labeling approach despite the much 
greater abundance of host cell proteins. Western blot analysis of the same samples with 
antibodies for Yops D, E and H showed the presence of these Yops in infected HeLa cells; 
antibody staining for Yersinia RpoA confirmed the absence of significant Yersinia cell lysis (Fig. 
2.3B). When we transferred HeLa cell lysates treated with alkyne-TAMRA to nitrocellulose 
membranes and probed the membranes with antibodies for Yops D and E, we found that the 
protein bands detected by these antibodies were also labeled with the TAMRA dye (Fig. 2.3C). 
To visualize injection, we used fluorescence confocal microscopy to detect Anl-labeled T3SS 
substrates in the HeLa cell cytoplasm. Anl-labeled proteins were tagged with alkyne-AlexaFluor 
488. We observed increased fluorescence in the cytoplasm of HeLa cells infected with the T3SS-
Wt strain as compared to infections with T3SS-Mut Yersinia (Figs. 2.3D and 2.3E), although a 
low level of background labeling was observed in experiments with the mutant strain (Fig. 2.3E). 
As expected, infections with Yersinia that lacked the NLL-MetRS resulted in HeLa cell rounding, 
but no evidence of labeled proteins in the cytoplasm (Fig. S2.8). These results indicate that Anl-
labeling can be used to detect injected virulence factors inside host cells. 
Identification of Virulence Factors 
As a first step toward identification of injected virulence factors, we performed a directed MS 
search for Anl-labeled Yops secreted under LCR conditions. We were able to detect incorporation 
of Anl at Met positions distributed throughout the secreted proteins (Figs. S2.9 – S2.11). We next 
sought to enrich and identify injected T3SS substrates from HeLa cells by using a shotgun MS 
approach. HeLa cells were infected with Y. enterocolitica in Anl-supplemented medium, and 
selectively lysed with digitonin after the infection. Cell lysates were treated with probe 4 for 
affinity enrichment of Anl-labeled proteins. Biotinylation was detectable by western blot analysis 
(Fig. S2.12), and labeled proteins were affinity-enriched on streptavidin resin (Fig. S2.13). In-gel 
tryptic digestion was performed on these samples and the resulting peptide mixtures were 
analyzed on a nanoLC-LTQ-FT mass spectrometer (Figs. S2.14 and S2.15). Type III-specific 
virulence factors were determined by comparison of lysates of HeLa cells infected by the T3SS-
Wt and T3SS-Mut strains (Fig. 2.3F). This analysis identified previously reported T3SS-specific 
substrates, including Yops D, E, H, M, N, P and Q, and LcrV.
17,22
 We did not find YopT or 
YopO, perhaps because these proteins are associated with host membranes. YopT was previously 
observed in the insoluble fraction of Hela cell lysates,
23,24
 and YpkA (the YopO counterpart in 





 It is also possible that YopT and YopO are made or secreted at low levels under our 
conditions. 
In addition to identifying proteins injected into HeLa cells, we investigated proteins that were 
secreted into the medium during infection (Fig. S2.16). This was done by precipitating the 
proteins from the infection medium and enriching Anl-labeled proteins. Comparison of T3SS 
substrates that were injected into HeLa cells with those secreted into medium during infection 
(Fig. 2.3G) showed that YopB, YscP and YscH/YopR were found only in the medium – not 
inside infected HeLa cells. This result supports a previously proposed mechanism of action of 
these Yops, in which secretion of YscP is followed by secretion of YopR into the extracellular 
medium, resulting in injection of YopN and other effector Yops into host cells.
19
  
Nineteen Yersinia proteins were found both in lysates prepared from HeLa cells infected with the 
secretion-competent strain and in those prepared from cells infected with the secretion-mutant 
strain (Fig. 2.3F). These proteins, which are not T3SS substrates, fall into two classes: i). highly 
abundant bacterial proteins, and ii). proteins associated with the bacterial cell surface. The highly 
abundant proteins (defined as those ranked among the top 10% of bacterial proteins in terms of 
abundance according to the PaxDb database)
26
 are listed in italic type in Fig. 2.3F, and include 
Tuf1 (ranked #1 of 3163 proteins in terms of abundance), TufA (ranked #4), GapA (#5), Eno 
(#6), GroL (#7) and DnaK (#10). We have also listed LivK in this group, although it falls at 
10.8% in terms of abundance, as well as MetG (MetRS), because it is over-expressed in both 
Yersinia strains. It seems likely that these highly abundant proteins are found in the HeLa cell 
lysate as a result of a low level of adventitious bacterial cell lysis, although we cannot rule out 
other mechanisms of transfer. Previous proteomic studies of factors secreted by Yersinia found 
subsets of these proteins, including HtpG, OmpA, GroL and several elongation factors 
27
,  as well 
as DnaK and Eno.
28
  
The second class of proteins found in experiments conducted with the secretion-mutant strain 
includes the membrane-associated proteins A1js30, Sif15, A1jpb8, OmpA and Ail. Yersinia 
surface proteins invasin, Ail and YadA mediate binding to host cells,
29
 and it has been shown that 
Ail mediates attachment and uptake of bacterially secreted outer membrane vesicles.
11
 Outer 
membrane protein A (OmpA), also identified in our analysis, is known to be present in such 
vesicles and released by Gram-negative bacteria. 
11,30
 OmpA has been observed in monocyte cell 
lysates after infection with Y. pesti, 
27
 is known to bind scavenger receptors,
31
 and is considered a 
potent Yersinia virulence factor.
30
 Sif15, also known as systemic factor protein-a (Sfpa), is 
35 
 
involved in systemic infection of Y. enterocolitica, is induced at 37°C, and is necessary for 
colonization of mesenteric lymph nodes in a mouse Peyer’s patch infection model.32 We also 
found the putative exported protein A1jpb8 and the outer membrane porin A1js30 in lysates 
prepared from HeLa cells infected with the secretion-mutant strain. Transfer of these proteins to 
the HeLa cell lysate could occur via a variety of mechanisms, including regulated release of outer 
membrane vesicles. Further work will be required to establish the mode of transfer of each 
protein. 
Identification of Virulence Factors Secreted by Internalized Bacterial Cells 
Many pathogens, including Yersinia strains, invade host cells during infection. Internalized 
pathogens may secrete virulence factors that are distinct from those released by extracellular 
bacteria.
33
 We used the gentamicin protection assay with pulsed Anl labeling to compare the type 
III secretion profiles of internalized and extracellular Yersinia cells. Two parallel infections were 
initiated with the T3SS-Wt strain. After 1 hour to allow internalization of the pathogen by HeLa 
cells, we added gentamicin to one of the samples, thereby inhibiting protein synthesis in the 
extracellular bacteria in this sample. Thereafter Anl was introduced into both samples for 
identical labeling times of 3 hours. Confocal microscopy verified selective labeling of Yersinia 
proteins inside infected HeLa cells (Fig. 2.4A). In the absence of gentamicin, both extracellular 
and intracellular Yersinia were labeled (Fig. S2.17, S2.18).  
Comparison of Anl-labeled proteins in HeLa cell lysates by in-gel fluorescence detection revealed 
a distinct pattern of proteins secreted by internalized Yersinia (Fig. 2.4B); internalized cells 
appear to secrete a subset of virulence factors. MS analysis, after enrichment of injected proteins, 
also indicated that a subset of Yops is secreted by internalized Yersinia (Fig. S2.19); Yops M, P 
and Q were not detected, while YopD, YopN, LcrV and effectors YopE and YopH were injected 
by the intracellular subpopulation. 
Yops are Injected in a Temporally Distinct Manner 
The BONCAT method is ideally suited to the study of time-dependent cellular phenomena. To 
analyze the order in which Yops are injected into host cells, we used an Anl pulse-labeling 
strategy wherein Anl was added to the medium at specified times following infection (Fig. 2.4C). 
MS analysis showed that injection of YopD, which is part of the type III needle complex that 
inserts into the host-cell membrane, is followed by injection of effector Yops E and H. 
Identification of YopD as the earliest injected substrate is supported by previous reports 
36 
 
indicating its injection is required to establish translocation of other Yops. 
34
 YopD, E and H have 
previously been detected on the surface of bacteria prior to contact with host cells, potentially 
allowing rapid injection of these substrates to stop phagocytosis.
35
 YopE disrupts the host cell 
cytoskeleton and can interfere with phagocytosis, and Yops E and H are thought to control 
injection of effector Yops.
36
 Our finding that Yops N and M are injected after YopE is supported 
by the fact that impassable YopE-DHFR fusion substrates can be used to block injection of Yops 
N and M.
37
 YopP was first detected 60-90 minutes after initiation of infection, in agreement with 
previous findings that its cytotoxic effect is not detected until 60 minutes post-infection, and its 
inhibition of NF-κB signaling in dendritic cells is detected starting at 90 minutes after infection.38 
Detection of YscM and YopO may indicate that Anl pulse-labeling may be particularly good for 
identification of low-abundance and transiently injected proteins that would otherwise be 
undetected. Taken together, these results demonstrate the capacity of the BONCAT method to 






Identification of effector proteins that are secreted or injected by pathogenic bacteria offers new 
opportunities for understanding pathogenesis mechanisms and developing novel therapeutics. 
Here we show that cell-selective, non-canonical amino acid tagging enables a new approach to 
the labeling, enrichment and identification of virulence factors secreted by pathogenic bacteria. 
Cell-selective proteomic labeling was achieved by outfitting Yersinia cells with the E. coli NLL-
MetRS, which charges Yersinia tRNA
Met
 with the azide-functionalized non-canonical amino acid 
Anl. Treatment of Anl-labeled proteins with alkyne affinity reagents provided a selective 
chemical tagging method, and enabled enrichment of secreted virulence factors from abundant 
host proteins. Yersinia proteins isolated from HeLa cell lysates included 8 T3SS substrates and 19 
proteins that were transferred via type III-independent mechanisms. Because some (or perhaps 
all) of the latter proteins may have been released via adventitious bacterial cell lysis, the overall 
selectivity of the method might be enhanced by further improvements in the removal of 
bacterially shed proteins and better host cell lysis techniques. For live cell applications, 
cyclooctyne-functionalized reagents can be used to tag the azide side chain of Anl residues in a 
copper-free manner.
39,40
 Our chemical tagging strategy is compatible with routine MS sample 




 and is easily combined with 
SILAC, iTRAQ and multiple-reaction monitoring quantitative MS methods.
44,45
 This approach 
can be complemented with candidate protein methods, such as expression of tagged substrates, to 
verify the secretion and identify the location of newly found substrates inside host cells.  
Pulsed Anl-labeling was combined with a gentamicin protection assay to identify proteins 
injected into HeLa cells by internalized Yersinia. These results demonstrate that the method can 
be used in different compartments of the host and should be applicable to studies of functional 
redundancy, wherein multiple effectors carry out similar functions.
46
 Pulsed Anl labeling was 
used to study the hierarchy of Yop injection, enabling direct elucidation of the injection order of 
T3SS substrates. As an alternative to pulsed Anl-labeling, spatial and temporal resolution may be 
achieved in future studies by putting the NLL-MetRS under control of specific promoters that are 
stage-specific or spatiotemporally regulated.
47
 This approach may allow for Anl labeling at 
different stages of infection, in particular host cells, or sub-cellular compartments. 
Straightforward extensions of the technology will enable investigation of both pathogen and host 
proteins during infections in animals. The simplicity of the approach makes it suitable for the 
study of numerous host-microbe interactions. 
38 
 
Materials and Methods  
Expression of the NLL-MetRS in Y. enterocolitica 
DH10B strains were used for genetic manipulations. The E. coli NLL-MetRS with mutations 
L13N, Y360L, and H301L, was isolated from pJTN1
7
 by Nhe1 digestion and inserted into pQE80 
(Qiagen). Kanamycin resistance was used for selection because Y. enterocolitica is resistant to 
ampicillin
48
 and nalidixic acid. The resulting plasmid, which carries NLL-MetRS under control of 
the endogenous E. coli MetG promoter is termed pAM1 and has been deposited in Addgene. The 
plasmid was transformed into electrocompetent Y. enterocolitica and transformants were grown at 
26°C on agar plates or in Luria-Bertani (LB) medium, both containing 50 µg/ml of kanamycin.  
 
Synthesis of Anl by Copper-Catalyzed Diazo Transfer 
The synthesis of Anl was based on a previously published protocol; the starting material was 
Boc-lysine.
49
 Briefly, 5.27 g (81.1 mmol) of sodium azide was treated with 2.7 ml (16 mmol) of 
distilled triflic anhydride in 13 ml of water for 2 hours. The triflic azide product was extracted 
with 10 ml methylene chloride and added dropwise to a flask containing Boc-Lys-OH (2 g, 8.1 
mmol), K2CO3 (1.68 g, 12.2 mmol) and CuSO4 (20 mg, 0.08 mmol) in 26 ml of water and 250 ml 
of methanol. After 20 hours at room temperature the product was extracted with ethyl acetate, 
redissolved in methylene chloride and purified by silica gel chromatography. After Boc 
deprotection with hydrochloric acid, the final product was purified by cation exchange 
chromatography.  
 
Copper-Catalyzed Click Reaction 
The copper-catalyzed azide-alkyne coupling reaction, and the synthesis of the requisite THPTA 
ligand were performed as described previously.
18
 Labeling was carried out at room temperature 
for 2 hours, at a final concentration of 0.2-0.5 mg/ml of HeLa lysate proteins, 0.1 mM copper 
sulfate, 0.5 mM THPTA ligand, 5 mM sodium ascorbate, 5 mM aminoguanidine and 100 µM 
alkyne probe. EDTA-free protease inhibitor (Roche) was added to all reactions and lysates.  
 
Secretion of T3SS Substrates under LCR Conditions 
Y. enterocolitica W2273 were diluted 1:50 from an overnight LB culture into M9 medium at 26 
°C with agitation at 250 rpm. At OD600=0.5, protein secretion was initiated by a temperature shift 
to 37°C. Labeling with Anl was performed in M9 medium lacking calcium and containing 1 mM 
Anl. After 2.5 hours, bacteria were sedimented for 15 minutes at 15000-rcf at 4°C. The medium 




HeLa Cell Infection and Anl Labeling of T3SS Substrates 
HeLa cells (ATCC) were routinely cultured in DMEM supplemented with 10% fetal bovine 
serum, trypsinized (Gibco) and expanded every 72 hours. Before infection, cells were washed 
twice with phosphate buffered saline (PBS) and resuspended in Opti-MEM medium (Gibco). Y. 
enterocolitica were diluted 1:25 from overnight cultures in LB and incubated at 26°C with 
agitation at 250 rpm until OD600=0.5 was reached. Yersinia were pre-incubated at 37°C for 3 
hours prior to start of infection. The pre-incubation time was determined by tracking T3SS 
injection of Anl labeled proteins (Fig. 2.S6). Labeling was performed at a multiplicity of infection 
of 100, with 10
7
 HeLa cells per condition, at 1 mM Anl and 50 µg/ml kanamycin. Infections were 
carried out for 3.5 hours. Infected HeLa cells were lysed with digitonin as described below for 
analysis of injected Yersinia proteins in HeLa cells (Fig. 2.3F).  
 
Selective Lysis of HeLa Cells after Infection 
After infection, HeLa cells were washed five times with PBS to remove surface bound proteins. 
Cells were incubated with 0.1% (w/v) digitonin in PBS for 20 minutes at room temperature with 
100 rpm agitation. EDTA-free protease inhibitor (Roche) was added to the lysis buffer. Lysis was 
increased by pipetting the lysis solution over the cells. Bacterial cells were removed from the 
lysates by centrifugation at 15000-rcf for 15 minutes at 4°C and filtration through a 0.2 µm filter. 
Western blot analysis with an antibody for RpoA was used to confirm absence of Yersinia lysis.  
 
Enrichment of Anl-Labeled Proteins 
Probe 4 was appended to Anl-labeled proteins by the copper-catalyzed azide-alkyne 
cycloaddition as described above. Proteins were precipitated with acetone, dissolved in 250 µl of 
4% SDS in PBS, and diluted to 0.1% SDS by addition of PBS supplemented with protease 
inhibitor (Roche). Proteins were incubated with 400 µl Streptavidin Plus Ultralink resin (Pierce) 
for 1.5 hours at room temperature. Affinity purification was performed according to a previously 
published protocol 
50
. Elution fractions were combined with Amicon Ultra 0.5 centrifuge filters 
(Millipore). Enrichment can also be performed with Click-iT alkyne-agarose resin (Invitrogen). 
 
Detection of Proteins in Gels and Western Blots 
Bicinchoninic acid protein quantification (Pierce) was used to equalize the amounts of proteins 
analyzed under different conditions. After dye labeling via the copper-catalyzed click reaction 
described above, proteins were washed with methanol to remove unreacted dye, and 
40 
 
electrophoresed on a Novex 12% Bis-Tris polyacrylamide gel (Invitrogen). Colloidal blue dye 
(Invitrogen) was used for nonspecific protein detection. Antibodies were used at the following 
dilutions: YopD: 1:20000, YopE: 1:40000, YopH: 1:4000, RpoA: 1:40000, α-tubulin (Abcam), 
anti-rabbit IgG-AlexaFluor 488 conjugate (Cell Signal Technologies, secondary antibody): 
1:1000. Fluorescence imaging of western blots and gels was performed with a Typhoon 9400 
molecular imager (GE Healthcare). 
 
Fluorescence Confocal Microscopy 
Adherent HeLa cells were infected as described above and fixed with 3.7% formaldehyde in PBS 
before labeling with 10 µg/ml Alexa Fluor 633-WGA conjugate (Invitrogen) in PBS for 30 
minutes. Cells were permeabilized with ice-cold methanol for 3 minutes. Labeling with alkyne-
TAMRA (Invitrogen) was performed as described above. Fluorescence confocal images were 
obtained on a Zeiss LSM 510 microscope.  
 
Comparison of Yops injected by extracellular and internalized Y. enterocolitica 
Y. enterocolitica (T3SS Wt) were diluted 1:25 from overnight cultures in LB and incubated at 
26°C with agitation until OD600=0.5 was reached. Two parallel infections of 5 x 10
7
 HeLa cells 
each were initiated at MOI of 100 in OptiMeM. After 1 hour of infection, gentamicin was added 
at 80 µg/ml to one sample of infected HeLa cells; the other sample did not contain the antibiotic. 
After 1 hour, the medium was changed to OptiMeM without gentamicin and Anl was added to 
both samples at 1 mM. The +gent condition was supplemented with 4 µg/ml gentamicin to 
maintain inhibition of protein synthesis by extracellular bacteria. After 3 hours of labeling, HeLa 
cells in both samples were lysed with 0.1% digitonin for enrichment and MS analysis or fixed 
with 3.7% formaldehyde for fluorescence confocal microscopy as described above. 
 
Determination of the order of Yop injection 
T3SS Wt Y. enterocolitica were diluted 1:25 from overnight cultures in LB and incubated at 26°C 
with agitation until OD600=0.5. Cells were pelleted at 5000-rcf and washed with PBS. Infection of 
four parallel samples, corresponding to the four time-windows of interest (Fig. 2.4C), was 
initiated as described above, with no pre-incubation at 37°C. Anl was added to the infection 
medium at 1 mM for the indicated times (Fig. 2.4C) and HeLa cells were lysed with digitonin at 
the end of each interval. HeLa cell lysates were treated with probe 4 as described above for 







Figure 2.1. Incorporation of Anl into injected pathogen proteins and enrichment of labeled 
proteins. (A) Structures of amino acids Met (1) and Met analogues Aha (2) and Anl (3). Alkyne-
functionalized biotin affinity probe (4) contains an acid-cleavable silane linker. The probe can be 
appended to the azide side chain of Anl. Cleavage with formic acid transfers a small mass tag to 
each modified Anl residue. (B) NLL-MetRS charges the tRNA
Met
 with Anl; its expression in the 
pathogen allows cell-selective labeling of pathogen proteins during infection. Injected pathogen 
proteins are enriched after labeling with 4 and identified by tandem MS. (C) Copper-catalyzed 











Figure 2.2. Labeling of secreted T3SS substrates. (A) Secretion competent (+) and secretion 
mutant (-) Y. enterocolitica strains harboring the NLL-MetRS were induced to secrete T3SS 
substrates under LCR conditions. Secreted proteins were labeled with alkyne-TAMRA and 
detected by in-gel fluorescence. (B) Detection of all secreted proteins in (A) by colloidal blue 
staining. (C) Western blot detection of YopD and YopE in samples from (A). (D) In-gel 
fluorescence detection of alkyne-TAMRA labeling of Y. enterocolitica lysates from conditions 
corresponding to lanes 3 and 4 in (A) shows proteome-wide incorporation of Anl; inset at bottom 





Figure 2.3. Detection and identification of injected Y. enterocolitica virulence factors in 
HeLa cells. (A) HeLa cells were infected with Y. enterocolitica in media containing 1 mM Anl. 
Proteins were labeled with alkyne-TAMRA and detected by in-gel fluorescence. Inset at bottom 
shows colloidal blue staining of the same gels. (B) Western blots of HeLa cell lysates with 
antibodies specific to YopD, YopE, YopH and bacterial RNA polymerase A (RpoA). Legend at 
the bottom of section A applies to section B. (C) Lysates of infected HeLa cells were treated with 
alkyne-TAMRA (click) and transferred to nitrocellulose membranes after SDS-PAGE. The same 
membranes were probed with antibodies specific to YopD and YopE. (D) Detection of injected 
Yersinia proteins in HeLa cells by fluorescence confocal microscopy. Anl-tagged proteins were 
labeled with alkyne-AlexaFluor 488 (green). An AlexaFluor 633-wheat germ agglutinin (WGA) 
conjugate was used to label membranes of HeLa cells (red). The same analysis was performed for 
infections with secretion mutant Y. enterocolitica in (E). (F) Shotgun proteomic identification of 
virulence factors injected into HeLa cells. Color code indicates the number of independent 
experiments in which each protein was detected. *YopQ was detected in only one infection. (G) 





Figure 2.4. Labeling of proteins injected into HeLa cells by internalized Y. enterocolitica and 
identification of the order of Yop injection into HeLa cells (A) Confocal fluorescence 
microscopy shows Anl incorporation into the proteome of internalized Y. enterocolitica. HeLa 
cell membranes were labeled with AlexaFluor 633-WGA conjugate (red). Anl residues were 
labeled with alkyne-AlexaFluor 488 (green). Arrow indicates labeled Y. enterocolitica inside 
HeLa cell. (B) Infected HeLa cells were selectively lysed with digitonin and treated with alkyne-
TAMRA to detect the proteins injected by internalized Y. enterocolitica. Inset at bottom shows 
colloidal blue staining of the same gel. In the presence of gentamicin only internalized Yersinia 
can inject proteins into HeLa cells. (C) The order of injection of Yops was determined by pulsed-
Anl labeling and shotgun MS. Anl was added only during the indicated times for each infection 
and HeLa cells were lysed with digitonin at the end of each time interval. (D) Western blot 
detection of Yops in pulsed-Anl labeling experiments. RpoA serves as control for bacterial lysis; 




Figure S2.1.  




Acid-cleavable biotin-alkyne affinity enrichment tag N-(2-(((hex-5-yn-1-
yloxy)diphenylsilyl)oxy)-2-methylpropyl)-1-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanamido)-3,6,9,12-tetraoxapentadecan-15-amide. Synthesis 
of the acid cleavable alkyne tag was based on our recent work on the analogous acid-sensitive 
dialkoxydiphenylsilane biotin-azide tag (45), with the exception that hex-5-yn-1-ol was used in 
place of 6-azidohexanol.
1
H NMR (500 MHz, CDCl3), δ (ppm): 7.72-7.50 (m, 4H), 7.40 (m, 6H), 
7.06-6.95 (m, 1H), 6.66 (s, 1H), 6.50 (t, J = 5.65, 5.65 Hz, 1H), 5.80 (s, 1H), 4.53-4.37 (m, 1H), 
4.34-4.19 (m, 1H), 3.73 (td, J = 19.58, 6.04, 6.04 Hz, 4H), 3.65-3.48 (m, 14H), 3.48-3.35 (m, 
2H), 3.35-3.22 (m, 1H), 3.11 (dd, J = 11.73, 7.06 Hz, 1H), 2.85 (td, J = 16.69, 8.51, 8.51 Hz, 
1H), 2.72 (t, J = 10.43, 10.43 Hz, 2H), 2.41 (t, J = 6.01, 6.01 Hz, 2H), 2.27-2.05 (m, 4H), 1.95 
(dd, J = 3.09, 2.17 Hz, 1H), 1.81-1.52 (m, 8H), 1.50-1.33 (m, 2H), 1.23 (d, J = 22.65 Hz, 6H); 
13
C NMR (126 MHz, CDCl3), δ (ppm): 173.5, 171.2, 164.1, 134.8 (m, 6C), 130.2 (m, 2C), 127.9 
(m, 4C), 84.3, 75.7, 70.4 (m, 8C), 68.6, 67.3, 62.6, 61.8, 60.2, 55.7, 50.4, 40.5, 39.1, 37.1, 35.9, 
31.3, 28.3, 28.0, 27.6, 25.6, 24.8, 18.1; m/z calculated for C43H67N7O9SSi [M+H]
+
: 840.4163, MS 





Figure S2.1 continued. 
 
NMR spectra of acid-cleavable biotin-alkyne tag (top, 
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Mass shifts at methionine positions as a result of Anl incorporation and addition of 
cleavable tag. Mass modifications associated with replacement of Met by Anl, with reaction of 
Anl with the biotin-alkyne affinity enrichment tag, and with cleavage of the tag by formic acid 
are represented. These three mass modifications are included as variable modifications for 






Sequence of the NLL-MetRS expression construct. DNA sequence of the NheI-flanked 
expression cassette with NLL-MetRS under control of the E. coli MetG promoter and followed 
by its natural E. coli transcriptional termination signal. The MetRS sequence is underlined. 




































Alkyne functionalized fluorescent dyes for visualization of Anl labeled proteins. Alkyne 
functionalized tetramethylrhodamine (TAMRA) or Alexa Fluor 488 dyes are appended to Anl 








HeLa cell morphology after labeling and infection by various Y. enterocolitica strains. HeLa 
cells were incubated with Y. enterocolitica at multiplicity of infection of 100 in the presence of 1 
mM Met or 1 mM Anl. Infections with secretion wild type Yersinia resulted in a rounded 
morphology, whereas infections with secretion mutant Yersinia did not change HeLa cell 










Identifying infection conditions to increase efficiency of Yop injection into HeLa cells. 
Optimal conditions for Anl labeling of injected Yops were identified by investigating Anl 
concentrations of 0.5, 1 and 2 mM, as well as the timing of T3SS activation. A. Anl incorporation 
was detected by labeling with TAMRA alkyne dye and in-gel fluorescence detection. Activation 
of T3SS machinery was induced by pre-incubation of Yersinia at 37 °C for various times (0-60 
min) before the start of infection. The labeling control (HeLa only) did not include any Yersinia 
cells. A pre-incubation step at 37 °C for 120 min was included to determine if longer pre-
incubation would result in more labeling of injected proteins. Higher Anl concentrations 
consistently yielded higher levels of labeling with TAMRA dye, and longer pre-incubation at 37 
°C resulted in more efficient injection. Secretion of Yops under LCR conditions (M) is included 
as a basis of comparison for the expected position of Yops B. Colloidal blue staining of the same 
gels shows equal protein loading across different conditions. Pre-incubation of Yersinia at 37 °C 
increases the efficiency of injection of labeled T3SS substrates. C. T3SS secretion competent Y. 
enterocolitica were pre-incubated at 37 °C for 1-5 hours before start of infection of HeLa cells. 
Infections were carried out in media containing 0.5, 1, 2 or 4 mM Anl. D. Colloidal blue dye 
staining of the same samples shows equal loading of HeLa lysates. H: HeLa lysates after infection 
with secretion WT Yersinia. M: Media secreted Yops under LCR conditions. Positions 











Selective lysis of HeLa cells in the presence of intact Y. enterocolitica. Digitonin was used as a 
detergent to disrupt the HeLa cell membrane but not the bacterial envelope. Co-cultures of HeLa 
and Yersinia cells were lysed with various concentrations of digitonin in PBS. Briefly, 6-well 
plates containing 1.5 x 10
6 
HeLa cells and Yersinia at MOI of 100 were lysed for 20 min at room 
temperature. After lysis of HeLa cells, Yersinia cells were removed by centrifugation at 15000 rcf 
and the remaining supernatant proteins were precipitated with chloroform/methanol. The proteins 
were resuspended in 1% SDS and electrophoresed on a 12% polyacrylamide gel and stained with 
colloidal blue. Efficient lysis of HeLa cells was observed with digitonin concentrations as low as 
0.025% v/w. In the absence of HeLa cells and presence of Yersinia, no protein could be observed 
after incubation with digitonin, indicating lack of Yersinia lysis. Western blot analysis with 
antibody specific for Yersinia RpoA confirmed the lack of bacterial lysis. A small amount of non-
specific binding was observed with this antibody under all conditions, including those with no 
bacteria. Yersinia lysis with 2% SDS served as a positive control for RpoA labeling. Western blot 
analysis with an antibody specific to α-tubulin was used as a loading control to show the extent of 
HeLa cell lysis. Western blots probed with α-tubulin antibody confirmed that 0.05% digitonin is 






Control conditions for detection of labeled proteins in absence of Anl incorporation. The 
images in this section are labeling controls for the infection studies shown in Fig. 2.3D, E of the 
main text. The images were obtained from infections in 1 mM Anl with secretion wild type Y. 
enterocolitica lacking the NLL-MetRS. Anl residues were labeled with alkyne-functionalized 
AlexaFluor 488; the resulting fluorescence is shown in green. AlexaFluor 633 conjugated to 
wheat germ agglutinin (WGA) labels membranes of HeLa cells; the corresponding fluorescence 
is shown in red. In the absence of NLL-MetRS, Anl is not incorporated into Yersinia proteins; 




The wild-type MetRS does not activate Anl to any appreciable extent; however the NLL-MetRS 
does activate Met. We have previously measured the kinetics of amino acid activation by NLL-








 for Anl. See Ref. 6 of the main text 
for measurement of the catalytic efficiency of MetRS variants. As shown in Figure 2.3A lane 5 of 
the main text, labeling in absence of NLL-MetRS is negligible. This is also evident in the images 
above as bacteria lacking the NLL-MetRS are not labeled, even in the presence of Anl. The 





Directed mass spectrometry search for gel-extracted peptides derived from Yops secreted 
under LCR conditions. A directed mass spectrometric search was used to determine the Met 
positions occupied by Anl in each Yop. Yops were secreted under LCR conditions in the presence 
of 1 mM Anl in 19-amino acid M9 medium supplemented with 25 µM Met and lacking calcium 
chloride. Secreted proteins were precipitated by chloroform/methanol treatment, resuspended in 
1% SDS in PBS, electrophoresed on a 12% bis-tris acrylamide gel and stained with colloidal 
blue. The resulting bands were cut out, and in-gel tryptic digestion was performed for each gel 
fragment. To help identify peptides corresponding to each Yop, an m/z inclusion list for expected 
peptide ions was generated taking into account 2 missed cleavages by trypsin as well as fixed 
carbamidomethyl modification of cysteine and variable oxidation of Met. Replacement of Met by 
Anl was included as a variable modification. This inclusion list was used to perform directed LC-
MS/MS experiments on an LTQ-FT Ultra mass spectrometer (Thermo Fisher Scientific) equipped 
with a nanoelectrospray ion source (Thermo Fisher Scientific) connected to an EASY-nLC II 
(Thermo Fisher Scientific).  
 
A. Image of the cut out gel fragments with the total number of identified spectra shown for each 
fragment. The corresponding Yop positions are indicated next to the image. B. The total number 
of Met positions based on the protein sequence for each Yop and the molecular weight is listed. 
C. The number of identified spectra for each Yop is shown for each extracted gel section, the 






















Detection of residue-specific incorporation of Anl in Yops. Directed mass spectrometry was 
performed based on an expected peptide ion list (see Fig. S2.9 for details) from gel-extracted 
Yops from proteins secreted under LCR conditions An example of this analysis for YopH is 
illustrated here showing the sequence coverage obtained in presence or absence of Anl labeling  
 
A. Highlighted sequences depict coverage by LC-MS/MS; modified Met residues are highlighted 
in green indicating oxidation of methionine in the “+Methionine” condition and incorporation of 
Anl in the “+Azidonorleucine” condition. Small differences were observed between the sequence 
coverages obtained for Met- and Anl-treated samples. B. The Met positions at which Anl was 
observed are shown for YopH as a function of residue position along the sequence. Black boxes 
are positions at which Anl was observed, and the frequencies at which Met and Anl were 
observed are shown for each position. C. A representative spectrum from an LC-MS/MS analysis 






YTLTIR peptide is shown, with y-
ions shown in blue and b-ions shown in red. A mass increment of 16 amu indicates that the Met at 
position 328 is oxidized. Anl is incorporated at positions 307 and 331, as indicated by mass shifts 
of 23 amu each. This mass shift corresponds to replacement of Met by Anl (Fig S2.2). A similar 





Identifying the pattern of residue-specific replacement of methionine by azidonorleucine in 
Yops as a function of protein molecular weight and number of methionines. Directed mass 
spectrometry was used to determine the total number of Met positions at which Anl incorporation 
was observed. A. The number of Met positions as a function of molecular weight for each Yop is 
plotted to show the number of methionines contained in sequence of each Yop. B. The 
experimentally observed number of Anl residues (replacement of methionine) for each Yop as 
identified by MS. C. The sequence coverage observed by MS for each Yop. Sequence coverage is 
represented in yellow, and the position of each Met is represented as a circle. Black circles 
represent detection of Anl at a given Met position. These results were obtained from secretion of 
Yops under LCR conditions. The extent of labeling and observed sequence coverage may differ 








Detection of biotin after click reaction of alkyne-biotin probe to proteins containing Anl. 
HeLa infections and secretion of Yops under LCR conditions were performed as described in the 
methods section of the main text. Proteins were treated with the biotin-alkyne affinity tag 
(structure 4 in the main text) and biotinylation was detected by western blot with a streptavidin 
Alexa fluor-633 conjugate antibody. Image below shows biotin labeling in injected HeLa cell 
lysates as well as proteins secreted under LCR conditions. Biotinylated horseradish peroxidase 







Affinity enrichment of injected Y. enterocolitica proteins from infected HeLa cell lysates. A. 
Infected HeLa cell lysates were treated with probe 4 and affinity purified on a streptavidin 
column. Flow-through (FT) and elution (EL) fractions were stained with colloidal blue. B. 
Western blot detection of YopE and mammalian α-tubulin in the same fractions as those 
represented in A. YopE was enriched from HeLa infections with T3SS-Wt Yersinia. Lack of α-







Comparison of MS/MS spectra from Yops secreted under LCR conditions and Yops 
injected into HeLa cells. A. Tandem mass spectrum corresponding to a peptide from YopD from 
proteins secreted under LCR conditions. B. Tandem mass spectrum identified from infected HeLa 
cell lysates and corresponding to the same peptide sequence as in A. Both samples were gel 
extracted and desalted on C18 ziptip columns. A doubly charged m/z 701.86 amu peptide ion 
corresponding to the sequence “EKEVNASIAANEK” gave a precursor mass of 1401.71 
(theoretical value 1401.7172). The y- and b-ions are color coded blue and red, respectively, along 
with the matching peptide sequence on top of each spectrum. Spectra were obtained on a nanoLc-







Representative MS/MS spectra from Yops peptides identified after enrichment of inected 
proteins from HeLa cell lysates. The sequence of the peptide is shown on top of each spectrum. 
The y- and b-ions are color coded blue and red, respectively, along with the matching peptide 
sequence. A mass modification of M+121 amu at each Met position indicates the mass addition 







Identification of secreted Yersinia proteins during infection. Infection medium was removed 
after the completion of HeLa infections, and proteins were precipitated with chloroform-
methanol. Anl labeled proteins were tagged with probe 4, enriched on a streptavidin column and 
analyzed by LC-MS. The secreted proteins identified here correspond to infections in Fig. 2.3F of 
main text. Three independent replicates were performed. The color-code next to the protein 
names indicates the number of identifications of each protein across experimental replicates. 







Anl labeling of intracellular and extracellular bacteria in the absence of gentamicin. 
Infections corresponding to Fig. 2.4A of the main text were carried out using identical conditions; 
infections were carried out in the absence of gentamicin. Extracellular bacteria incorporated Anl 
into newly synthesized proteins and can be readily observed outside HeLa cells. In the image 
below, confocal fluorescence microscopy shows labeling of Anl residues with alkyne-AlexaFluor 






Fluorescence confocal microscopy shows internalized Yersinia inside infected HeLa cells. 
Confocal planes from top to bottom of HeLa cell samples are numbered 1-12. AlexaFluor 633 
conjugated to WGA was used to label the membranes of HeLa cells; the associated fluorescence 
is shown in red. Anl-labeled proteins were treated with alkyne-functionalized AlexaFluor 488; the 
associated fluorescence is shown in green. A. Gentamicin was added in this experiment to kill 
extracellular bacteria before Anl incorporation. Internalized Yersinia can be observed inside 




B. Gentamicin was not added in this experiment, and labeling was performed as described above. 
Both extracellular and intracellular bacteria have incorporated Anl into newly synthesized 
proteins and are labeled with alkyne-functionalized AlexaFluor 488 (green). See intracellular and 








Comparison of injected proteins in HeLa cells in presence or absence of gentamicin. Lysates 
of HeLa cells from infections corresponding to Fig 2.4B of the main text were analyzed by 
shotgun MS. Both infection mixtures were labeled with Anl for the same duration under identical 
conditions (except for the presence or absence of gentamicin). Anl labeled proteins were enriched 
using probe 4 before MS identification. Venn diagram shows the T3SS substrates identified under 






Proteins identified in infections with secretion wild type and secretion mutant Y. 
enterocolitica. Peptides were fractionated on a 15 cm reversed phase analytical column (75 μm 
ID) in-house packed with 3 μm C18 beads (ReproSil-Pur C18-AQ medium; Dr. Maisch GmbH) 
with a 60-minute gradient from 5% to 28% acetonitrile in 0.2% formic acid, over 50 minutes, 
followed by 10 minutes at 80 % acetonitrile in 0.2% formic acid, at a flow rate of 350 nl per 
minute.  
 
The mass spectrometers were operated in data-dependent mode automatically switching between 
full-scan MS and tandem MS acquisition. Survey full scan mass spectra were acquired after 
accumulation of 500,000 ions, with a resolution of 60,000 (Orbitrap) and 50,000 (LTQ-FT) at 400 
m/z. The top ten most intense ions from the survey scan were isolated and, after the accumulation 
of 5000 ions, fragmented in the linear ion trap by collision induced dissociation. Preview scan 
mode was enabled in the Orbitrap but not in the LTQ-FT. Precursor ion charge state screening 
was enabled and singly charged and unassigned charge states were rejected. The dynamic 
exclusion list was enabled with a relative mass window of 10 ppm and early expiration turned on.  
 
T3SS substrates in HeLa infections were identified by a bottom up shotgun approach. MGF files 
were generated from Thermo RAW files using ReAdW4Mascot2 (v. 20090305a). The MGF files 
were searched using Mascot software (Matrix science, v2.2.06). The files were searched against 
the Y. enterocolitica proteome (5109 sequences, Uniprot) and a set of common contaminants (262 
sequences). A decoy database consisting of the target protein sequences reversed was constructed 
to estimate the false discovery rate. The database search included mass modifications associated 
with Anl tagging (outlined in Fig. S2.2), as well as fixed carbamidomethyl modification of 
cysteine (+57.0214), variable oxidation of methionine (+15.9949) and N-terminal acetylation. A 
precursor tolerance of 10 ppm and fragment tolerance of 0.5 Da were used. Trypsin was the 
specified digestion enzyme and up to two missed cleavages were allowed. Scaffold software 
(Proteome software v3) was used to generate the list of identified proteins, using 99.9% protein 
probability, minimum of 2 peptides per protein and 95% peptide probability (Table S2.1) as 
thresholds for acceptance. Each identified protein was present in at least three independent 
infections. The false discovery rate was less than 1% in all experiments. MS analysis was 
performed on a nanoLC LTQ-FT mass spectrometer. MS data were analyzed by Mascot and 




All identified proteins had a false discovery rate of less than 1%. The criterion for inclusion of a 
protein found in the HeLa cell lysate was that it was observed in at least three different samples 
(of a total of six infections). The number of times a proteins was present was counted 
independently for secretion WT and secretion Mut infections; the larger of the two numbers is 
reported by the color code. For proteins secreted into the medium, the protein had to be present in 
two different samples (in a total of three infections) to be included in the Venn diagram. If a 
protein was observed in both the secretion WT and Mut infections in any of these samples, it was 
considered to be present in the joint distribution. YopQ was observed once in the secretion WT 
infection in HeLa cells and YscP was observed once in the secreted fraction isolated from 
infection with secretion WT Yersinia. YopE was observed once in the HeLa fraction of infections 
with secretion Mut Yersinia, but because it was present in every sample of injected proteins with 
secretion WT Yersinia it was retained in the secretion WT fraction in Fig. 2.3F. A1js30 was 
observed in three independent HeLa injections as reported in Fig. 2.3F. A1js30 was observed in 
only one of the samples of secreted proteins; although it did not meet the standard for inclusion in 
the secreted proteins, we included it to show that this protein may be present in the infection 
medium. Experiments are listed in reverse chronological order in the table below. Proteins 
identified in each experiment are sorted from highest to lowest based on the number of identified 
peptides and listed as such in the table. For time-series measurements using pulse-Anl labeling, 
three replicates were performed for early and intermediate time-points of 60 and 120 minutes 
respectively and identification was based on at least one observation of T3SS substrates across 
the samples. For the 210 minute sample we used the same list of proteins as that identified for 
Fig. 2.3F of the paper because these experiments used identical Anl labeling windows and 
infections. Variations in the numbers of identified proteins were observed as we improved our 
enrichment methods and instrument settings. Final enrichment methods and instrument settings 
are reported in the methods section.  
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Secretion Wt Injected Proteins 1 Accession Number 
Yop effector YopE OS=Yersinia enterocolitica GN=yopE PE=4 SV=1 Q7BRY7_YEREN  
Yop effector YopH OS=Yersinia enterocolitica GN=yopH PE=4 SV=1 Q7BRY8_YEREN  
60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1 CH60_YERE8 
YopN OS=Yersinia enterocolitica GN=yopN PE=4 SV=1 O68333_YEREN 
Elongation factor Tu A (Fragment) OS=Yersinia enterocolitica GN=tufA PE=4 SV=1 B6RBB1_YEREN 
Yop effector YopP OS=Yersinia enterocolitica GN=yopP PE=4 SV=1 O52162_YEREN 
Chaperone protein htpG OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=htpG PE=3 
SV=1 
HTPG_YERE8 
Chaperone protein dnaK OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=dnaK PE=2 
SV=1 
DNAK_YERE8 
Enolase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=eno PE=3 SV=1 ENO_YERE8 
Attachment invasion locus protein OS=Yersinia enterocolitica GN=ail PE=4 SV=1 D7PM19_YEREN  
Yop effector YopM OS=Yersinia enterocolitica GN=yopM PE=4 SV=1 P74988_YEREN 
Elongation factor G OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=fusA PE=3 SV=1 A1JS54_YERE8 
Elongation factor Ts OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tsf PE=3 SV=1 EFTS_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE3039 
PE=3 SV=1 
A1JP43_YERE8  
Elongation factor Tu 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tuf1 PE=3 
SV=1 
EFTU1_YERE8 
50S ribosomal protein L1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplA PE=3 
SV=1 
RL1_YERE8 
Glyceraldehyde 3-phosphate dehydrogenase A OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=gapA PE=3 SV=1 
A1JQH1_YERE8 
Peptidoglycan-associated lipoprotein Pal OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=pal PE=3 SV=1 
A1JRK6_YERE8 
Virulence-associated V antigen OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=lcrV 
PE=4 SV=1 
A1JU73_YERE8  
Trigger factor OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tig PE=3 SV=1 TIG_YERE8 
Outer membrane porin protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=YE2463 PE=4 SV=1 
A1JS30_YERE8 
Adhesin yadA OS=Yersinia enterocolitica GN=yadA PE=1 SV=1 YADA1_YEREN  
Putative outer membrane porin A protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 




Cell division protein ftsZ OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=ftsZ PE=3 
SV=1 
A1JJJ8_YERE8 
Methionyl-tRNA synthetase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=metG 
PE=3 SV=1 
SYM_YERE8 
Secretion Wt Injected Proteins 2 Accession Number 
60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1 CH60_YERE8 
Yop effector YopE OS=Yersinia enterocolitica GN=yopE PE=4 SV=1 Q7BRY7_YEREN  
Translocator protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=yopD PE=4 SV=1 A1JU70_YERE8  
Chaperone protein dnaK OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=dnaK PE=2 
SV=1 
DNAK_YERE8 
Elongation factor Tu 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tuf1 PE=3 
SV=1 
EFTU1_YERE8 
Yop effector YopH OS=Yersinia enterocolitica GN=yopH PE=4 SV=1 Q7BRY8_YEREN  
Chaperone protein htpG OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=htpG PE=3 
SV=1 
HTPG_YERE8 
Elongation factor G OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=fusA PE=3 SV=1 A1JS54_YERE8 
Elongation factor Ts OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tsf PE=3 SV=1 EFTS_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE3039 
PE=3 SV=1 
A1JP43_YERE8  
Enolase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=eno PE=3 SV=1 ENO_YERE8 
Glyceraldehyde 3-phosphate dehydrogenase A OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=gapA PE=3 SV=1 
A1JQH1_YERE8 
Clp ATPase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=clpB PE=3 SV=1 A1JK85_YERE8 
Transaldolase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tal PE=3 SV=1 TAL_YERE8 
Methionyl-tRNA synthetase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=metG 
PE=3 SV=1 
SYM_YERE8 
Branched-chain amino acid-binding protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=livK PE=3 SV=1 
A1JIC6_YERE8 
Ribosome-recycling factor OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=frr PE=3 
SV=1 
RRF_YERE8 
Protein tolB OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tolB PE=3 SV=1 TOLB_YERE8 
Putative outer membrane porin A protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=ompA PE=3 SV=1 
A1JMT3_YERE8 





ATP-dependent protease ATPase subunit HslU OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=hslU PE=3 SV=1 
HSLU_YERE8 
Trigger factor OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tig PE=3 SV=1 TIG_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE2166 
PE=3 SV=1 
A1JPB8_YERE8 
3-oxoacyl-[acyl-carrier protein] reductase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fabG PE=3 SV=1 
A1JN73_YERE8 
Cell division protein ftsZ OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=ftsZ PE=3 
SV=1 
A1JJJ8_YERE8 
Phosphoglycerate kinase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=pgk PE=3 
SV=1 
PGK_YERE8 
3-oxoacyl-[acyl-carrier-protein] synthase I OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fabB PE=3 SV=1 
A1JKM0_YERE8 
Putative outer membrane porin F protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=ompF PE=3 SV=1 
A1JMN7_YERE8 
DNA-directed RNA polymerase subunit alpha OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=rpoA PE=3 SV=1 
RPOA_YERE8 
Ribose-phosphate pyrophosphokinase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=prsA PE=3 SV=1 
A1JRV4_YERE8 
ATP synthase subunit beta OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=atpD PE=3 
SV=1 
ATPB_YERE8  
Lysyl-tRNA synthetase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=lysS PE=3 
SV=1 
SYK_YERE8 
Secretion Wt Injected Proteins 3 Accession Number 
60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1 CH60_YERE8 
Elongation factor Tu 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tuf1 PE=3 
SV=1 
EFTU1_YERE8 
Yop effector YopE OS=Yersinia enterocolitica GN=yopE PE=4 SV=1 Q7BRY7_YEREN  
Yop effector YopH OS=Yersinia enterocolitica GN=yopH PE=4 SV=1 Q7BRY8_YEREN  
Chaperone protein htpG OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=htpG PE=3 
SV=1 
HTPG_YERE8 
Chaperone protein dnaK OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=dnaK PE=2 
SV=1 
DNAK_YERE8 
Clp ATPase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=clpB PE=3 SV=1 A1JK85_YERE8 
Enolase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=eno PE=3 SV=1 ENO_YERE8 
Glyceraldehyde 3-phosphate dehydrogenase A OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 




YopD OS=Yersinia enterocolitica GN=yopD PE=4 SV=1 C5IZG7_YEREN  
Elongation factor Ts OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tsf PE=3 SV=1 EFTS_YERE8 
Elongation factor G OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=fusA PE=3 SV=1 A1JS54_YERE8 
Ribosome-recycling factor OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=frr PE=3 
SV=1 
RRF_YERE8 
Phosphoglycerate kinase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=pgk PE=3 
SV=1 
PGK_YERE8 
Elongation factor Tu A (Fragment) OS=Yersinia enterocolitica GN=tufA PE=4 SV=1 B6RBB1_YEREN 
3-oxoacyl-[acyl-carrier-protein] synthase I OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fabB PE=3 SV=1 
A1JKM0_YERE8 
Serine hydroxymethyltransferase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=glyA PE=3 SV=1 
GLYA_YERE8 
ATP-dependent protease ATPase subunit HslU OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=hslU PE=3 SV=1 
HSLU_YERE8 
Trigger factor OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tig PE=3 SV=1 TIG_YERE8 
Putative alkyl hydroperoxide reductase subunit c OS=Yersinia enterocolitica serotype O:8 / biotype 1B 
(strain 8081) GN=ahpC PE=4 SV=1 
A1JNT6_YERE8 
Formate acetyltransferase 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=pflB 
PE=1 SV=1 
A1JMG9_YERE8 
Aldehyde-alcohol dehydrogenase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=adhE PE=4 SV=1 
A1JQ89_YERE8 
Fructose-bisphosphate aldolase class II OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fbaA PE=4 SV=1 
A1JPQ8_YERE8 
ATP synthase subunit alpha OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=atpA 
PE=3 SV=1 
ATPA_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=cpxP PE=3 
SV=1 
A1JHZ1_YERE8 
3-oxoacyl-[acyl-carrier protein] reductase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fabG PE=3 SV=1 
A1JN73_YERE8 
Transaldolase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tal PE=3 SV=1 TAL_YERE8 
Methionyl-tRNA synthetase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=metG 
PE=3 SV=1 
SYM_YERE8 
LcrV OS=Yersinia enterocolitica GN=lcrV PE=4 SV=1 O87495_YEREN 
YopN OS=Yersinia enterocolitica GN=yopN PE=4 SV=1 O68333_YEREN 
DNA protection during starvation protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 




30S ribosomal protein S1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsA PE=4 
SV=1 
A1JMI7_YERE8 
DNA-directed RNA polymerase subunit alpha OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=rpoA PE=3 SV=1 
RPOA_YERE8 
PTS system, mannose-specific IIAB component OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=manX PE=4 SV=1 
A1JMB5_YERE8 
Deoxyribose-phosphate aldolase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=deoC PE=3 SV=1 
DEOC_YERE8 
50S ribosomal protein L10 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplJ PE=3 
SV=1 
RL10_YERE8 
Attachment invasion locus protein OS=Yersinia enterocolitica GN=ail PE=4 SV=1 D7PM19_YEREN  
Phosphoribosylaminoimidazole-succinocarboxamide synthase OS=Yersinia enterocolitica serotype O:8 / 
biotype 1B (strain 8081) GN=purC PE=3 SV=1 
PUR7_YERE8 
30S ribosomal protein S3 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsC PE=3 
SV=1 
RS3_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE3039 
PE=3 SV=1 
A1JP43_YERE8  
Branched-chain amino acid-binding protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=livK PE=3 SV=1 
A1JIC6_YERE8 
2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase OS=Yersinia enterocolitica serotype O:8 
/ biotype 1B (strain 8081) GN=dapD PE=3 SV=1 
DAPD_YERE8 
30S ribosomal protein S5 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsE PE=3 
SV=1 
RS5_YERE8 
Phosphate acetyltransferase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=pta 
PE=4 SV=1 
A1JLD1_YERE8 
50S ribosomal protein L1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplA PE=3 
SV=1 
RL1_YERE8 
50S ribosomal protein L4 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplD PE=3 
SV=1 
RL4_YERE8 
50S ribosomal protein L9 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplI PE=3 
SV=1 
RL9_YERE8 
Putative inner membrane protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=YE2442 PE=4 SV=1 
A1JRX6_YERE8  
50S ribosomal protein L3 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplC PE=3 
SV=1 
RL3_YERE8 
Global stress requirement protein GsrA OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=gsrA PE=3 SV=1 
A1JJQ8_YERE8  
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE2166  A1JPB8_YERE8 
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Secreted thiol:disulfide interchange protein DsbA OS=Yersinia enterocolitica serotype O:8 / biotype 1B 
(strain 8081) GN=dsbA PE=3 SV=1 
A1JHT2_YERE8 
Pyruvate kinase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=pykF PE=3 SV=1 A1JPB0_YERE8 
Virulence plasmid protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=yopQ PE=4 
SV=1 
A1JU64_YERE8  
PTS sytem, enzyme I component OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=ptsI 
PE=3 SV=1 
A1JL94_YERE8 
Probable alcohol dehydrogenase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=YE2821 PE=3 SV=1 
A1JU12_YERE8 
Oligopeptidase A OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=opdA PE=3 SV=1 A1JSQ3_YERE8 
ATP synthase subunit beta OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=atpD PE=3 
SV=1 
ATPB_YERE8  
Yop effector YopP OS=Yersinia enterocolitica GN=yopP PE=4 SV=1 O52162_YEREN 
Beta-lactamase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=ampC PE=4 SV=1 A1JRW9_YERE8  
DNA-directed RNA polymerase subunit beta' OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=rpoC PE=3 SV=1 
RPOC_YERE8 
Glutathione S-transferase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=gst PE=4 
SV=1 
A1JNU4_YERE8 
30S ribosomal protein S4 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsD PE=3 
SV=1 
RS4_YERE8 
50S ribosomal protein L11 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplK PE=3 
SV=1 
RL11_YERE8 
50S ribosomal protein L2 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplB PE=3 
SV=1 
RL2_YERE8  
Uridylate kinase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=pyrH PE=3 SV=1 PYRH_YERE8 
Adenylate kinase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=adk PE=3 SV=1 KAD_YERE8 
Acetate kinase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=ackA PE=3 SV=1 A1JLD2_YERE8 
DNA-binding protein Hns OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=hns PE=4 
SV=1 
A1JQA0_YERE8  
Transketolase 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tktA PE=4 SV=1 A1JPR2_YERE8 
GMP synthase [glutamine-hydrolyzing] OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=guaA PE=3 SV=1 
GUAA_YERE8 
Peptidyl-prolyl cis-trans isomerase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=ppiB PE=3 SV=1 
A1JNQ1_YERE8 
50S ribosomal protein L15 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplO PE=3  RL15_YERE8 
Protein tolB OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tolB PE=3 SV=1 TOLB_YERE8 
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Malate dehydrogenase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=mdh PE=3 
SV=1 
MDH_YERE8 
30S ribosomal protein S7 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsG PE=3 
SV=1 
RS7_YERE8 
Cell division protein ftsZ OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=ftsZ PE=3 
SV=1 
A1JJJ8_YERE8 
30S ribosomal protein S9 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsI PE=3 
SV=1 
RS9_YERE8 
DnaK suppressor protein homologue OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=dksA PE=4 SV=1 
A1JJP2_YERE8 
50S ribosomal protein L17 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplQ PE=3 
SV=1 
RL17_YERE8 
Translation initiation factor IF-3 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=infC 
PE=3 SV=1 
IF3_YERE8 
10 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groS PE=3 SV=1 CH10_YERE8  
DNA-directed RNA polymerase subunit beta OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=rpoB PE=3 SV=1 
RPOB_YERE8 
6-phosphofructokinase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=pfkA PE=3 
SV=1 
K6PF_YERE8 
Outer membrane protein C, porin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=meoA PE=3 SV=1 
A1JLE1_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=yrbC PE=3 
SV=1 
A1JRA6_YERE8 
Putative D-ribose-binding periplasmic protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=rbsB PE=3 SV=1 
A1JHS3_YERE8 
Cationic 19 kDa outer membrane protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=ompH PE=3 SV=1 
A1JP72_YERE8  
Adhesin yadA OS=Yersinia enterocolitica GN=yadA PE=1 SV=1 YADA1_YEREN 
UPF0234 protein YE3147 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE3147 
PE=3 SV=1 
Y3147_YERE8 
Putative uncharacterized protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=YE1738 PE=4 SV=1 
A1JLU4_YERE8 
Yop effector YopM OS=Yersinia enterocolitica GN=yopM PE=4 SV=1 P74988_YEREN 
Cysteine synthase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=cysK PE=3 SV=1 A1JL97_YERE8 
Single-stranded DNA-binding protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=ssb PE=4 SV=1 
A1JRR5_YERE8 





UPF0304 protein YE1336 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE1336 
PE=3 SV=1 
Y1336_YERE8 
Galactose-binding protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=mglB PE=3 
SV=1 
A1JU06_YERE8 
NADH:flavin oxidoreductase / NADH oxidase family protein OS=Yersinia enterocolitica serotype O:8 / 
biotype 1B (strain 8081) GN=YE2152 PE=4 SV=1 
A1JP27_YERE8 
cAMP-regulatory protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=crp PE=4 
SV=1 
A1JS98_YERE8  
Uracil phosphoribosyltransferase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=upp 
PE=3 SV=1 
UPP_YERE8 
Putative stringent starvation protein A OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=sspA PE=4 SV=1 
A1JR91_YERE8 
Putative lipoprotein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE1703 PE=4 
SV=1 
A1JME2_YERE8 
PTS system, glucose-specific IIA component OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=crr PE=4 SV=1 
A1JL89_YERE8 
Ribose-phosphate pyrophosphokinase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=prsA PE=3 SV=1 
A1JRV4_YERE8 
UPF0082 protein YE2395 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE2395 
PE=3 SV=1 
Y2395_YERE8 
Biotin carboxylase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=accC PE=4 SV=1 A1JRK3_YERE8 
D-lactate dehydrogenase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=ldhA PE=4 
SV=1 
A1JN94_YERE8 
Thioredoxin reductase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=trxB PE=3 
SV=1 
A1JME7_YERE8 
Putative lipoprotein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE1719 PE=3 
SV=1 
A1JLF7_YERE8 
Heat-shock chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=hslO PE=3 
SV=1 
A1JSE6_YERE8 
Protease OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=degQ PE=3 SV=1 A1JR98_YERE8 
Asparaginyl-tRNA synthetase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=asnS 
PE=3 SV=1 
SYN_YERE8 
Seryl-tRNA synthetase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=serS PE=3 
SV=1 
SYS_YERE8 
Transcription antitermination protein nusG OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=nusG PE=3 SV=1 
A1JIH5_YERE8 





Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE3737 
PE=3 SV=1 
A1JR88_YERE8 
Putative NAD(P)H-dependent FMN reductase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=ssuE PE=3 SV=1 
A1JT96_YERE8 
50S ribosomal protein L16 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplP PE=3 
SV=1 
RL16_YERE8 
Triosephosphate isomerase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tpiA 
PE=3 SV=1 
TPIS_YERE8 
ABC transporter protein, ATP-binding component OS=Yersinia enterocolitica serotype O:8 / biotype 1B 
(strain 8081) GN=YE0584 PE=4 SV=1 
A1JJB0_YERE8 
Peptidoglycan-associated lipoprotein Pal OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=pal PE=3 SV=1 
A1JRK6_YERE8 
Bifunctional purine biosynthesis protein purH OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=purH PE=3 SV=1 
PUR9_YERE8 
Secretion Wt Injected Proteins 4 Accession Number 
Translocator protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=yopD PE=4 SV=1 A1JU70_YERE8 
Yop effector YopE OS=Yersinia enterocolitica GN=yopE PE=4 SV=1 Q7BRY7_YEREN  
Type III secretion outer membrane protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=yopN PE=4  
A1JU81_YERE8 
Yop effector YopH OS=Yersinia enterocolitica GN=yopH PE=4 SV=1 Q7BRY8_YEREN  
Virulence-associated V antigen OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=lcrV 
PE=4 SV=1 
A1JU73_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE3039 
PE=3 SV=1 
A1JP43_YERE8 
60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1 CH60_YERE8  
Chaperone protein dnaK OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=dnaK PE=2 
SV=1 
DNAK_YERE8 
Yop type III secretion system effector protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=yopM PE=4  
A1JU68_YERE8 
Secretion Wt Injected Proteins 5 Accession Number 
Yop effector YopE OS=Yersinia enterocolitica GN=yopE PE=4 SV=1 Q7BRY7_YEREN  
60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1 CH60_YERE8  
Yop effector YopH OS=Yersinia enterocolitica GN=yopH PE=4 SV=1 Q7BRY8_YEREN  
Virulence-associated V antigen OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=lcrV 
PE=4 SV=1 
A1JU73_YERE8  
Translocator protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=yopD PE=4 SV=1 A1JU70_YERE8  
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YopN OS=Yersinia enterocolitica GN=yopN PE=4 SV=1 O68333_YEREN 
Yop effector YopM OS=Yersinia enterocolitica GN=yopM PE=4 SV=1 P74988_YEREN 
Secretion Wt Injected Proteins 6 Accession Number 
LcrV OS=Yersinia enterocolitica GN=lcrV PE=4 SV=1 O87495_YEREN 
Yop effector YopE OS=Yersinia enterocolitica GN=yopE PE=4 SV=1 Q7BRY7_YEREN  
YopD OS=Yersinia enterocolitica GN=yopD PE=4 SV=1 C5IZG7_YEREN  
YopN OS=Yersinia enterocolitica GN=yopN PE=4 SV=1 O68333_YEREN 
Yop effector YopH OS=Yersinia enterocolitica GN=yopH PE=4 SV=1 Q7BRY8_YEREN  
Yop effector YopM OS=Yersinia enterocolitica GN=yopM PE=4 SV=1 P74988_YEREN 
60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1 CH60_YERE8  
Secretion Mut Injected Proteins 1 Accession Number 
60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1 CH60_YERE8 
Elongation factor Tu 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tuf1 PE=3 
SV=1 
EFTU1_YERE8 
Chaperone protein dnaK OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=dnaK PE=2 
SV=1 
DNAK_YERE8 
Chaperone protein htpG OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=htpG PE=3 
SV=1 
HTPG_YERE8 
Enolase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=eno PE=3 SV=1 ENO_YERE8 
Clp ATPase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=clpB PE=3 SV=1 A1JK85_YERE8 
Glyceraldehyde 3-phosphate dehydrogenase A OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=gapA PE=3 SV=1 
A1JQH1_YERE8 
50S ribosomal protein L1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplA PE=3 
SV=1 
RL1_YERE8 
Branched-chain amino acid-binding protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=livK PE=3 SV=1 
A1JIC6_YERE8 
Global stress requirement protein GsrA OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=gsrA PE=3 SV=1 
A1JJQ8_YERE8  
Elongation factor G OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=fusA PE=3 SV=1 A1JS54_YERE8 
Elongation factor Ts OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tsf PE=3 SV=1 EFTS_YERE8 
3-oxoacyl-[acyl-carrier-protein] synthase I OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fabB PE=3 SV=1 
A1JKM0_YERE8 





Elongation factor Tu A (Fragment) OS=Yersinia enterocolitica GN=tufA PE=4 SV=1 B6RBB1_YEREN 
Trigger factor OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tig PE=3 SV=1 TIG_YERE8 
Primosomal protein n' OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=priA PE=4 
SV=1 
A1JI12_YERE8 
Methionyl-tRNA synthetase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=metG 
PE=3 SV=1 
SYM_YERE8 
ATP-dependent protease ATPase subunit HslU OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=hslU PE=3 SV=1 
HSLU_YERE8 
Putative alkyl hydroperoxide reductase subunit c OS=Yersinia enterocolitica serotype O:8 / biotype 1B 
(strain 8081) GN=ahpC PE=4 SV=1 
A1JNT6_YERE8 
50S ribosomal protein L10 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplJ PE=3 
SV=1 
RL10_YERE8 
3-oxoacyl-[acyl-carrier protein] reductase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fabG PE=3 SV=1 
A1JN73_YERE8 
Putative D-ribose-binding periplasmic protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=rbsB PE=3 SV=1 
A1JHS3_YERE8 
PTS sytem, enzyme I component OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=ptsI 
PE=3 SV=1 
A1JL94_YERE8 
Aldehyde-alcohol dehydrogenase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=adhE PE=4 SV=1 
A1JQ89_YERE8 
Secretion Mut Injected Proteins 2 Accession Number 
60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1 CH60_YERE8 
Elongation factor Tu 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tuf1 PE=3 
SV=1 
EFTU1_YERE8 
Chaperone protein dnaK OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=dnaK PE=2 
SV=1 
DNAK_YERE8 
Chaperone protein htpG OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=htpG PE=3 
SV=1 
HTPG_YERE8 
Elongation factor G OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=fusA PE=3 SV=1 A1JS54_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE3039 
PE=3 SV=1 
A1JP43_YERE8  
Methionyl-tRNA synthetase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=metG 
PE=3 SV=1 
SYM_YERE8 
Trigger factor OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tig PE=3 SV=1 TIG_YERE8 
Enolase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=eno PE=3 SV=1 ENO_YERE8 
Elongation factor Tu A (Fragment) OS=Yersinia enterocolitica GN=tufA PE=4 SV=1 B6RBB1_YEREN 
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Glyceraldehyde 3-phosphate dehydrogenase A OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=gapA PE=3 SV=1 
A1JQH1_YERE8 
3-oxoacyl-[acyl-carrier protein] reductase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fabG PE=3 SV=1 
A1JN73_YERE8 
Elongation factor Ts OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tsf PE=3 SV=1 EFTS_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE2166 
PE=3 SV=1 
A1JPB8_YERE8 
Branched-chain amino acid-binding protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=livK PE=3 SV=1 
A1JIC6_YERE8 
3-oxoacyl-[acyl-carrier-protein] synthase I OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fabB PE=3 SV=1 
A1JKM0_YERE8 
Secretion Mut Injected Proteins 3 Accession Number 
60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1 CH60_YERE8 
Elongation factor Tu 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tuf1 PE=3 
SV=1 
EFTU1_YERE8 
Chaperone protein dnaK OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=dnaK PE=2 
SV=1 
DNAK_YERE8 
Clp ATPase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=clpB PE=3 SV=1 A1JK85_YERE8 
Chaperone protein htpG OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=htpG PE=3 
SV=1 
HTPG_YERE8 
Glyceraldehyde 3-phosphate dehydrogenase A OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=gapA PE=3 SV=1 
A1JQH1_YERE8 
Elongation factor Ts OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tsf PE=3 SV=1 EFTS_YERE8 
Elongation factor G OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=fusA PE=3 SV=1 A1JS54_YERE8 
Putative alkyl hydroperoxide reductase subunit c OS=Yersinia enterocolitica serotype O:8 / biotype 1B 
(strain 8081) GN=ahpC PE=4 SV=1 
A1JNT6_YERE8 
Enolase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=eno PE=3 SV=1 ENO_YERE8 
Flagellar hook-associated protein 2 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fliD PE=4 SV=1 
A1JSR2_YERE8 
Elongation factor Tu A (Fragment) OS=Yersinia enterocolitica GN=tufA PE=4 SV=1 B6RBB1_YEREN 
Trigger factor OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tig PE=3 SV=1 TIG_YERE8 
FliC OS=Yersinia enterocolitica GN=fliC PE=4 SV=1 C9EHF4_YEREN 
30S ribosomal protein S1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsA PE=4 S A1JMI7_YERE8 
ATP-dependent protease ATPase subunit HslU OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 




Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE3039 
PE=3 SV=1 
A1JP43_YERE8  
Aldehyde-alcohol dehydrogenase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=adhE PE=4 SV=1 
A1JQ89_YERE8 
Ribosome-recycling factor OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=frr PE=3 
SV=1 
RRF_YERE8 
3-oxoacyl-[acyl-carrier protein] reductase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fabG PE=3 SV=1 
A1JN73_YERE8 
ATP synthase subunit beta OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=atpD PE=3 
SV=1 
ATPB_YERE8 
ATP synthase subunit alpha OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=atpA 
PE=3 SV=1 
ATPA_YERE8 
30S ribosomal protein S3 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsC PE=3 
SV=1 
RS3_YERE8 
3-oxoacyl-[acyl-carrier-protein] synthase I OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fabB PE=3 SV=1 
A1JKM0_YERE8 
DNA-directed RNA polymerase subunit alpha OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=rpoA PE=3 SV=1 
RPOA_YERE8 
Global stress requirement protein GsrA OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=gsrA PE=3 SV=1 
A1JJQ8_YERE8  
Protease OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=degQ PE=3 SV=1 A1JR98_YERE8 
50S ribosomal protein L3 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplC PE=3 
SV=1 
RL3_YERE8 
Fructose-bisphosphate aldolase class II OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fbaA PE=4 SV=1 
A1JPQ8_YERE8 
Formate acetyltransferase 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=pflB 
PE=1 SV=1 
A1JMG9_YERE8 
Methionyl-tRNA synthetase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=metG 
PE=3 SV=1 
SYM_YERE8 
Transaldolase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tal PE=3 SV=1 TAL_YERE8 
Adhesin, Ail protein OS=Yersinia enterocolitica (type O:3) GN=ail PE=4 SV=1 Q70AM3_YEREN 
30S ribosomal protein S5 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsE PE=3 
SV=1 
RS5_YERE8 
50S ribosomal protein L4 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplD PE=3 
SV=1 
RL4_YERE8 
50S ribosomal protein L9 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplI PE=3 SV RL9_YERE8 
Putative inner membrane protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 




Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=cpxP PE=3 
SV=1 
A1JHZ1_YERE8 
PTS sytem, enzyme I component OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=ptsI 
PE=3 SV=1 
A1JL94_YERE8 
PTS system, mannose-specific IIAB component OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=manX PE=4 SV=1 
A1JMB5_YERE8 
DNA protection during starvation protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=dps PE=3 SV=1 
DPS_YERE8 
Deoxyribose-phosphate aldolase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=deoC PE=3 SV=1 
DEOC_YERE8 
50S ribosomal protein L1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplA PE=3 
SV=1 
RL1_YERE8 
Protein recA OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=recA PE=3 SV=1 RECA_YERE8 
50S ribosomal protein L10 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplJ PE=3 
SV=1 
RL10_YERE8 
50S ribosomal protein L17 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplQ PE=3 
SV=1 
RL17_YERE8 
Branched-chain amino acid-binding protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=livK PE=3 SV=1 
A1JIC6_YERE8 
50S ribosomal protein L5 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplE PE=3 
SV=1 
RL5_YERE8 
30S ribosomal protein S2 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsB PE=3 
SV=1 
RS2_YERE8 
Serine hydroxymethyltransferase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=glyA PE=3 SV=1 
GLYA_YERE8 
DNA-directed RNA polymerase subunit beta' OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=rpoC PE=3 SV=1 
RPOC_YERE8 
Malate dehydrogenase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=mdh PE=3 
SV=1 
MDH_YERE8 
30S ribosomal protein S4 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsD PE=3 
SV=1 
RS4_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE2166 
PE=3 SV=1 
A1JPB8_YERE8 
Probable alcohol dehydrogenase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=YE2821 PE=3 SV=1 
A1JU12_YERE8 
Translation initiation factor IF-3 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=infC 
PE=3 SV=1 
IF3_YERE8 




Pyruvate kinase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=pykF PE=3 SV=1 A1JPB0_YERE8 
Cell division protein ftsZ OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=ftsZ PE=3 
SV=1 
A1JJJ8_YERE8 
Yop effector YopE OS=Yersinia enterocolitica GN=yopE PE=4 SV=1 Q7BRY7_YEREN  
Beta-lactamase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=ampC PE=4 SV=1 A1JRW9_YERE8  
Dihydrolipoyl dehydrogenase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=lpdA 
PE=3 SV=1 
A1JJM0_YERE8 
Asparaginyl-tRNA synthetase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=asnS 
PE=3 SV=1 
SYN_YERE8 
Uridylate kinase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=pyrH PE=3 SV=1 PYRH_YERE8 
Putative membrane protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=hflK 
PE=4 SV=1 
A1JIR7_YERE8 
Ribose-phosphate pyrophosphokinase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=prsA PE=3 SV=1 
A1JRV4_YERE8 
UPF0234 protein YE3147 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE3147 
PE=3 SV=1 
Y3147_YERE8 
50S ribosomal protein L2 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplB PE=3 
SV=1 
RL2_YERE8  
Triosephosphate isomerase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tpiA 
PE=3 SV=1 
TPIS_YERE8 
50S ribosomal protein L11 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplK PE=3 
SV=1 
RL11_YERE8 
Peptidyl-prolyl cis-trans isomerase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=ppiB PE=3 SV=1 
A1JNQ1_YERE8 
Seryl-tRNA synthetase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=serS PE=3 
SV=1 
SYS_YERE8 
30S ribosomal protein S7 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsG PE=3 
SV=1 
RS7_YERE8 
Outer membrane porin protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=YE2463 PE=4 SV=1 
A1JS30_YERE8 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex OS=Yersinia 
enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=aceF PE=3 SV=1 
A1JJL9_YERE8 
Flagellar hook-associated protein 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=flgK PE=3 SV=1 
A1JSZ7_YERE8 
Secretion Mut Injected Proteins 4 Accession Number 
60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1 CH60_YERE8 
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Elongation factor Tu 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tuf1 PE=3 
SV=1 
EFTU1_YERE8 
Enolase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=eno PE=3 SV=1 ENO_YERE8 
Glyceraldehyde 3-phosphate dehydrogenase A OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=gapA PE=3  
A1JQH1_YERE8 
Chaperone protein dnaK OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=dnaK PE=2 
SV=1 
DNAK_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=cpxP PE=3 
SV=1 
A1JHZ1_YERE8 
Outer membrane porin protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=YE2463 PE=4 SV=1 
A1JS30_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE2166 
PE=3 SV=1 
A1JPB8_YERE8 
Secretion Mut Injected Proteins 5 Accession Number 
60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1 CH60_YERE8 
Elongation factor Tu 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tuf1 PE=3 
SV=1 
EFTU1_YERE8 
Enolase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=eno PE=3 SV=1 ENO_YERE8 
Chaperone protein dnaK OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=dnaK PE=2 
SV=1 
DNAK_YERE8 
Glyceraldehyde 3-phosphate dehydrogenase A OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=gapA PE=3  
A1JQH1_YERE8 
Outer membrane porin protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=YE2463 PE=4 SV=1 
A1JS30_YERE8 
Attachment invasion locus protein OS=Yersinia enterocolitica GN=ail PE=4 SV=1 D7PM19_YEREN  
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE2166 
PE=3 SV=1 
A1JPB8_YERE8 
Secretion Mut Injected Proteins 6 Accession Number 
Chaperone protein dnaK OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=dnaK PE=2 
SV=1 
DNAK_YERE8 
Attachment invasion locus protein OS=Yersinia enterocolitica GN=ail PE=4 SV=1 D7PM19_YEREN  
Pulsed Anl labeling, 0-30 min Accession Number 
 60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1  CH60_YERE8 
 Elongation factor Tu 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tuf1 PE=3 
SV=1 
 EFTU1_YERE8 
 Major outer membrane lipoprotein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081)   A1JPB4_YERE8 
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 30S ribosomal protein S3 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsC PE=3 
SV=1 
 RS3_YERE8 
 50S ribosomal protein L1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplA PE=3 
SV=1 
 RL1_YERE8 
 Putative uncharacterized protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=YE3042 PE=4 SV=1 
 A1JNW8_YERE8 
 Elongation factor Tu A (Fragment) OS=Yersinia enterocolitica GN=tufA PE=4 SV=1  B6RBB1_YEREN 
 Elongation factor Tu (Fragment) OS=Yersinia enterocolitica GN=tuf PE=4 SV=1  D1MWR3_YEREN 
 Elongation factor Ts OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tsf PE=3 SV=1  EFTS_YERE8 
 Flagellar basal-body rod protein flgB OS=Yersinia enterocolitica GN=flgB PE=3 SV=3  FLGB_YEREN 
 Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE1132 
PE=3 SV=1 
 A1JL02_YERE8 
 YopD OS=Yersinia enterocolitica GN=yopD PE=4 SV=1  D0FH99_YEREN 
 Preprotein translocase subunit secY OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=secY PE=3 SV=1 
 A1JS07_YERE8 
 Citrate lyase acyl carrier protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=citD 
PE=3 SV=1 
 CITD_YERE8 
 DNA-binding protein Hns OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=hns PE=4 
SV=1 
 A1JQA0_YERE8 
 Pseudouridine synthase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rluA PE=3 
SV=1 
 A1JJF9_YERE8 
 Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE3439 
PE=3 SV=1 
 A1JPV0_YERE8 
Pulsed Anl labeling, 30-60 min Accession Number 
 Outer membrane virulence protein yopE OS=Yersinia enterocolitica GN=yopE PE=2 SV=1  YOPE_YEREN 
 60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1  CH60_YERE8 
 Tyrosine-protein phosphatase yopH OS=Yersinia enterocolitica GN=yopH PE=1 SV=1  YOPH_YEREN 
 Major outer membrane lipoprotein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=lpp PE=3 SV=1 
 A1JPB4_YERE8 
 Elongation factor Tu 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tuf1 PE=3 
SV=1 
 EFTU1_YERE8 
 30S ribosomal protein S3 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsC PE=3 
SV=1 
 RS3_YERE8 
 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase OS=Yersinia enterocolitica serotype O:8 / 
biotype 1B (strain 8081) GN=gpmA PE=3 SV=1 
 GPMA_YERE8 
 Elongation factor Tu (Fragment) OS=Yersinia enterocolitica GN=tuf PE=4 SV=1  D1MWR3_YEREN 
87 
 
 Elongation factor Tu A (Fragment) OS=Yersinia enterocolitica GN=tufA PE=4 SV=1  B6RBB1_YEREN 
 Pseudouridine synthase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rluA PE=3 
SV=1 
 A1JJF9_YERE8 
 Putative uncharacterized protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=YE3042 PE=4 SV=1 
 A1JNW8_YERE8 
 Primosomal protein n' OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=priA PE=4 
SV=1 
 A1JI12_YERE8 
 Translocator protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=yopD PE=4 
SV=1 
 A1JU70_YERE8 
 50S ribosomal protein L15 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplO PE=3 
SV=1 
 RL15_YERE8 
Pulsed Anl labeling, 60-90 min Accession Number 
 Tyrosine-protein phosphatase yopH OS=Yersinia enterocolitica GN=yopH PE=1 SV=1  YOPH_YEREN 
 Outer membrane virulence protein yopE OS=Yersinia enterocolitica GN=yopE PE=2 SV=1  YOPE_YEREN 
 60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1  CH60_YERE8 
 YopD OS=Yersinia enterocolitica GN=yopD PE=4 SV=1  D0FH99_YEREN 
 Yop effector YopP OS=Yersinia enterocolitica GN=yopP PE=4 SV=1  O52162_YEREN 
 Elongation factor Tu 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tuf1 PE=3 
SV=1 
 EFTU1_YERE8 
 Elongation factor Tu 2 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tuf2 PE=3 
SV=1 
 EFTU2_YERE8 
 30S ribosomal protein S3 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsC PE=3 
SV=1 
 RS3_YERE8 
 YopN OS=Yersinia enterocolitica GN=yopN PE=4 SV=1  O68333_YEREN 
 Type III secretion outer membrane protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=yopN PE=4 SV=1 
 A1JU81_YERE8 
 Chaperone protein dnaK OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=dnaK PE=2 
SV=1 
 DNAK_YERE8 
 Elongation factor Tu (Fragment) OS=Yersinia enterocolitica GN=tuf PE=4 SV=1  D1MWR3_YEREN 
 50S ribosomal protein L1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplA PE=3 
SV=1 
 RL1_YERE8 
 Glyceraldehyde 3-phosphate dehydrogenase A OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=gapA PE=3 SV=1 
 A1JQH1_YERE8 
 30S ribosomal protein S5 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsE PE=3 
SV=1 
 RS5_YERE8 
 Pseudouridine synthase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rluA PE=3   A1JJF9_YERE8 
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 Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE3039 
PE=3 SV=1 
 A1JP43_YERE8 
 Elongation factor Ts OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tsf PE=3 SV=1  EFTS_YERE8 
 Flagellar basal-body rod protein flgB OS=Yersinia enterocolitica GN=flgB PE=3 SV=3  FLGB_YEREN 
 Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE1132 
PE=3 SV=1 
 A1JL02_YERE8 
 30S ribosomal protein S8 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsH PE=3 
SV=1 
 RS8_YERE8 
 Major outer membrane lipoprotein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=lpp PE=3 SV=1 
 A1JPB4_YERE8 
 Putative prophage integrase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE0993 
PE=4 SV=1 
 A1JKH9_YERE8 
 PduX OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=pduX PE=4 SV=1  A1JSN3_YERE8 
 Yop effector YopM OS=Yersinia enterocolitica GN=yopM PE=4 SV=1  P74988_YEREN 
 Putative methyl-accepting chemotaxis protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=aer PE=4 SV=1 
 A1JLQ5_YERE8 
 50S ribosomal protein L5 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplE PE=3 
SV=1 
 RL5_YERE8 
 Arginine transport system permease protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=artM PE=3 SV=1 
 A1JM76_YERE8 
 Primosomal protein n' OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=priA PE=4 
SV=1 
 A1JI12_YERE8 
Pulsed Anl labeling, 90-180 min Accession Number 
 Tyrosine-protein phosphatase yopH OS=Yersinia enterocolitica GN=yopH PE=1 SV=1  YOPH_YEREN 
 Outer membrane virulence protein yopE OS=Yersinia enterocolitica GN=yopE PE=2 SV=1  YOPE_YEREN 
 60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1  CH60_YERE8 
 Protein yopD OS=Yersinia enterocolitica GN=yopD PE=4 SV=1  YOPD_YEREN 
 Putative outer membrane virulence protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=YEP0053 PE=3 SV=1 
 A1JUA9_YERE8 
 Translocator protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=yopD PE=4 
SV=1 
 A1JU70_YERE8 
 Yop effector YopP OS=Yersinia enterocolitica GN=yopP PE=4 SV=1  O52162_YEREN 
 YopN OS=Yersinia enterocolitica GN=yopN PE=4 SV=1  O68333_YEREN 





 Type III secretion system effector protein (Putative targeted effector protein) OS=Yersinia enterocolitica 
serotype O:8 / biotype 1B (strain 8081) GN=yopJ PE=4 SV=1 
 A1JUC5_YERE8 
 Type III secretion outer membrane protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=yopN PE=4 SV=1 
 A1JU81_YERE8 
 Yop effector YopM OS=Yersinia enterocolitica GN=yopM PE=4 SV=1  P74988_YEREN 
 Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=cpxP PE=3 
SV=1 
 A1JHZ1_YERE8 
 Attachment invasion locus protein (Fragment) OS=Yersinia enterocolitica (type O:3) GN=ail PE=4 SV=1  Q4ZJF6_YEREN 
 Protein yopQ OS=Yersinia enterocolitica GN=yopQ PE=4 SV=1  YOPQ_YEREN 
 Protein kinase YopO OS=Yersinia enterocolitica GN=yopO PE=4 SV=1  O85239_YEREN 
 Chaperone protein htpG OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=htpG PE=3 
SV=1 
 HTPG_YERE8 
 Chaperone protein dnaK OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=dnaK PE=2 
SV=1 
 DNAK_YERE8 
 Major outer membrane lipoprotein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=lpp PE=3 SV=1 
 A1JPB4_YERE8 
 Elongation factor Tu A (Fragment) OS=Yersinia enterocolitica GN=tufA PE=4 SV=1  B6RBB1_YEREN 
 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase OS=Yersinia enterocolitica serotype O:8 / 
biotype 1B (strain 8081) GN=gpmA PE=3 SV=1 
 GPMA_YERE8 
 ORF protein (Fragment) OS=Yersinia enterocolitica GN=ORF PE=4 SV=1  Q56881_YEREN 
 Protein yopB OS=Yersinia enterocolitica GN=yopB PE=4 SV=1  YOPB_YEREN 
 Virulence-associated V antigen OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=lcrV 
PE=4 SV=1 
 A1JU73_YERE8 
 Regulatory protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=yscM2 PE=4 SV=1  A1JUC6_YERE8 
 30S ribosomal protein S3 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsC PE=3 
SV=1 
 RS3_YERE8 
 Peptidoglycan-associated lipoprotein Pal OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=pal PE=3 SV=1 
 A1JRK6_YERE8 
 Outer membrane porin protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=YE2463 PE=4 SV=1 
 A1JS30_YERE8 
 50S ribosomal protein L1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplA PE=3 
SV=1 
 RL1_YERE8 
 Global stress requirement protein GsrA OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=gsrA PE=3 SV=1 
 A1JJQ8_YERE8 
 Enolase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=eno PE=3 SV=1  ENO_YERE8 
 Putative alkyl hydroperoxide reductase subunit c OS=Yersinia enterocolitica serotype O:8 / biotype 1B   A1JNT6_YERE8 
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 Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE3039 
PE=3 SV=1 
 A1JP43_YERE8 
 Yop proteins translocation protein M OS=Yersinia enterocolitica GN=yscM PE=2 SV=1  YSCM_YEREN 
 Pseudouridine synthase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rluA PE=3 
SV=1 
 A1JJF9_YERE8 
 Protein tolB OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tolB PE=3 SV=1  TOLB_YERE8 
 Elongation factor Ts OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tsf PE=3 SV=1  EFTS_YERE8 
 Putative transcription accessory protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=teX PE=4 SV=1 
 A1JSG5_YERE8 
 DNA-directed RNA polymerase subunit beta' OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=rpoC PE=3 SV=1 
 RPOC_YERE8 
 Gluconate utilization system Gnt-I transcriptional repressor OS=Yersinia enterocolitica serotype O:8 / 
biotype 1B (strain 8081) GN=gntR PE=4 SV=1 
 A1JSK2_YERE8 
 LysR-family transcriptional regulatory protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=YE3720 PE=4 SV=1 
 A1JR54_YERE8 
 Ni/Fe-hydrogenase 2 b-type cytochrome subunit OS=Yersinia enterocolitica serotype O:8 / biotype 1B 
(strain 8081) GN=hybB PE=4 SV=1 
 A1JQK5_YERE8 
 PduX OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=pduX PE=4 SV=1  A1JSN3_YERE8 
 Putative methyl-accepting chemotaxis protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=aer PE=4 SV=1 
 A1JLQ5_YERE8 
 Recombinase OS=Yersinia enterocolitica GN=ORF2 PE=4 SV=1  Q70W49_YEREN 
 Probable terminase, ATPase subunit OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=gpP PE=4 SV=1 
 A1JNI4_YERE8 
 Protease OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=degQ PE=3 SV=1  A1JR98_YERE8 
 Glyceraldehyde 3-phosphate dehydrogenase A OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=gapA PE=3 SV=1 
 A1JQH1_YERE8 
 Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=yacK PE=3 
SV=1 
 A1JJN0_YERE8 
Secretion Wt Injected Proteins Gentamicin Accession Number 
Yop effector YopE OS=Yersinia enterocolitica GN=yopE PE=4 SV=1 Q7BRY7_YEREN  
Yop effector YopH OS=Yersinia enterocolitica GN=yopH PE=4 SV=1 Q7BRY8_YEREN  
LcrV OS=Yersinia enterocolitica GN=lcrV PE=4 SV=1 O87495_YEREN 
Elongation factor Tu 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tuf1 PE=3 
SV=1 
EFTU1_YERE8 
Translocator protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=yopD PE=4 SV=1 A1JU70_YERE8  
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Chaperone protein dnaK OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=dnaK PE=2 
SV=1 
DNAK_YERE8 
60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1 CH60_YERE8  
Chaperone protein htpG OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=htpG PE=3 
SV=1 
HTPG_YERE8 
YopN OS=Yersinia enterocolitica GN=yopN PE=4 SV=1 O68333_YEREN 
Elongation factor Tu A (Fragment) OS=Yersinia enterocolitica GN=tufA PE=4 SV=1 B6RBB1_YEREN 
Elongation factor G OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=fusA PE=3 SV=1 A1JS54_YERE8 
Methionyl-tRNA synthetase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=metG 
PE=3 SV=1 
SYM_YERE8 
Secretion Wt Media Secreted Proteins 1 Accession Number 
YopD OS=Yersinia enterocolitica GN=yopD PE=4 SV=1 C5IZG7_YEREN  
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE2166 
PE=3 SV=1 
A1JPB8_YERE8 
Yop effector YopE OS=Yersinia enterocolitica GN=yopE PE=4 SV=1 Q7BRY7_YEREN  
Putative outer membrane porin A protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=ompA PE=3 SV=1 
A1JMT3_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=cpxP PE=3 
SV=1 
A1JHZ1_YERE8 
LcrV OS=Yersinia enterocolitica GN=lcrV PE=4 SV=1 O87495_YEREN 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE2930 
PE=3 SV=1 
A1JRP4_YERE8 
Protein tolB OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tolB PE=3 SV=1 TOLB_YERE8 
Putative D-ribose-binding periplasmic protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=rbsB PE=3 SV=1 
A1JHS3_YERE8 
Arginine-binding periplasmic protein 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=artI PE=3 SV=1 
A1JM82_YERE8 
Branched-chain amino acid-binding protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=livK PE=3 SV=1 
A1JIC6_YERE8 
Secreted thiol:disulfide interchange protein DsbA OS=Yersinia enterocolitica serotype O:8 / biotype 1B 
(strain 8081) GN=dsbA PE=3 SV=1 
A1JHT2_YERE8 
Yop effector YopH OS=Yersinia enterocolitica GN=yopH PE=4 SV=1 Q7BRY8_YEREN  
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE3039 
PE=3 SV=1 
A1JP43_YERE8  





Iron(III)-binding periplasmic protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=yfuA PE=3 SV=1 
A1JLH5_YERE8 
YopB OS=Yersinia enterocolitica GN=yopB PE=4 SV=1 C5IZG6_YEREN  
Putrescine-binding periplasmic protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=potF PE=3 SV=1 
A1JM59_YERE8 
Outer-membrane lipoprotein carrier protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=lolA PE=3 SV=1 
LOLA_YERE8 
Cationic 19 kDa outer membrane protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=ompH PE=3 SV=1 
A1JP72_YERE8  
Peptidoglycan-associated lipoprotein Pal OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=pal PE=3 SV=1 
A1JRK6_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE2080 
PE=3 SV=1 
A1JN51_YERE8 
Periplasmic dipeptide transport protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=dppA PE=3 SV=1 
A1JSV0_YERE8 
Secretion Wt Media Secreted Proteins 2 Accession Number 
YopD OS=Yersinia enterocolitica GN=yopD PE=4 SV=1 C5IZG7_YEREN  
Yop effector YopH OS=Yersinia enterocolitica GN=yopH PE=4 SV=1 Q7BRY8_YEREN  
Beta-lactamase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=ampC PE=4 SV=1 A1JRW9_YERE8  
LcrV OS=Yersinia enterocolitica GN=lcrV PE=4 SV=1 O87495_YEREN  
Yop effector YopE OS=Yersinia enterocolitica GN=yopE PE=4 SV=1 Q7BRY7_YEREN  
YopB OS=Yersinia enterocolitica GN=yopB PE=4 SV=1 C5IZG6_YEREN  
Branched-chain amino acid-binding protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=livK PE=3 SV=1 
A1JIC6_YERE8 
Putative type III secretion protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=yscH PE=3 SV=1 
A1JU99_YERE8  
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=cpxP PE=3 
SV=1 
A1JHZ1_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE2166 
PE=3 SV=1 
A1JPB8_YERE8 
YscP OS=Yersinia enterocolitica (type O:2.3) GN=yscP PE=4 SV=1 B6DX70_YEREN  
Secreted thiol:disulfide interchange protein DsbA OS=Yersinia enterocolitica serotype O:8 / biotype 1B 
(strain 8081) GN=dsbA PE=3 SV=1 
A1JHT2_YERE8 
Periplasmic dipeptide transport protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=dppA PE=3 SV=1 
A1JSV0_YERE8 
60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1 CH60_YERE8  
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Elongation factor Tu 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tuf1 PE=3 
SV=1 
EFTU1_YERE8 
Maltose-binding periplasmic protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=malE PE=3 SV=1 
A1JRV3_YERE8 
Periplasmic oligopeptide-binding protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=oppA PE=3 SV=1 
A1JQ72_YERE8 
Putative D-ribose-binding periplasmic protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=rbsB PE=3 SV=1 
A1JHS3_YERE8 
Secretion Wt Media Secreted Proteins 3 Accession Number 
YopD OS=Yersinia enterocolitica GN=yopD PE=4 SV=1 C5IZG7_YEREN  
Yop effector YopH OS=Yersinia enterocolitica GN=yopH PE=4 SV=1 Q7BRY8_YEREN 
Yop effector YopE OS=Yersinia enterocolitica GN=yopE PE=4 SV=1 Q7BRY7_YEREN 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=cpxP PE=3 
SV=1 
A1JHZ1_YERE8 
Beta-lactamase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=ampC PE=4 SV=1 A1JRW9_YERE8  
Global stress requirement protein GsrA OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=gsrA PE=3 SV=1 
A1JJQ8_YERE8  
YopB OS=Yersinia enterocolitica GN=yopB PE=4 SV=1 C5IZG6_YEREN  
Putative outer membrane porin A protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=ompA PE=3 SV=1 
A1JMT3_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE3039 
PE=3 SV=1 
A1JP43_YERE8  
Putative type III secretion protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=yscH PE=3 SV=1 
A1JU99_YERE8  
Protease OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=degQ PE=3 SV=1 A1JR98_YERE8 
50S ribosomal protein L9 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplI PE=3 
SV=1 
RL9_YERE8 
3-oxoacyl-[acyl-carrier-protein] synthase I OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fabB PE=3 SV=1 
A1JKM0_YERE8 
Outer membrane porin protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=YE2463 PE=4 SV=1 
A1JS30_YERE8 
50S ribosomal protein L1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplA PE=3 
SV=1 
RL1_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE2166 
PE=3 SV=1 
A1JPB8_YERE8 
Secretion Mut Media Secreted Proteins 1 Accession Number 
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Branched-chain amino acid-binding protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=livK PE=3 SV=1 
A1JIC6_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=cpxP PE=3 
SV=1 
A1JHZ1_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE2166 
PE=3 SV=1 
A1JPB8_YERE8 
Putative outer membrane porin A protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=ompA PE=3 SV=1 
A1JMT3_YERE8 
Protein tolB OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tolB PE=3 SV=1 TOLB_YERE8 
Putative D-ribose-binding periplasmic protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=rbsB PE=3 SV=1 
A1JHS3_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE3039 
PE=3 SV=1 
A1JP43_YERE8  
Secreted thiol:disulfide interchange protein DsbA OS=Yersinia enterocolitica serotype O:8 / biotype 1B 
(strain 8081) GN=dsbA PE=3 SV=1 
A1JHT2_YERE8 
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=YE2930 
PE=3 SV=1 
A1JRP4_YERE8 
Osmotically inducible protein Y OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=osmY 
PE=3 SV=1 
A1JJ93_YERE8 
Putrescine-binding periplasmic protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=potF PE=3 SV=1 
A1JM59_YERE8 
Secretion Mut Media Secreted Proteins 2 Accession Number 
FliC OS=Yersinia enterocolitica GN=fliC PE=4 SV=1 C9EHF4_YEREN 
Flagellar hook-associated protein 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=flgK PE=3 SV=1 
A1JSZ7_YERE8 
Flagellar hook-associated protein 2 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fliD PE=4 SV=1 
A1JSR2_YERE8 
60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1 CH60_YERE8  
Global stress requirement protein GsrA OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=gsrA PE=3 SV=1 
A1JJQ8_YERE8  
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=cpxP PE=3 
SV=1 
A1JHZ1_YERE8 
3-oxoacyl-[acyl-carrier protein] reductase OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fabG PE=3 SV=1 
A1JN73_YERE8 
3-oxoacyl-[acyl-carrier-protein] synthase I OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=fabB PE=3 SV=1 
A1JKM0_YERE8 





Glyceraldehyde 3-phosphate dehydrogenase A OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
8081) GN=gapA PE=3 SV=1 
A1JQH1_YERE8 
Elongation factor Tu A (Fragment) OS=Yersinia enterocolitica GN=tufA PE=4 SV=1 B6RBB1_YEREN  
50S ribosomal protein L10 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rplJ PE=3 
SV=1 
RL10_YERE8 
FliC3 OS=Yersinia enterocolitica GN=fliC3 PE=4 SV=1 C9EHF3_YEREN 
30S ribosomal protein S3 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=rpsC PE=3 
SV=1 
RS3_YERE8 
Secretion Mut Media Secreted Proteins 3 Accession Number 
60 kDa chaperonin OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=groL PE=3 SV=1 CH60_YERE8  
Global stress requirement protein GsrA OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) 
GN=gsrA PE=3 SV=1 
A1JJQ8_YERE8  
Putative exported protein OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=cpxP PE=3 
SV=1 
A1JHZ1_YERE8 
Elongation factor Tu 1 OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 8081) GN=tuf1 PE=3 
SV=1 
EFTU1_YERE8 
Glyceraldehyde 3-phosphate dehydrogenase A OS=Yersinia enterocolitica serotype O:8 / biotype 1B (strain 
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A Genetically Encoded AND Gate for Cell-Targeted 




We describe a genetic AND gate for cell-targeted metabolic labeling and proteomic analysis in 
complex cellular systems. The centerpiece of the AND gate is a bisected methionyl-tRNA 
synthetase (MetRS) that charges the Met surrogate azidonorleucine (Anl) to tRNA
Met
. Cellular 
protein labeling occurs only upon activation of two different promoters that drive expression of 
the N- and C-terminal fragments of the bisected MetRS.  Anl-labeled proteins can be tagged with 
fluorescent dyes or affinity reagents via either copper-catalyzed or strain-promoted azide-alkyne 
cycloaddition. Protein labeling is apparent within five minutes after addition of Anl to bacterial 
cells in which the AND gate has been activated. This method allows spatial and temporal control 
of proteomic labeling and identification of proteins made in specific cellular subpopulations.  The 
approach is demonstrated by selective labeling of proteins in bacterial cells immobilized in the 
center of a laminar-flow microfluidic channel, where they are exposed to overlapping, opposed 
gradients of inducers of the N- and C-terminal MetRS fragments.  The observed labeling profile 
is predicted accurately from the strengths of the individual input signals. 
 
 
This chapter has been published as: 
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The bio-orthogonal non-canonical amino acid tagging (BONCAT) method of proteomic analysis 
enables enrichment and identification of selected subsets of cellular proteins
1
. The initial 
demonstration of the BONCAT method used the methionine (Met) surrogate azidohomoalanine 
(Aha) as a metabolic label; addition of Aha to cells at selected time points provides temporal 
control of proteomic labeling. In contrast to Aha, which is incorporated into proteins in all cells 
through the action of the wild-type methionyl-tRNA synthetase (MetRS), the bulkier Met 
surrogate azidonorleucine (Anl) can be used to restrict labeling to cells that express a mutant 
MetRS (designated NLL-MetRS)
2
. Sensitivity to cell state (e.g., to oxidative stress) can be 
achieved by controlling expression of the mutant synthetase with carefully chosen promoters
3
. 
However, it is not yet possible to specify cell state more precisely in such experiments, and to 
control proteomic labeling by integrating multiple signals to activate the NLL-MetRS.   
Here we introduce a new approach in which multiple promoters (P1 and P2) are used to regulate 
Anl incorporation into the E. coli proteome. The approach relies on construction of a split MetRS 
that generates a translational output only in cells in which the P1 and P2 inputs are 





Results and Discussion 
We used protein fragment complementation to make a bisected MetRS
4
, prompted by the work of 
Schimmel and coworkers who showed that the E. coli MetRS could be cut at six different sites to 
yield functional split variants
5
. To assess which of the peptide bonds in the MetRS backbone 
should be broken to create fragments that associate to form the most active enzymes, transposase 
mutagenesis was used to construct a library of vectors that express split MetRS
6
 and active 
variants were selected via bacterial complementation. To avoid variants that require only a single 
fragment for activity, a gene fragment encoding MetRS residues 1-548 (designated MetRS 
henceforth) was used to construct the vector library (Figure 3.2a). The 1-548 variant is the 
smallest MetRS fragment that has been reported to exhibit near-native activity and stability
7
. E. 
coli strain CS50 was used for selecting functional variants on medium lacking Met
8
; growth was 
visible only when cells expressed an active MetRS (Figure 3.2b). 
Selection by CS50-DE3 complementation yielded hundreds of colonies with varying 
complementation strengths (Figure S3.1). DNA sequencing of these clones identified MetRS 
variants with backbone cleavage sites lying within all four domains of the synthetase (Figure 
3.2c, Table TS3.1). Variants with the greatest complementation strength were cut within the 
connective polypeptide and Rossmann domains. Mapping the locations of backbone cleavage 
onto the MetRS structure (Figure 3.2d) revealed that cleavage in these domains yields fragments 
that make large numbers of intermolecular residue-residue contacts in the assembled enzyme 
(Figure S3.2). 
We have shown previously that two MetRS triple mutants, L13N/Y260/H301 (NLL) and 
L13P/Y260/H301 (PLL), charge Anl with good efficiency
9
. The corresponding mutations were 
introduced into the vectors encoding the bisected MetRS variants that exhibited the strongest 
complementation (those with cut sites at residues 48, 131, 183, 247, 272, 278, and 456) (Figure 
S3.3). E. coli CS50-DE3 cells transformed with each mutant vector were grown to mid-log phase 
in liquid culture, and labeling was initiated by addition of 1 mM Anl (1, Figure 3.2e). After 1 h, 
cells were lysed and total cellular proteins were treated with alkyne-tetramethylrhodamine 
(TAMRA) dye (2, Figure 3.2e) for labeling via copper-catalyzed azide-alkyne cycloaddition (3, 
Figure 3.2e)
10-12
. After SDS-PAGE, TAMRA-labeled proteins were detected by in-gel 
fluorescence imaging (Figure 3.2f). All fourteen of the NLL and PLL split MetRS variants 
enabled Anl incorporation into cellular proteins. On the basis of this result and the strong 
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complementation observed for wild-type MetRS(247) (Figure 3.2b), NLL-MetRS(247) was 
selected for further development. 
To construct an AND gate for controlled labeling of cellular proteins with Anl, the coding 
sequences for the N- and C-terminal fragments of NLL-MetRS(247) were placed in a pair of 
vectors under control of PT5 and PBAD promoters, respectively. As expected, NLL-MetRS(247) 
showed IPTG- and arabinose-dependent activity, with the highest levels of metabolic protein 
labeling observed in cultures supplemented with both inducers. To be useful as an AND gate, the 
system described here should be active only when both IPTG and arabinose are present – not in 
the presence of a single inducer. However, we observed some activity even in the absence of 
IPTG, presumably as a consequence of leaky expression of the N-terminal fragment (Figure 
S3.4). This activity was readily eliminated by catabolite repression (Figure S3.5)
13
; in glucose-
supplemented media, Anl labeling was observed only upon addition of both IPTG and arabinose 
(Figure 3.3a-c).  
To investigate how the output of the AND gate was controlled by variation in input levels, we 
used varying combinations of arabinose and IPTG concentrations to induce MetRS fragment 
expression and Anl incorporation. We found concentration-dependent expression of the N- and 
C-terminal fragments (Figure S3.6) and steep transitions between the on and off states (Figure 
3.3d, and Figure S3.6). The time-dependence of Anl-labeling under control of the activated AND 
gate was monitored by detection of labeled proteins with an azadibenzocyclooctyne-TAMRA 
dye; labeling was apparent within 5 min after addition of Anl (Figure 3.3e). The rate of AND-gate 
activation upon induction by IPTG and arabinose was also measured (Figure S3.7). The rate of 
activation will depend on the particular promoters used to drive fragment expression. 
Spatially controlled proteomic labeling of cells within complex multi-cellular systems is useful 
for study of a variety of important biological phenomena including biofilm formation and 
developmental patterning
14,15
. The MetRS AND gate provides a useful solution to such challenges 
because it can be activated by spatially regulated signals. As a step toward this goal, we sought to 
control Anl labeling in cells that are subjected to spatial gradients of activators. A laminar-flow 
microfluidic channel was used to expose surface-immobilized bacterial cells harboring the AND 
gate to opposing gradients of IPTG and arabinose. Anl incorporation should occur only in cells 
that encounter sufficient levels of both inducers (Figure 3.4a). The diffusion of IPTG and 
arabinose in the microfluidic channel was modeled (Figure S3.8) and diffusion analysis results 
were used to estimate inducer profiles across the width of the channel (Figure 3.4b).  
104 
 
Dye diffusion experiments enabled visualization of similar gradients during flow, and confirmed 
the modeling results (Figure S3.9). To estimate the strengths of the individual AND-gate inputs, 
E. coli DH10B cells were transformed with constructs that expressed GFP under control of the 
same PT5 and PBAD promoters that were used for expression of the N- and C-terminal fragments 
of the AND gate. GFP expression revealed the activation profile of each promoter as a function of 
position across the width of the channel (Figure 3.4c-e). 
Cells harboring the AND gate were immobilized in the microfluidic channel, exposed to the 
inducer gradients and Anl for 4 h, then fixed and treated with an alkyne-functionalized 
AlexaFluor 488 dye. Fluorescence imaging showed that Anl incorporation was confined to cells 
in the center of the channel (Figure 3.4e).  
To confirm that the observed labeling profile is predictable from the strengths of the input signals, 
we used the activation profile of each promoter as reported by GFP expression. As expected, 
either for a bimolecular binding equilibrium or for a Boolean AND operation, the scalar product 
of the inputs closely matched the output signal as measured by Anl incorporation (Figure 3.4e). 
This result suggests that the protein labeling profile can be adjusted, by tuning the input promoter 
strengths, to be more- or less-sharply dependent on the gradients of local activators or 
morphogens. Conversely, using endogenous promoters to drive the AND gate should provide 
labeling outputs that closely match spatial patterns of promoter activation.  
 
Conclusions 
This work introduces a new AND gate based on protein fragment complementation
4
. The AND 
gate can be used to restrict protein labeling to subsets of cells in which specified promoters or 
genes of interest are active. Because the AND gate is genetically encoded, it should be easily 
integrated with previously reported transcription-based logic gates (e.g., AND, OR, NOR, and 
XOR gates)
13,16,17
 to create more complex genetic circuits with protein labeling as the output. As 
shown previously
1,18,19
, azide-labeled proteins can be affinity-tagged and purified for analysis by 
mass spectrometry. Thus the AND gate provides a powerful new tool for targeted analysis of 





Materials and Methods  
Creating a Library of Vectors that Express Fragmented MetRS 
A metG fragment encoding MetRS residues 1-548 was cloned into the NcoI and SalI sites of 
pPROEX1 (Life Technologies) to yield pPROEX-MetRS, a vector that uses a leaky Trc promoter 
for expression. To make this vector compatible with library construction 
6
, it was digested (XbaI 
and SpeI) and ligated to create pPROEX-MetRS∆NotI-XS1, which lacks a NotI site. This vector 
was used for library construction. A NotI-flanked artificial transposon encoding chloramphenicol 
resistance (M1-CamR, Finnzymes) was inserted into pPROEX-MetRS∆NotI-XS1 using 
HyperMu, a mutant MuA transposase with increased activity (Epicentre). Reaction mixtures (20 
µL) containing HyperMu buffer, 300 ng of pPROEX-MetRS∆NotI-XS1, 100 ng M1-CamR, and 
1 U of HyperMu MuA transposase were incubated at 37°C for 16 h. Reactions were terminated 
by adding 2 µL of HyperMu 10x Stop Solution, gently mixing, and incubating each reaction at 
70°C for 10 min. Total DNA was purified (Zymo Research) and electroporated into E. coli 
MegaX DH10B. Colonies (~180,000) appearing after 24 h on selective medium (20 µg/mL 
chloramphenicol) were harvested from plates and pooled, and total plasmid DNA was purified 
using a Qiagen Miniprep Kit to obtain a library of vectors encoding MetRS genes with a 
transposon (M1-CamR) inserted at different locations. This library was digested with restriction 
enzymes (BspHI, ClaI, and NdeI) that cut at two sites within metG (base pairs 73-78 and 1603-8) 
and five sites within the pPROEX vector. MetRS genes (base pairs 73-1608) containing M1-
CamR were separated from other DNA fragments by agarose gel electrophoresis, purified, and 
cloned back into pPROEX-MetRS∆NotI-XS1. These vectors containing size-selected MetRS 
genes were electroporated into E. coli MegaX DH10B, colonies (~118,000) appearing on LB-
agar plates containing 20 µg/mL chloramphenicol were harvested, and total DNA was purified to 
obtain a size-selected library. The M1-CamR was removed from the size-selected library by NotI 
digestion and replaced with f1-kan
R
, a DNA insert that terminates translation preceding the insert 
and initiates transcription and translation following the insert 
6
. The resulting two-promoter 
library was electroporated into E. coli MegaX DH10B, plated onto LB-agar medium containing 
25 µg/mL kanamycin and incubated for 24 h at 37°C. Colonies (~248,000) were harvested, and 
total DNA was purified to obtain the two-promoter library used for functional selections. 
 
An E. coli Selection for Functional MetRS 
The λDE3 Lysogenization Kit (Novagen) was used to generate DE3 lysogens of E. coli CS50 
(Yale Stock Center), a strain that grows slowly in the absence of methionine because of a MetRS 
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mutation that increases the KM for Met 
8
. To identify a CS50-DE3 lysogen that constitutively 
expresses T7 RNA polymerase, cells were transformed with pET-Venus-Grx2
20
 and their 
fluorescence was measured using a Tecan M1000 plate reader. An E. coli CS50-DE3 strain from 
this screen was electroporated with the final two-promoter library, plated on M9 minimal media 
containing all amino acids except methionine, and grown for 24 hours at 37°C. Vectors from one 
hundred colonies were picked and used to inoculate LB cultures containing 50 µg/mL ampicillin. 
DNA purified from each overnight culture was sequenced.  
 
Evaluation of MetRS Complementation Strength 
After sequencing, complementing vectors were transformed into E. coli CS50-DE3, plated onto 
LB-agar plates containing 50 µg/mL ampicillin, and incubated at 37°C for 24 h to obtain 
colonies. Overnight LB cultures from three separate colonies of each variant were diluted to 
OD600 = 2.0, 0.2, 0.02, and 0.002, and 10 µL of each was spotted onto +Met and –Met M9-agar 
plates. Prior to spotting, cells were harvested by centrifugation, washed three times with 25% 
glycerol, and resuspended in 25% glycerol to OD600 = 2. Growth was visually assessed after 24 h, 
when cells harboring pPROEX showed no visible growth and cells containing pPROEX-
MetRS∆NotI-XS1 grew at all titers. Cell growth was scored on a scale of 1 to 4, based on the 
number of dilutions where growth was visible. MetRS-NLL did not complement E. coli CS50-
DE3 growth after 24 h, and thus could not be used as a parent for laboratory evolution 
experiments. 
 
Calculation of Residue-Residue Contacts in Each Split Variant 
The number of intermolecular contacts made between fragments of all possible split MetRS 
variants was calculated as the number of residue pairs with atoms within a distance cutoff of 4.5 




Introduction of Active Site Mutations into Selected MetRS Vectors 
Site-directed mutagenesis (Stratagene) was used to mutate MetRS residues L13, Y260 and H301 
to PLL (or NLL) in seven complementing vectors selected from the two-promoter library 
(pPROEX-MetRS∆NotI-XS1 derived), including variants 48, 131, 183, 247, 272, 278 and 456 
(see Fig. S3.3). Split proteins with mutations are designated NLL-MetRS(cut site) and PLL-
MetRS(cut site), respectively. 
 
Vectors for Regulated Protein Expression 
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A fragment of the MetRS gene encoding NLL-MetRS residues 1-247 was cloned into pQE80L-
Kan between the BamH1 and Sal1 restriction sites to create pQE80His6_N247. This vector drives 
expression of the N-terminal MetRS fragment with an N-terminal His6-tag under control of an 
IPTG-inducible T5 promoter. A fragment of the MetRS gene encoding NLL-MetRS residues 
247-548 was cloned into pBAD33 between the Sac1 and Kpn1 restriction sites to create 
pBAD33HA_C247. This vector drives expression of the C-terminal MetRS fragment with a C-
terminal hemagglutinin tag (YPYDVPDYA) under control of an arabinose-inducible and glucose-
repressible PBAD promoter. Translational initiation on pBAD33-derived mRNAs was 
accomplished by introducing before the ATG start codon a DNA sequence 
(AGGAGGAATTCACC) that encodes a ribosome-binding site. Vectors for assessing promoter 
activities in gradients of inducers were generated by cloning GFP into pBAD33 and pQE80L-Kan 
to create pQE80L-GFP and pBAD33-GFP, respectively. 
 
Synthesis of Azidonorleucine 
Azidonorleucine synthesis was based on a previous protocol for synthesis of azidohomoalanine, 
using Boc-lysine as the starting material 
22
. Briefly, 5.27 g (81.1 mmol) of sodium azide was 
treated with 2.7 mL (16 mmol) of distilled triflic anhydride in 13 mL of water for 2 h.  The triflic 
azide product was extracted with 10 mL methylene chloride and added dropwise to a flask 
containing Boc-Lys-OH (2 g, 8.1 mmol), K2CO3 (1.68 g, 12.2 mmol) and CuSO4 (20 mg, 0.08 
mmol) in 26 mL of water and 250 mL of methanol. After 20 h at room temperature the product 
was extracted with ethyl acetate, redissolved in methylene chloride and purified by silica gel 
chromatography. After Boc deprotection with hydrochloric acid, the final product was purified by 
cation exchange chromatography.  
 
Metabolic Incorporation of Anl into Cells Grown in Liquid Culture 
To test metabolic incorporation of Anl into proteins in E. coli cells expressing split MetRS 
variants, overnight LB cultures were used to inoculate cultures containing M9 minimal media 
containing 19 amino acids (100 μM), 100 μM methionine, and 1% glycerol. Cells were grown in 
minimal media to an OD600 = 0.25, Anl was added at a final concentration of 1 mM, and cells 
were grown for 1 h to allow for metabolic incorporation of Anl into newly synthesized proteins. 
For experiments involving cells transformed with pairs of inducible vectors (e.g., 
pQE80His6_N247 and pBAD33HA_C247), cells were grown to an OD600 = 0.25, arabinose and 
IPTG inducers were added at varying concentrations, cells were grown for 2 h, Anl was added at 
a final concentration of 1 mM, and cells were grown for 1 h to allow for metabolic incorporation 
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of Anl into newly synthesized proteins. For AND-gate expression, based on the two vector 
system (pQE80His6_N247, pBAD33HA_C247), 50 μg/ml of kanamycin and 100 μg/ml of 
chloramphenicol were used. Cells were harvested by centrifugation at 10,000 rcf for 5 minutes 
and lysed with 4% SDS (10 µL for cell pellets resulting from 1 mL of culture medium) prior to 
labeling of the lysate with alkyne-TAMRA dye (structure 2, Fig. 3.2E).  
 
Labeling Anl-tagged Proteins in Cell Lysates with an Alkyne-TAMRA Dye 
Cells were lysed with 4% SDS in phosphate buffered saline (PBS). Ethylenediaminetetraacetic 
acid (EDTA)-free protease inhibitor (Roche) was added to the lysates to reduce protease activity. 
The EDTA-free version of the protease inhibitor was required for copper-catalyzed cycloaddition 
reactions because EDTA chelates copper ions and interferes with copper-dependent reactions. 
PBS was added to dilute the SDS concentration to 1%, and cell lysates were centrifuged at 14,000 
rcf for 10 min to remove cellular debris. Protein concentrations were measured by using a 
bicinchoninic protein quantification kit (BCA assay; Pierce, Rockford, IL). The same amount of 
protein was used for each condition; concentrations ranged from 0.1 to 0.4 mg/mL. Copper-
catalyzed reactions were performed at room temperature for 2 h in 1.5 mL centrifuge tubes, 
according to the following protocol: (i) alkyne-TAMRA dye was added to protein solution to a 
final concentration of 100 µM; (ii) tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) and 
copper sulfate were pre-incubated together for 1 min and then added to the protein solution to 
final concentrations of 0.1 mM copper sulfate and 0.5 mM THPTA; (iii) aminoguanidine was 
added followed by sodium ascorbate (made fresh in water), and (iv) the solution was mixed once 
and protected from light with no further mixing. The final concentrations of aminoguanidine and 
sodium ascorbate were 5 mM. The THPTA ligand was synthesized according to methods 
published by Finn and coworkers 
12
. Proteins were precipitated with chloroform/methanol, 
washed with methanol to remove unreacted dye and resuspended in protein loading buffer 
containing 2% SDS and 10% mM 2-mercaptoethanol. Proteins were electrophoresed using 12% 
Bis-Tris polyacrylamide gels (Invitrogen). TAMRA (λexcitation = 555 nm and λemission = 580 nm) 
was excited at 532 nm and detected with a 580 band-pass 30 nm filter. In-gel fluorescence images 
were acquired on a Typhoon 9400 instrument (GE Healthcare).  
 
Copper-free Protein Labeling with Dibenzocyclooctyne-TAMRA 
Cells were lysed with reducing buffer containing 5 mM dithiothreitol, 4% SDS in PBS and 
incubated for 30 min at 50ºC. The SDS concentration was then reduced to 1% by addition of 
PBS. The lysates were subsequently incubated in the dark for 30 min with 100 mM 
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iodoacetamide. The reduction and alkylation steps were used to reduce background labeling due 
to reaction with free thiols. After reduction and alkylation, the proteins were reacted with 20 µM 
azadibenzocyclooctyne-TAMRA dye conjugate (Click Chemistry Tools, AZ) for 15 min at room 
temperature, precipitated with chloroform/methanol and washed with methanol to remove 
unreacted dye. 
 
Western Blot Detection of Split-MetRS Fragment Expression 
N-terminal fragments expressed from pQE80His6_N247 contained N-terminal His6 tags. These 
fragments were detected by western blot analysis using an AlexaFluor 488 conjugated anti-penta-
His antibody (Qiagen). AlexaFluor 488 (λexcitation = 495 nm and λemission = 520 nm) was excited at 
488 nm and detected with a 520 band-pass 40 nm filter. C-terminal fragments expressed from 
pBAD33HA_C247 contained C-terminal hemagglutinin (HA) tags. HA-tagged proteins were 
detected by western blot analysis with AlexaFluor 633 conjugated anti-HA antibody (Santa 
Cruz). AlexaFluor 633 (λexcitation = 632 nm and λemission = 647 nm) was excited at 633 nm and 
detected with a 670 band pass 30 nm filter. All images were obtained on a Typhoon 9400 
instrument (GE Healthcare).  
 
Fabrication of the Microfluidic Laminar Flow Device 
The microfluidic device was fabricated using rapid prototyping in polydimethylsiloxane (PDMS) 
23
. The channel geometry is shown in Fig. S3.8. Inlet channel widths were 850 μm; the main 
channel width was 870 μm. The channel depth was 175 μm. The PDMS mold was plasma 
oxidized and attached to a 0.17 mm thick glass slide. The attached PDMS mold and glass slide 
were heat cured at 110°C for 10 min. To render the glass surface and channel surface cell-
adhesive, the device was filled with 1 mg/mL Poly-D-lysine (Millipore, MA) in PBS and then 




Modeling Diffusion in the Microfluidic Channel 
The channel geometry was constructed in AutoCad 2012 (Autodesk Student version) software 
and diffusion simulations were performed using COMSOL® Multiphysics v4.2a with the 
Laminar Flow module and Transport of Diluted Species module. A mesh with a maximum 
element size of 25 μm was used for this analysis. For these simulations, we used a flow rate of 1 
μL/min and inlet concentrations of arabinose and IPTG of 5 mM and 1 mM, respectively. The 
diffusion coefficients of arabinose and IPTG were estimated using the Stokes-Einstein equation 






















IPTG. These values are in agreement with previously reported diffusion coefficients of arabinose 
26
 and IPTG 
27
 at 37 ⁰C.  See Fig. S3.8-S3.9 for further details. 
 
Imaging Dye Diffusion in the Microfluidic Channel 
Dye diffusion experiments were performed to measure dye profiles in the channel and compare 
the measured and predicted profiles. One inlet contained a solution of AlexaFluor488 dye at a 
concentration of 2.82 µM; the second inlet contained PBS. Fluorescence images were obtained 
with a Leica DMI6000 microscope (Leica, CT) with a 10× (0.40 N.A.) objective, which was 
coupled to a cooled-CCD camera with 12-bit, 1344×1024 resolution (Hamamatsu Photonics, UK) 
and a 0.6× coupler. The filter cube (Leica) had excitation range: BP 480/40; dichromatic mirror: 
505; suppression filter: BP527/30. Images were obtained at the solid-liquid interface on the glass 
surface of the channel. Imaging the dye diffusion at the glass-liquid interface was done as a 
surrogate for the PDMS-liquid interface on which the cells are seeded, to reduce effects from bulk 
fluorescence of the dye. 
 
Cell Seeding and Induction in the Microfluidic Channel 
Overnight LB cultures were inoculated into M9 minimal media containing 19 amino acids (100 
μM), 100 μM Met, and 1% glycerol, and incubated at 37⁰C until they reached an OD600 = 0.4. 
The cells were seeded on the PDMS surface of the microfluidic channel for 2 h at 30°C with no 
fluid flow. The micro-channel was flushed with M9 minimal medium containing 0.5 mg/mL 
glucose. Cells were incubated in this medium at 37°C for 30 min prior to induction, with no flow. 
M9 minimal media containing 1 mM Anl and one of the two inducers (1 mM IPTG or 5 mM 
arabinose) were loaded into two different 250 μL gas-tight Hamilton syringes (Hamilton 
Company, MA), and the two converging laminar streams were pumped through the device. Flow 
rates were controlled using syringe pumps (Harvard Apparatus, MA); a flow rate of 1 μL/min was 
used for each stream. Inductions were performed for 4 h. After induction, inducer solutions were 
flushed from the channel with PBS, and cells were fixed with 3.7% formaldehyde at 37°C for 15 
min and washed for 10 min with PBS. Cells expressing GFP were imaged in PBS, whereas cells 
expressing the split MetRS were permeabilized with methanol for 3 min, washed with PBS for 10 
min, and treated with alkyne-AlexaFluor 488 dye prior to imaging (under the same conditions 
described above for labeling of lysates with alkyne-TAMRA dye). The dye was washed out of the 




Fluorescence Imaging of Cells in the Microfluidic Channel 
Fluorescence and bright field images were obtained with a Leica DMI6000 microscope (Leica, 
CT). We used a 10× (0.40 N.A.) objective, which was coupled with a cooled CCD camera with 
12-bit, 1344×1024 resolution (Hamamatsu Photonics, UK) with a 0.6× coupler. MetaMorph 
Imaging software (version 7.7) was used for image acquisition. The filter cube (Leica) used for 
GFP was L5 (Excitation range: BP 480/40; Dichromatic mirror: 505; Suppression filter: 
BP527/30), the same filter set was used for imaging alkyne-AlexaFluor 488 dye.  
 
Quantification of Fluorescence in the Microfluidic Channel 
Fluorescence images of the cells in the microfluidic channel were analyzed using ImageJ 
software. For quantification of fluorescence, the width of the channel was divided into 17 equally 
spaced boxes (as shown in Fig. 3.4C), starting 50 µm from each wall to avoid edge effects. Each 
box was 45 µm in height and 420 µm in length; a picture of one box located 50 µm from the edge 
is shown in Fig. 3.4C. The mean fluorescence intensity in each box was measured. This 
measurement was performed at three adjacent locations, with the upstream edge of the first box 
located 2 mm downstream from the y-junction of the channel, and adjacent boxes placed 
immediately downstream. Fluorescence measurements were used to calculate the mean and 
standard deviation at each position across the width of the channel. Fluorescence intensities are 
reported relative to the highest value. 
 
Fluorescence Confocal Images of Labeled Proteins in Cells 
Fluorescence confocal images were not obtained directly from the microfluidic channel due to the 
thickness of the glass slide. Overnight LB cultures were inoculated using the same method used 
for seeding in the microfluidic channel. Cells were seeded into a 6-well chamber slide (Lab-Tek, 
Thermo Fischer Scientific), and induction was performed according to the method used for the 
microfluidic channel. After induction, cells were fixed with 3.7% formaldehyde at 37°C for 15 
min and washed three times with PBS. Cells were permeabilized with methanol for 3 min and 
washed three times with PBS. The copper-catalyzed dye-labeling reaction was performed 
(according to the conditions described for labeling of lysates with alkyne-TAMRA dye above) 
using alkyne-AlexaFluor 488 dye. The reaction volume was 200 µL per well. After dye-labeling 
for 2 h, the cells were washed with five sequential PBS washes of 300 µL each, over a period of 2 
h. The chamber slide was removed from the glass slide, and the cells were covered with 10% 
glycerol in PBS under a coverslip. Imaging of AlexaFluor 488 fluorescence was performed on a 
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Figure 3.1. A genetic AND gate for proteomic labeling. Two promoters (P1 and P2) are used as 
inputs to drive expression of E. coli MetRS fragments F1 and F2. tRNAMet is charged with Anl 
only when the MetRS fragments are both expressed, and associate to form a functional enzyme. 
Ribosomes use Anl-charged tRNAMet during protein synthesis in competition with Met-charged 
tRNAMet.  Newly synthesized proteins are labeled with azide groups, which can be selectively 
tagged by the azide-alkyne cycloaddition
10
. Diverse promoter inputs can be plugged into the 








Figure 3.2. Identifying fragmented MetRS variants that metabolically label proteins with 
Anl. (a) DNA that contains a terminator, promoter (PT7), and ribosomal binding site was 
randomly inserted into the MetRS gene to create a library of vectors that express two-piece 
MetRS variants
6
. (b) Growth of E. coli CS50-DE3 cells in the absence of Met is compared for 
cells that express a functional MetRS truncation comprised of residues 1-548 and split MetRS 
variants. Ten-fold serial dilutions of cells were spotted on M9-agar plates and growth was imaged 
after 24 h. (c) Complementation strengths of fragmented MetRS variants, which were named 
based on the last residue encoded by their N-terminal fragments. (d) Color coding of the 
connective polypeptide [CP, blue], Rossmann fold [R, green], KMSKS [K, orange], and 
anticodon-binding [AB, purple] domains maps the locations of backbone fission (yellow spheres) 
in functional variants onto the MetRS structure
29
. (e) Structure of Anl (1), which can be detected 
in proteins after reaction with alkyne-functionalized tetramethylrhodamine (TAMRA) dye (2). 
Copper-catalyzed azide-alkyne cycloaddition (3) results in a stable triazole linkage. (f) Cells 
expressing the split NLL-MetRS and PLL-MetRS from the vectors selected using bacterial 
complementation were grown in the presence of Anl, and cell lysates were treated with TAMRA-
alkyne dye. In-gel fluorescence image shows TAMRA labeling, which indicates Anl 
incorporation into cellular proteins. Colloidal blue staining (bottom) was performed to compare 




Figure 3.3. Genetic control of Anl incorporation into proteins in cells that express the N- 
and C-terminal fragments of NLL-MetRS(247) under control of IPTG- and arabinose-
inducible promoters. (a) Anl labeling of E. coli proteins in the presence or absence of IPTG (1 
mM), arabinose (5 mM), and Anl (1 mM). Cell lysates were treated with an alkyne-TAMRA dye, 
and in-gel TAMRA fluorescence was imaged to detect Anl incorporation. (b) Colloidal blue 
staining of the gel in (a) confirms similar total protein in each sample. (c) Western blot detection 
of the N-terminal (green) fragment containing a His6 tag and the C-terminal (blue) fragment 
containing a hemagglutinin tag. (d) Effects of arabinose and IPTG levels on Anl incorporation. 
Cell lysates were treated with alkyne-TAMRA, and the in-gel fluorescence signal from TAMRA-
labeled proteins was used to determine relative Anl incorporation levels. Dots on the surface 
show conditions under which Anl incorporation was measured. (e) Time-dependence of protein 
labeling upon addition of Anl to cells harboring the activated AND gate.  IPTG (1 mM) and 
arabinose (5 mM) were added to activate the AND gate; Anl (1 mM) was added 3 h later (at 0 
min on the time axis). Anl-labeled proteins were detected by treatment with 
azadibenzocyclooctyne-TAMRA dye (R1); labeling was quantified by in-gel fluorescence 
detection. When the AND gate was not activated but Anl was present, no measurable 




Figure 3.4. Spatial control of protein labeling. (a) A laminar flow microfluidic channel was 
used to expose surface-immobilized cells to gradients of arabinose and IPTG. In this device, the 
AND gate should be activated only in the center of the channel, where cells are exposed to both 
IPTG and arabinose. (b) Modeling of inducer diffusion was used to determine cross-channel 
concentration profiles of arabinose and IPTG at the locations shown by the arrows in (c, d, and e). 
Schematic shows that cells in the middle of the channel should incorporate Anl (gray); those on 
the periphery should not be labeled (purple). (c) Fluorescence image of the microfluidic channel 
(top) seeded with cells expressing GFP under IPTG control, and images of individual cells 
(bottom) that were incubated with varying combinations of inducers (left to right;  5 mM 
arabinose, 1 mM arabinose plus 0.1 mM IPTG, and 1 mM IPTG). GFP fluorescence was 
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quantified as a function of distance from the wall of the channel at positions indicted by the 
arrows, and is plotted to the right. Fluorescence values were normalized by setting the maximum 
fluorescence to 1. (d) Fluorescence detection of arabinose-regulated GFP expression under 
conditions identical to (c); the corresponding normalized fluorescence values are plotted to the 
right. (e) Detection of Anl incorporation by labeling with TAMRA-alkyne dye. Conditions are 
identical to those used for (c). The plot to the right shows the TAMRA fluorescence intensity 
(red) as a function of distance from the wall of the channel. TAMRA fluorescence values 
represent the experimental output of the AND gate, and were normalized by setting the maximum 
fluorescence to 1. Black dots represent the products of the GFP fluorescence signals from plots in 
(c) and (d), which were point-wise multiplied to provide a measure of the predicted output of the 
AND gate.  The products were normalized by setting the maximum signal to 1 in order to allow 
direct comparison to the TAMRA fluorescence values.  
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Table TS3.1  
Functional MetRS variants discovered using E. coli CS50-DE3 complementation. For each 
variant, we indicate: (i) the MetRS residues produced by the first open reading frame, ORF1, (ii), 
the relative orientations of the promoters preceding and within metG
6
, (iii) if open reading frame 
following the internal promoter is in frame, (iv) the MetRS residues predicted to be produced by 
ORF2 following the internal promoter, (v) the relative complementation strength of each variant 
scored on a scale of 1-4, and (vi) the number of occurrences of each unique variant within the 
sequenced clones. In cases where ORF2 is out of frame, the MetRS residues present in the second 
fragment are unknown and the initial residue is designated alternative (alt) start codon. In the 














1-31 parallel no alt-548 3 1 
1-40 parallel no alt-548 2 1 
1-43 parallel yes 43-548 2 1 
1-48 parallel yes 48-548 2 1 
1-52 parallel no alt-548 2 1 
1-55 parallel yes 55-548 3 1 
1-114 parallel no alt-548 2 1 
1-131 parallel yes 131-548 3 1 
1-138 parallel no alt-548 2 1 
1-152 parallel no alt-548 2 1 
1-183 parallel no alt-548 2 1 
1-183 parallel yes 183-548 3 2 
1-221 parallel no alt-548 2 1 
1-247 parallel yes 247-548 4 46 
1-272 parallel yes 272-548 3 1 
1-273 parallel no alt-548 1 2 
1-274 parallel yes 274-548 3 1 
1-278 parallel yes 278-548 3 2 
1-294 parallel yes 294-548 1 1 
1-373 parallel no alt-548 2 1 
1-393 parallel yes 393-548 2 1 
1-416 parallel no alt-548 2 1 
1-454 parallel no alt-548 2 1 
1-456 parallel yes 456-548 2 1 
1-494 parallel yes 494-548 2 1 
1-534 parallel no alt-548 2 1 




Figure S3.1.  
Complementation of E. coli CS50-DE3 by selected MetRS variants. Growth after 24 hours at 
37°C of E. coli CS50-DE3 transformed with: i) pPRO-EX, ii) pPROEX-MetRS∆NotI-XS1, and 
pPRO-EX vectors that express fragmented MetRS variants discovered in selections. After 
sequencing, each vector was transformed into CS50-DE3 to obtain individual colonies on LB-
agar plates, and the complementation of three separate colonies was analyzed on minimal 
medium containing or lacking methionine. Serial dilutions (1x, 10x, 100x, and 1000x) of the 
resuspended cells (10 µL each) were spotted in triplicate onto two M9-agar plates. NLL-MetRS 





Figure S3.2.  
Intermolecular contacts between fragments. The number of intermolecular interactions 
between fragments in each split MetRS variant was calculated by counting the number of 
residue–residue contacts across the inter-fragment interface. Residues were considered interacting 
if any of their atoms were within 4.5 Å of one another. Calculations are based on the MetRS 









Figure S3.3.  
Structural models for fragmented MetRS variants. PDB structure 2CSX
30
 was used to 
generate structural models for the seven split MetRS variants that were screened for Anl labeling 
activity after mutation of residues L13, Y260 and H301 to NLL and PLL, respectively.  These 
variants were chosen because they were among the most active fragmented MetRS in bacterial 
complementation measurements. The backbone cleavage sites were distributed through different 
domains of the protein in these variants.  For each variant, residues in the N-terminal MetRS 
fragment are shown in blue, residues from the C-terminal fragment are shown in magenta, and 
bound tRNA is shown in orange. Split MetRS are named based on the last residue within the N-
terminal fragment before peptide backbone cleavage, e.g., MetRS(247). This residue is duplicated 











Figure S3.4.  
Anl labeling in cells expressing NLL-MetRS(247) under control of regulated promoters. E. 
coli DH10B cells transformed with vectors encoding NLL-MetRS(247) [pQE80His6_N247 and 
pBAD33HA_C247] were grown in M9 minimal media containing 19 amino acids, 100 μM 
methionine, and 1% glycerol. At OD600 = 0.25, IPTG and arabinose were added to final 
concentrations of 1 mM and 5 mM, respectively. Cells were grown for 2 h after induction, Anl 
was added to a final concentration of 1 mM, and cells were grown for an additional 1 h to allow 
for Anl incorporation into newly synthesized proteins. Cells were lysed, and lysates were treated 
with a TAMRA-alkyne dye. Proteins from the cell lysate were separated by SDS-PAGE, and 










Figure S3.5.  
Effect of glucose on NLL-MetRS(247) activity.  E. coli DH10B cells transformed with vectors 
encoding NLL-MetRS(247) [pQE80His6_N247 and pBAD33HA_C247] were grown in M9 
minimal media containing 19 amino acids, 100 μM methionine, 1% glycerol, and varying glucose 
concentrations (0, 0.1, 0.5, 1, 5 mg/ml). At OD600 = 0.25, IPTG and arabinose were added to final 
concentrations of 1 mM and 5 mM, respectively. Cells were grown for 2 h after induction, Anl 
was added to a final concentration of 1 mM, and cells were grown for 1 h to allow Anl 
incorporation into newly synthesized proteins. Cells were lysed and lysates were treated with a 
TAMRA-alkyne dye. Proteins from the cell lysate were separated by SDS-PAGE and Anl-labeled 
proteins were detected by in-gel fluorescence imaging. Colloidal blue staining of the same gel 
shows similar protein levels in each lane. Labeling observed under similar conditions with cells 
expressing intact NLL-MetRS under control of its endogenous MetG promoter in pQE80
2
 is 










Figure S3.6.  
Effect of varying IPTG and arabinose concentrations on NLL-MetRS(247) activity. E. coli 
DH10B cells transformed with vectors encoding NLL-MetRS(247) [pQE80His6_N247 and 
pBAD33HA_C247] were grown in M9 minimal media containing 19 amino acids, 100 μM 
methionine, 1% glycerol, and 0.5 mg/mL glucose. At OD600 = 0.25, 25 different concentrations of 
arabinose and IPTG were added to cultures. IPTG was added to final concentrations of 0 µM, 10 
µM, 100 μM, 1 mM and 5 mM.  Arabinose was added to final concentrations of 0 mM, 0.1 mM, 
1 mM, 6.7 mM and 12 mM. Cells were grown for 2 h after induction, Anl was added to a final 
concentration of 1 mM, and cells were grown for 1 h to allow Anl incorporation into newly 
synthesized proteins. Cells were lysed and lysates were treated with a TAMRA-alkyne dye. 
Proteins from the cell lysate were separated by SDS-PAGE, and Anl-labeled proteins were 
detected by in-gel fluorescence imaging (top panel). The bottom gel shows a Western blot of the 
cell lysates using an AlexaFluor488-conjugated anti penta-His antibody that detects the N-
terminal MetRS fragment (green) and an AlexaFluor647-conjugated anti hemagglutinin antibody 











Figure S3.7.  
Kinetics of AND-gate activation and protein labeling. (a) Kinetics of AND gate activation: E. 
coli DH10B cells transformed with vectors encoding NLL-MetRS(247) [pQE80His6_N247 and 
pBAD33HA_C247] were grown in M9 minimal medium containing 19 amino acids, 100 μM 
methionine, 1% glycerol, and 0.5 mg/mL glucose. The N- and C-terminal fragments were 
induced by addition of IPTG and arabinose at 1 mM and 5 mM, respectively. Anl was added at 1 
mM at the time of induction. As a control for background labeling, cells were also incubated in 1 
mM Anl without IPTG and arabinose for 200 min. After Anl incorporation for various times (0 – 
180 min), cells were lysed and treated with azadibenzocyclooctyne-TAMRA dye (see 
supplementary methods). TAMRA labeling (top left) indicating Anl incorporation was detected 
by in-gel fluorescence imaging.  Colloidal blue labeling of the same gel (bottom left) was used to 
compare protein loading across lanes. Quantification of Anl incorporation was done by measuring 
TAMRA fluorescence at three different bands in each lane and dividing these values by the band 
intensities from colloidal blue labeling, thereby normalizing for differences in protein amounts 
between different conditions. The level of Anl labeling in the absence of IPTG and arabinose was 
also measured after 200 min, and is represented by the red dot in the mean-normalized TAMRA 





(b) Kinetics of Anl incorporation under control of the activated AND gate: cells transformed with 
vectors encoding NLL-MetRS(247) [pQE80His6_N247 and pBAD33HA_C247] were grown in 
M9 minimal media containing 19 amino acids, 100 μM methionine, 1% glycerol, and 0.5 mg/mL 
glucose. The N- and C-terminal fragments were induced by addition of IPTG and arabinose at 1 
mM and 5 mM, respectively, for 3 h. Anl was then added at 1 mM. Under these conditions, 
fragment expression is not the rate-limiting step for Anl incorporation. As a control for 
background labeling, cells were also incubated in 1 mM Anl without IPTG and arabinose for 65 
min; the TAMRA signal for this control is shown by red symbol in the quantification results. 




Figure S3.8.  
Modeling the diffusion of IPTG and arabinose in the microfluidic channel. To determine the 
profiles of IPTG and arabinose in the microfluidic channel, the dimensions of the channel shown 
in (A) were entered into AutoCad software and imported into Comsol software to model diffusion 
at the liquid-liquid interface. A flow rate of 1 µL/min was used for each inducer.  
 
 
(B) Model-predicted IPTG inducer concentration profile. Inlet concentration is 1 mM. 





Figure S3.9.  
Model prediction and experimental measurement of dye diffusion in the microfluidic 
channel. The diffusion of AlexaFluor488 dye in the microfluidic channel was computed under 
the conditions used for the experiments. Reported values for the diffusion coefficient of 





















 because this value is commonly used
38-45
 as the diffusion coefficient for 
this dye in water or aqueous buffer at room temperature. The diffusion profiles 0 mm, 6 mm and 
12 mm downstream from the y-junction were predicted for AlexaFluor488. To verify these 
predictions, dye diffusion experiments were performed; the results closely matched the predicted 
concentration profiles. These results validated the prediction from simulations.  
(A) To visualize diffusion in the laminar flow microfluidic channel, two liquid streams containing 
AlexaFluor488 dye (2.82 µM) and PBS were used. Fluorescence images were obtained from the 
glass-liquid interface inside the microfluidic channel. A series of images was obtained along the 
length of the channel and images were stitched together to provide the entire profile along the 
channel. Diffusion of dye at the interface of the two streams is visible along the length of the 
channel. (B) Diffusion of AlexaFluor488 dye in the microfluidic channel was modeled and the 
predicted profile of dye concentration at the liquid-surface interface along the entire length of the 







Figure S3.9 continued.  
 
(c) Comparison of predicted and measured dye concentration profiles in the microfluidic channel. 
Predicted cross-channel dye profiles 0, 6, and 12 mm downstream from the y-junction are plotted 
as solid lines with color codes black, red and blue, respectively. Fluorescence quantification was 
also performed at these locations. Experimental data points are plotted as open circles, color 
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Cell-Selective Identification of Newly Synthesized Proteins in 





Cell-selective identification of newly synthesized proteins will facilitate studies of biological 
processes in multicellular organisms. We have previously developed methods to identify newly 
made proteins in a cell-selective manner in bacterial cells; however, comparable strategies for 
proteomic analysis in mammalian cells are not available. Here we introduce a mutant mammalian 
methionyl tRNA synthetase (AnlRS) that incorporates the non-canonical amino acid 
azidonorleucine (Anl) into newly synthesized proteins. Controlled expression of this enzyme 
restricts protein labeling to cells of interest and facilitates identification by mass spectrometry. 
This approach does not require expression of orthogonal tRNAs or the removal of canonical 
amino acids. Successful Anl incorporation in a variety of mammalian cells demonstrates the 






The incorporation of non-canonical amino acids into newly synthesized proteins has emerged as 
an important tool for study of proteome dynamics in cells.
1-3
 This approach, named BONCAT,
4
 
utilizes the metabolic incorporation of non-canonical amino acids into newly made proteins to 
enable their enrichment and subsequent identification by mass spectrometry. A number of recent 
studies have used a combination of BONCAT and SILAC techniques
5
 to quantitatively analyze 
proteins in mammalian cell lines.
6-8
 A similar strategy was used to identify the secretome of 
different cell lines in serum containing media.
9
 These studies highlight the importance of methods 
for analyzing proteome dynamics in mammalian cells. However, the inability to restrict labeling 
and thereby identify newly made proteins from subsets of mammalian cells has thus far limited 
the scope of problems that can be addressed using BONCAT. Here we introduce a new enzyme 
that allows cell-selective, time-resolved, identification of newly synthesized proteins in 
mammalian cells.  
The BONCAT method was initially extended to achieve cell-selective protein labeling in 
bacterial cells
10
 and we subsequently demonstrated an application of this approach to study host-
pathogen interactions wherein the proteins of pathogenic microbes were selectively labeled and 
identified in the presence of host cells.
11
 These studies utilized a mutant E. coli methionyl-tRNA 
synthetase (MetRS), which is a class I aminoacyl-tRNA synthetase (aaRS). The triple mutant 
(L13N/Y260L/H301L)
10 
MetRS variant, designated NLL-MetRS, charges the non-canonical 
amino acid L-azidonorleucine (Anl) to tRNA
Met
 and thereby enables incorporation of Anl at Met 
codons. Since the wild-type MetRS does not charge Anl, only cells that express the NLL-MetRS 
incorporate Anl. Controlled expression of NLL-MetRS using various promoters enabled the 
context-dependent and time-resolved labeling of newly synthesized proteins in bacteria.
12,13
 
Ideally, one could use an analogous approach for cell-selective protein labeling in mammalian 
cells (Scheme 4.1a). However, the E.coli NLL-MetRS enzyme only charges Anl to initiator tRNA 
(tRNA
fMet
) and not the elongator mammalian tRNA (tRNA
Met
). Therefore, this enzyme 
incorporates Anl site-selectively at N-terminal positions and not at internal Met residues in 
mammalian proteins. Based on this observation as well as the fact methionine aminopeptidase 
(MetAP) removes N-terminal Met residues from a wide range of proteins,
14
 we sought to identify 
new enzyme variants to incorporate Anl into mammalian cell proteins. Newly synthesized 
proteins can be detected in fixed cells or cell lysates by 3+2 cycloaddition reactions between the 
azide side-chain of Anl and alkyne
15
 or alkynyl probes
16,17
 (Scheme 4.1b). Anl-labeled proteins 
can be tagged for affinity enrichment and identified by tandem mass spectrometry (Scheme 4.1c).  
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Results and Discussion 
We investigated two complementary approaches towards cell-selective Anl incorporation in 
mammalian cells. The first approach aimed to identify mutant mammalian aaRSs that charge Anl 
to the endogenous tRNA
Met
. The second approach involved co-expression of E. coli NLL-MetRS 
and E. coli elongator tRNA
Met 
in mammalian cells. Reports by Rajbhandary and co-workers 
showing successful concomitant expression of an active E. coli glutaminyl-tRNA synthetase and 
a functional glutamine-inserting amber suppressor tRNA that is not aminoacylated in vivo by any 
mammalian aaRS suggested to us that the mammalian translation machinery could co-opt an E. 
coli elongator tRNA
Met
 that is charged by the NLL-MetRS.
18,19
 Additionally, the fact that NLL-




 (and that the E. coli MetRS only 




 provided further evidence for the potential feasibility of 
this approach.  
To identify mutant mammalian aaRSs that charge Anl to the endogenous tRNA
Met
, we started 
with residues 13, 260 and 301 in the Met-binding pocket of E. coli MetRS
22
 which can be 
mutated to expand the substrate specificity towards Anl.
23
 Although there are no reported 
structures of a mammalian MetRS, we used sequence alignment to determine the corresponding 
positions in eukaryotic MetRSs (Figure 4.1a). Based on the similarity of eukaryotic MetRSs and 
the conservation of residues that align with E. coli MetRS residues 13/260/301, we hypothesized 
that site-directed mutagenesis of corresponding positions in the mouse methionyl tRNA 
synthetase (Mars) would potentially yield active variants that charge Anl. Therefore, we 
constructed a small mutant library in which residues L274, Y527, H562 of the Mars enzyme were 
mutated to SLL, CLL, PLL and NLL respectively. We also made an L274G mutant. These 
mutations correspond to E. coli MetRS variants that charge Anl in E. coli (Figure S4.1-S4.6). In 
addition we also overexpressed the wild-type Mars enzyme to assess the level of background 
incorporation. The various MetRS variants were expressed under control of a CMV promoter 
(Figure 4.1b).  
To express the E. coli elongator tRNA, we followed the work of the Rajbhandary group and used 
5’ and 3’ flanking sequences from the human initiator tRNA, which enable proper RNA editing 
(the E. coli version of these sequences are not recognized in mammalian cells)
18
 (Figure 4.1c). 
Notably, efficient transcription by mammalian RNA polymerase III requires a purine at position 9 
of the tRNA coding sequence.  In this case, adenine was used. This adenine lies in the A box of 
the internal promoter of eukaryotic tRNA genes.
18
 Transcription of the tRNA is terminated by a 
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stretch of thymidines. The 5’ sequence of the tRNA is removed by RNase P, and the 3’ end is 
removed by tRNase Z
24. In mammalian cells, the 3’ CCA tail is added by a 
nucleotidyltransferase;
24
 therefore, we tested tRNA sequences with and without a CCA tail 
(Figure S4.7-S4.9). We measured the activity of these various constructs for Anl incorporation by 
transiently transfecting several widely used mammalian cell lines, including Chinese hamster 
ovary (CHO) cells, monkey kidney cells (COS7) and an immortalized human cervical cancer cell 
line (HeLa). Cells were incubated in serum containing media supplemented with 1.5 mM Anl for 
a total of 10 hours and thereafter lysed. Total cellular proteins were treated with alkyne-
tetramethylrhodamine (TAMRA) dye (Figure S4.10) for labeling via copper-catalyzed azide-
alkyne cycloaddition (reaction 1, scheme 4.1b)
15,25,26
. After SDS-PAGE, TAMRA-labeled 
proteins were detected by in-gel fluorescence imaging (Figure 4.1d). As expected, Anl was not 
charged to any appreciable extent by the wild-type translation machinery of the cells. Anl 
incorporation was detected in cells carrying the E. coli NLL-MetRS. We did not observe a 
significant increase in Anl incorporation as a function of tRNA expression. The variability of 
incorporation across different cell lines suggests that the expression levels of the tRNA and the 
synthetase may need to be optimized for each cell type, thereby limiting the general applicability 
of this approach. Nonetheless, this strategy may prove to be useful for protein labeling in specific 
cases. For example, a similar strategy was used to incorporate several non-canonical amino acids 
using a genetically encoded pyrrolysyl-tRNA synthetase/tRNA pair in Drosophila.
27
  
In contrast to our results with the E. coli NLL-MetRS/tRNA
Met 
(Figure 4.1D, E. coli MetRS), the 
L274G version of the mouse Mars enzyme (henceforth called AnlRS) resulted in robust Anl 
incorporation across all three cell lines while none of the other mutant Mars variants charged Anl 
(Figure 4.1D, mouse Mars). This result was encouraging because it demonstrates that a single 
mutation to the endogenous mammalian MetRS sequence is sufficient for Anl incorporation 
without requiring expression of exogenous tRNAs.      
An important parameter for characterizing incorporation of non-canonical amino acids is the 
selectivity of a mutant aaRS towards a non-canonical amino acid versus its cognate substrate. To 
determine the selectivity of the AnlRS for Anl over Met, we aimed to measure enzyme activity in 
a manner that is most relevant to typical labeling experiments in mammalian cells, for example by 
measuring enzyme activity in the context of live cells. Therefore, we measured protein labeling in 
CHO cells by incubating the cells at different Anl concentrations in serum containing media. The 
DMEM component of media typically contains 150-200 µM of Met. After Anl incorporation, 
proteins from cell lysates were labeled with an alkyne-TAMRA dye (Figure 4.2a). We also 
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performed Met competition assays by incubating CHO cells with 1.5mM Anl at different Met 
concentrations (Figure 4.2b). We reasoned that because the same enzyme can charge both Anl 
and Met, it is important to know its selectivity as determined by the ratio of 𝑘𝑐𝑎𝑡 𝑘𝑀⁄  for Anl 
versus Met. Based on the enzyme kinetics of activation for both substrates, we obtained the 
following expression for product formation rate V (see figure S4.11 for derivation): 
𝑉 =  
𝐴(𝐾𝐴 𝐾𝑀⁄ ) 𝐶






 are 𝑘𝑐𝑎𝑡 𝑘𝑀⁄  for Anl and Met, respectively. Met and Anl concentrations (as 
depicted by M and A) are known, and C is a constant. Fitting this equation to the quantified 
TAMRA dye fluorescence measurements (which provide a direct measure of Anl incorporation in 
newly synthesized proteins) yielded a selectivity value of 0.25 for Anl versus Met (i.e., 1 Anl 
residue is incorporated for every 4 Met residues under these conditions). These results 
demonstrate the ability to tune the level of Anl incorporation by controlling extracellular Anl 
concentration as required for various biological studies. Previous work involving incorporation of 
the non-canonical amino acid azidohomoalanine (Aha), also a Met surrogate, that is incorporated 
non-cell-selectively by the endogenous MetRS, showed that an incorporation of approximately 
6% of total Met codons was sufficient for proteomic identification.
7
  
The ability to restrict AnlRS expression to cells of interest should enable the cell-selective 
labeling of proteins for targeted analysis of protein synthesis under specific conditions. To 
validate this concept, we developed a reporter construct expressing both AnlRS and mCherry 
under a CMV promoter (pMarsC). A T2A linker was used to express two disjointed proteins in 
the same open reading frame; we reasoned that fusing AnlRS and mCherry might alter the 
activity of the synthetase and confound protein labeling results (Figure 4.3a). As an additional 
control, we developed a similar expression construct without mCherry (pMars) (Figure S4.12-
13).When transfected into CHO cells, both constructs labeled cellular proteins at comparable 
levels, indicating that AnlRS was functional in both contexts. A C-terminal Myc tag on the 
mCherry protein showed that AnlRS and mCherry are expressed as two separate proteins and not 
a fusion (Figures 4.3b and S4.14). We therefore used the mCherry signal to track expression of 
AnlRS in the pMarsC transfected cells. Cells expressing mCherry should also contain AnlRS and 
incorporate Anl. CHO cells transfected with pMarsC and incubated with Anl (1.5 mM, 6h) were 
fixed, permeabilized and reacted with alkyne-TAMRA through a copper-catalyzed cycloaddition 
reaction. We observed TAMRA fluorescence exclusively in the mCherry-expressing cells which 
indicated cell-selective incorporation of Anl (Figure 4.3c). In addition to promoter controlled 
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expression of AnlRS, it would be convenient to develop complementary methods for conditional 
and regulatable transgene expression. Towards this aim, we explored the use of site-specific Cre-
Lox recombinase technology because a variety of well-established Cre reporter constructs, Cre-
expressing organisms, and cell lines are readily available. We therefore developed a proof-of-
concept Cre-Lox system for the conditional expression of AnlRS. 
We first developed a stable CHO cell line containing an AnlRS-T2A-mCherry gene under a CMV 
promoter that is inactive because of the presence of a loxP-flanked stop sequence (Figure 4.4d). 
These cells were transiently transfected with a second (activating) construct containing a strong 
elongation factor (Ef1α) promoter that drives the expression of an eGFP-Cre fusion protein. We 
used the eGFP signal to track expression of Cre and followed the mCherry signal to monitor the 
successful recombination of the loxP sites. As expected, in the subset of cells that expressed Cre 
(as determined by the GFP signal), we observed mCherry expression, which is indicative of loxP 
recombination mediated AnlRS expression and TAMRA labeling which demonstrates selective 
Anl incorporation. These results show that cell-selective proteomic labeling can be achieved 
through regulatable transgene expression. Based on these results we anticipate that targeted 
insertion of LoxP-AnlRS reporter constructs into the ROSA26 locus of mouse embryonic stem 
(ES) cells
28
 would potentially lead to the development of Cre-Lox mice in which tissue-selective 
proteomic studies can be performed. To validate that the labeled proteins can be identified by 
shotgun proteomics, we used an affinity chromatography column containing 
azadibenzocyclooctyne-functionalized beads to chemoselectively tag (using reaction 3, scheme 
4.1) and enrich Anl-labeled proteins from lysates of CHO cells. After on-resin trypsinization of 
purified proteins, we analyzed the resulting tryptic peptides by tandem mass spectrometry (Table 
S1). We identified a total of 820 proteins using a short (60 minute) run on a linear trap 
quadrupole (LTQ) Orbitrap mass spectrometer. We detected proteins from a variety of cellular 
components including nuclear, cytoskeletal, organelle-specific and membrane proteins (Figure 
4.3e). Comparing these results to complementary methods of translation profiling, such as 
ribosome profiling,
29-32
 may provide valuable information regarding similarities and differences 
between snapshots of translation and the distribution of newly synthesized proteins in cells. Such 
analysis may be useful to study mechanisms of the folding, maturation and processing of newly 





This work introduces a mutant mouse MetRS that metabolically incorporates the non-canonical 
amino acid Anl into mammalian cell proteins. This enzyme can be both genetically encoded and 
conditionally activated for time-resolved and cell-selective identification of newly synthesized 
proteins. Targeted expression of this enzyme provides a readily accessible approach for proteome 






Materials and Methods  
Development of Mammalian Vectors for Expression of E. Coli NLL-MetRS/tRNA
Met
 
For PCR and cloning purposes, unless otherwise state, we used chemically competent E. coli 
MegaX DH10B (Zymo Research). Plasmid DNA was purified using a Miniprep kit (Qiagen), 
colony selection was performed on LB-agar plates with 100 µg/mL ampicillin. All plasmids were 
verified by sequencing (Laragen). The E. Coli NLL-MetRS enzyme was obtained from pAM1 
vector (Addgene plasmid 51401) through PCR amplification using a Nhe1 forward primer and an 
Xho1 reverse primer and inserted into the multiple cloning site of the mammalian expression 
vector pCDNA3.1+ (Invitrogen). This vector contains a CMV promoter, a bovine growth 
hormone (BGH) transcriptional stop sequence, and a neomycin resistance gene for G418 
selection. The resulting plasmid was named pMetRSNLL_G. For simultaneous expression of E. 
Coli tRNA
Met
/NLL-MetRS, the mouse tRNA
Met
 sequence was synthesized (Integrated DNA 
Technologies) with 5’ and 3’ flanking sequences of the human tRNAfMet as well as flanking BglII 
restriction enzyme cut sites, this construct was inserted into the BglII site in the backbone of the 
pMetRSNLL_G plasmid to produce the pMetRSNLLtRNA_G plasmid (sequence included in 
Figure S4.8). The pMetRSNLLtRNA_G plasmid is a pCDNA3.1+-based vector expressing the 
NLL-MetRS under CMV control as well as the E. Coli tRNA
Met
. A second tRNA sequence 
lacking the C-terminal CCA tail was synthesized (Integrated DNA Technologies) and inserted 
into the BglII restriction site of MetRSNLL_G to make the pMetRSNLLtRNAdcca_G plasmid 
(sequence included in Figure S4.9).   
 
Introduction of Mutations into the Endogenous Mars Sequence and Development of 
Associated Mammalian Expression Vectors 
The endogenous sequence of mammalian Mars enzyme was obtained from a cDNA clone from 
American Type Culture Collection clone ID 6414029 (ATCC). Site-directed mutagenesis 
(Agilent) was used to introduce the NLL, CLL, PLL and SLL mutations at residues L274, Y527 
and H562 respectively. The L274G mutation was also introduced. These sequences were PCR 
amplified with a Nhe1 forward primer and an Xho1 reverse primer and inserted into pCDNA3.1+ 
(Invitrogen), resulting in plasmids: pMarsWT_G, pMarsL274G_G/pMars_G, pMarsSLL _G, 
pMarsPLL_G, pMarsCLL_G, pMarsNLL_G (with sequences in Figures S4.1-S4.6 respectively).  
 
Development of Mammalian Expression Vectors for Cell-Selective Proteomic Labeling and 
Cre-Lox Mediated Regulatable Expression Vector 
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For the pMarsC plasmid, the L274G Mars enzyme sequence was connected to an mCherry 
sequence through a T2A linker sequence by sewing PCR. Briefly, first the Mars enzyme sequence 
(obtained from pMarsL274G_G/pMars) was PCR amplified using a Nhe1 forward primer 
containing a Flag sequence tag and reverse primer containing a T2A sequence. The mCherry 
sequence was amplified using a matching T2A sequence in the forward primer and a reverse 
primers consisting of a C-terminal Myc-tag and stop codon. Sewing PCR was used to amplify the 
final product with the following sequence components: “Nhe1-FlagTag-Mars-T2A-Mcherry-
MycTag-Xho1”. This sequence was inserted between the Nhe1 and Xho1 cut sites of a 
pCDNA3.1+ vector containing a hygromycin resistance cassette (Invitrogen)  to yield the pMarsC 
plasmid (sequence in Figure S4.12). For Cre-Lox mediated recombination, a LoxP flanked 
transcriptional stop sequence was inserted after the CMV promoter in the pMarsC plasmid. The 
LoxP flanked transcriptional stop sequence consisting of forward LoxP 
(‘ATAACTTCGTATAGCATACATTATACGAAGTTAT’) sequences flanking the 
transcriptional stop sequence was appended with Nhe1 restriction sites on both ends and 
synthesized (Integrated DNA Technologies). This insert was ligated into the Nhe1 cut site of 
pMarsC plasmid to yield the Cre-Lox plasmid pMarsC_lox_H (sequence in Figure S4.13). The 
correct orientation of the insert into the Nhe1 cut site was verified by sequencing.  
 
Cell Culture and Media Compositions 
Cells were passaged every 3 days on tissue-culture treated plates and incubated at 37°C and 5% 
CO2. CHO-K1 cells were maintained in RMPI (Invitrogen) media with 10% fetal bovine serum, 
and supplemented with Pen/Strep, L-glutamine and non-essential amino acids (Invitrogen). HeLa 
and COS7 cells were cultured in DMEM (Invitrogen) media with 10% fetal bovine serum, and 
supplemented with Pen/Strep, L-glutamine and non-essential amino acids (Invitrogen). 
  
Cell Transfection, Selection and Conditional Transgene Activation 
Mammalian expression plasmids were amplified in E. coli MegaX DH10B and purified using 
endotoxin-free plasmid Maxi-kit (Qiagen). Lipfecatmine 2000 (Invitrogen) was used for all 
transfections according to manufacturer recommended procedures. For identification of MetRS 
variants that charge Anl and to study Anl incorporation, all cells were transiently transfected 30 
hours prior to Anl labeling. For Cre-Lox transgene activation study, the pMarsC_lox_H was 
linearized using the BglII cut site in the backbone of the plasmid and transfected into CHO cells. 
After selection on hygromycin at 100 µg/ml for 10 days, surviving colonies were picked and 
expanded to yield a stable cell line. Cre-mediated recombination in these cells was achieved 
143 
 
through transient transfection with a plasmid expressing eGFP-Cre under control of a EF1α 
promoter (Addgene plasmid 11923).  
 
Synthesis of Azidonorleucine 
Azidonorleucine synthesis was based on a previous protocol for azidohomoalanine synthesis, 
using Boc-lysine as the starting material.
33
 Briefly, 5.27 g (81.1 mmol) of sodium azide was 
treated with 2.7 mL (16 mmol) of distilled triflic anhydride in 13 mL of water for 2 h.  The triflic 
azide product was extracted with 10 mL dichloromethane and added dropwise to a flask 
containing Boc-Lys-OH (2 g, 8.1 mmol), K2CO3 (1.68 g, 12.2 mmol) and CuSO4 (20 mg, 0.08 
mmol) in 26 mL of water and 250 mL of methanol. After 20 h at room temperature the product 
was extracted with ethyl acetate, redissolved in dichloromethane and purified by silica gel 
chromatography. After Boc deprotection with hydrochloric acid, the final product was purified by 
cation exchange chromatography. 
  
Copper Catalyzed Reaction of Alkyne-TAMRA Dye with Anl-labeled Proteins in Cell 
Lysates and Detection by In-gel Fluorescence 
Cells were lysed with 4% SDS in phosphate buffered saline (PBS). Ethylenediaminetetraacetic 
acid (EDTA)-free protease inhibitor (Roche) was added to the lysates to reduce protease activity. 
PBS was added to dilute the SDS concentration to 1%, and cell lysates were centrifuged at 14,000 
rcf for 10 min to remove cellular debris. Protein concentrations were measured by using a 
bicinchoninic protein quantification kit (BCA assay; Pierce). The same amount of protein was 
used for each condition; concentrations ranged from 0.1 to 0.4 mg/mL.  Copper-catalyzed 
reactions was performed using Click-IT TAMRA protein analysis kit (Invitrogen). Proteins were 
precipitated with chloroform/methanol, washed with methanol to remove unreacted dye and 
resuspended in protein loading buffer containing 2% SDS and 10% mM 2-mercaptoethanol. 
Proteins were electrophoresed using 12% Bis-Tris polyacrylamide gels (Invitrogen). TAMRA 
(λexcitation = 555 nm and λemission = 580 nm) was excited at 532 nm and detected with a 580 band-
pass 30 nm filter. In-gel fluorescence images were acquired on a Typhoon 9400 instrument (GE 
Healthcare).  
 
Detection of Proteins in Gels and Western Blots 
Bicinchoninic acid protein quantification (Pierce) was used to equalize the amounts of proteins 
analyzed under different conditions. After dye labeling via the copper-catalyzed click reaction 
described above, proteins were washed with methanol to remove unreacted dye and then 
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electrophoresed on a Novex 12% Bis-Tris polyacrylamide gel (Invitrogen). Colloidal blue dye 
(Invitrogen) was used for nonspecific protein detection. For Western blots the proteins were 
transferred to a nitrocellulose membrane (GE Healthcare), and probed with a Myc-tag-Alexa 
Fluor 488 conjugate monoclonal antibody (Cell Signal Technologies) used at 1:1000 dilution in 
PBS with 0.2% v/w Tween20 (Sigma). Imaging of Western blots and gels was performed with a 
Typhoon 9400 molecular imager (GE Healthcare).  
 
Copper Catalyzed Reaction of Alkyne-TAMRA Dye in Adherent Cells and Fluorescence 
Confocal Microscopy 
Copper catalyzed azide-alkyne cycloaddition reaction and synthesis of requisite THPTA ligand 
were performed as described previously
26,33
. Adherent CHO cells seeded onto glass bottom tissue 
culture plates (MatTek) were incubated in fresh CHO media, as described above, supplemented 
with Anl at 1.5mM for 6 hours. Thereafter the cells were washed twice with PBS, fixed with 
3.7% formaldehyde in PBS for 15 min at room temperature, followed by permeabilization with 
4°C cold methanol for 10 min, and washed three times with PBS at room temperature. Labeling 
with alkyne-TAMRA (Invitrogen) was performed at room temperature in pH 7.4 PBS for 2 hours, 
using a final concentration of 0.1mM copper sulfate, 0.5mM THPTA ligand, 5mM sodium 
ascorbate, 5mM aminoguanidine and 10 µM of alkyne-TAMRA. To remove unreacted dye and 
reaction components the cells were washed five times at 30 min intervals with PBS. Cell nuclei 
were stained with 300nM DAPI in PBS for 30 minutes at room temperature and washed three 
times with PBS before imaging. Fluorescence confocal images were obtained on a Zeiss LSM 
510 microscope.  
 
Affinity Enrichment of Anl-labeled Proteins using Azadibenzocyclooctyne Functionalized 
Resin 
Cells were lysed with 4% SDS in PBS supplemented with (EDTA)-free protease inhibitor 
(Roche) and 100 mM chloroacetamide. Alkylation step was used to reduce background reaction 
with free thiols. Cell lysate was sonicated using a tip sonicator to reduce viscosity and thereafter 
centrifuged at 14,000 rcf for 15 min to remove cellular debris. PBS was added to reduce SDS 
concentration to 1% and 1.5ml of lysate at 1mg/ml was reacted with 200µl of 
azadibenzocyclooctyne resin which is 50% slurry by volume (Click Chemistry Tools) for 20 min 
at room temperature on a rotating table. Direct conjugation of proteins to resin allows for 
stringent washing conditions without loss of labeled proteins and is advantageous because of lack 
of any streptavidin. Resin was washed 10 times with 1% SDS in PBS, proteins were reduced 
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using 1.25 µL of 500mM TCEP in water for 10 min, and alkylated using 5 µL of 500mM 
iodoactamide (fresh and dissolved in water) and incubate for 15 minutes at room temperature in 
the dark. Thereafter the resin was washed extensively first with 1% SDS in PBS for 20 times at 
room temperature, and an additional 20 times with PBS to remove residual SDS, and finally 
washed three times with Tris-HCl pH 8.5.  
 
Trypsinization of Affinity Purified Proteins and Sample Preparation for Mass 
Spectrometry 
After affinity enrichment, protein-bound resin was resuspended in 200µl Tris-HCl pH 8.5.  On 
resin digestion was carried out with addition of 10µL of 0.1µg/µL of Lysyl endopeptidase(Wako) 
in 100mM Tris-HCl pH 8.5. Sample was incubated for 4 hrs at room temperature in the dark. 
Thereafter 20µL of 0.5µg/µL trypsin(Wako) in water was added and the sample was incubated in 
the dark overnight at room temperature.  The eluent was centrifuged at 14000 rcf for 20 min using 
a 10kDa molecular weight cutoff spin filter (Pierce) to remove undigested proteins as well as 
trypsin which remains in the filter, the flow-through containing tryptic peptides was retained. 
This solution was acidified to 0.2% CF3COOH. Solution containing peptides was desalted based 
on a previously published desalting protocol by Mann can coworkers
34
 using a 3ml MILI-SPE 
C18-SD extraction disk cartridge (3M) as follows: 1) Cartridge was first washed with 1ml of 
CH3OH and centrifuged at 1500 rcf for 1min. 2) Cartridge was washed once with 0.5ml of 0.1% 
CF3COOH, 70% CH3CN in water and centrifuged at 1500 rcf for 1min. 3) The cartridge was 
washed with 0.1% CF3COOH in water and centrifuged at 1500 rcf for 1 min. 4) Peptide sample 
was loaded to the cartridge and passed through three times, each time the cartridge was 
centrifuged at 150 rcf for 3min. 5) The cartridge was washed twice with 0.5 ml of 0.1% 
CF3COOH in water and centrifuged at 150 rcf for 3 min. 6) To elute the desalted peptides, 
cartridge was washed with 0.5ml of CH3CN in water and centrifuged at 150 rcf for 3 min, the 
eluent containing desalted peptides was retained. The desalted peptides were lyophilized and 
stored at 4°C before analysis by mass spectrometry.  
  
Mass Spectrometry 
Analyses were performed with a hybrid LTQ-Orbitrap (Thermo Fisher Scientific) equipped with 
a nanoelectrospray ion source connected to an EASY-nLC II instrument (Thermo Fisher 
Scientific). Fractionation of peptides was performed using a 15 cm reversed phase analytical 
column (75 μm ID) with 3 μm C18 beads (ReproSil-Pur C18-AQ) with a 60-minute gradient from 
5% to 28% acetonitrile in 0.2% formic acid, over 50 minutes, followed by 10 minutes at 80 % 
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acetonitrile in 0.2% formic acid. The mass spectrometer was operated in data-dependent mode. 
Survey full scan mass spectra were acquired with a resolution of 60,000 at 400 m/z. The top ten 
most intense ions from the survey scan were isolated and, after the accumulation of 5000 ions, 
fragmented in the linear ion trap by collision induced dissociation. Precursor ion charge state 
screening was enabled and singly charged and unassigned charge states were rejected. The 
dynamic exclusion list was enabled containing trypsin peptide sequences, with a relative mass 











Scheme 4.1. Targeted expression of genetically encoded mutant aminoacyl tRNA synthetase 
(aaRS) for cell-selective BONCAT in mammalian cells. (a) The endogenous mammalian aaRS 
charges Met but not Anl. A mutant aaRS is used to charge Anl to tRNA
Met
. (b) The azide side 
chain of Anl in proteins (R1) is chemoselectively tagged through azide-alkyne cycloaddition 
reactions. Reaction 1 uses Cu
I
 as a catalyst, and reactions 2-3 are copper-free. (c) The controlled 
expression of mutant aaRS in cells of interest restricts labeling to those cells and enables the 










Figure 4.1. Identification of MetRS variants for the metabolic incorporation of Anl in 
mammalian cells. (a) Sequence alignment of various MetRS enzymes with positions 13/260/301 
of the E. coli MetRS highlighted. (b) Constructs for the expression of MetRS and E. Coli tRNA
Met
 
under the CMV promoter and an internal promoter of eukaryotic tRNAs, respectively (c) E. coli 
tRNA
Met coding sequence containing 5’ and 3’ flanking sequences from human initiator tRNAMet. 
(d) In-gel fluorescence image shows TAMRA labeling, which indicates Anl incorporation in 
cellular proteins. tRNA* designates the presence of a 3’ CCA tail in the tRNA coding sequence. 
The wild type mouse MetRS enzyme is indicated by WT and the ±Anl conditions correspond to 









Figure 4.2. Measuring selectivity of AnlRS. In-gel TAMRA fluorescence and coomassie 
staining show Anl incorporation and total protein content, respectively. Fluorescence values 
were quantified and normalized to total protein levels. (a) Protein labeling in CHO media using 
the AnlRS at different Anl concentrations. (b) Protein labeling using both the AnlRS enzyme and 
the E. coli NLL-MetRS at increasing Met concentrations and 1.5 mM Anl. Plots on the bottom 
show Anl incorporation based on quantitated TAMRA fluorescence values. Error bars indicate 
standard deviation, and the dotted line represents line of best fit based on the equation above, and 






Figure 4.3. Cell-selective proteomic labeling and identification. (a) Design of pMarsC and 
pMars constructs for the expression of AnlRS and a C-terminal Myc-tagged mCherry protein to 
track synthetase expression. (b) Metabolic incorporation of Anl by pMars- and pMarsC-
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transfected CHO cells. The in-gel fluorescence image on top shows TAMRA labeling, which 
indicates Anl incorporation. A western blot at the bottom using anti-Myc antibody shows the 
detection of mCherry at approximately 25 kDa (c) Fluorescence confocal microscopy image of 
CHO cells containing the pMarsC construct. DAPI shows the position of cell nuclei. (d) 
Fluorescence confocal microscopy image of CHO cells with a LoxP-containing AnlRS-T2A-
mCherry sequence transiently transfected with an eGFP-Cre containing vector. The GFP signal 
corresponds to cells expressing Cre; the mCherry signal corresponds to cells in which AnlRS is 
expressed. (e) Identification of Anl-labeled proteins by tandem mass spectrometry and annotation 
of proteins into different cellular components using STRAP software
35
. Proteins in each group are 






Figure S4.1.  
The pMarsWT_G vector for expression of wild-type Mars enzyme under CMV promoter 
control. Restriction enzymes are highlighted in yellow and the enzyme coding sequence is 
































ORF frame 3 5639..5103






































































































































Figure S4.2.  
The pMarsL274G_G vector for expression of L274G mutant Mars enzyme under CMV 
promoter control. Restriction enzymes are highlighted in yellow and the enzyme coding 































ORF frame 3 5639..5103







































































































































Figure S4.3.  
The pMarsSLL_G vector for expression of SLL Mars enzyme under CMV promoter 
control. Restriction enzymes are highlighted in yellow and the enzyme coding sequence is 
































ORF frame 3 5639..5103





































































































































Figure S4.4.  
The pMarsPLL_G vector for expression of SLL Mars enzyme under CMV promoter 
control. Restriction enzymes are highlighted in yellow and the enzyme coding sequence is 
























ORF frame 3 5639..5103












































































































































Figure S4.5.  
The pMarsCLL_G vector for expression of SLL Mars enzyme under CMV promoter 
control. Restriction enzymes are highlighted in yellow and the enzyme coding sequence is 



























ORF frame 3 5639..5103










































































































































Figure S4.6.  
The pMarsNLL_G vector for expression of SLL Mars enzyme under CMV promoter 
control. Restriction enzymes are highlighted in yellow and the enzyme coding sequence is 
































ORF frame 3 5639..5103





































































































































Figure S4.7.  
The pMetRSNLL_G vector for expression of the E. Coli NLL-MetRS under CMV promoter 
control. Restriction enzymes are highlighted in yellow, start codon in red, and the enzyme coding 































ORF frame 3 4964..4428
ORF frame 3 4119..4913
NeoR/KanR 4122..4910
Ampicillin 7275..6415























































































































Figure S4.8.  
The pMetRSNLLtRNA_G vector for expression of the E. Coli NLL-MetRS under CMV 
promoter control. Restriction enzymes are highlighted in yellow, start codon in red, and the 
enzyme coding sequence is highlighted in green. The expressed protein sequence is included after 
the plasmid sequence. This plasmid also contains the tRNA expression cassette as outlined in 
Figure 4.1b of the main text. The tRNA cassette was inserted into the BglII restriction site in the 



































ORF frame 3 5085..4549























































































































Figure S4.9.  
The pMetRSNLLtRNAdcca_G vector for expression of the E. Coli NLL-MetRS under 
CMV promoter control. Restriction enzymes are highlighted in yellow, start codon in red, and 
the enzyme coding sequence is highlighted in green. The expressed protein sequence is included 
after the plasmid sequence. This plasmid also contains the tRNA expression cassette as outlined 
in Figure 4.1b of the main text, wherein the CCA tail of the tRNA was removed in this sequence. 
The tRNA cassette was inserted into the BglII restriction site in the backbone of the plasmid and 

























ORF frame 3 5081..4545




































































































































Figure S4.10.  





















Figure S4.11.  
Derivation of equation for selectivity of MetRS for Anl versus Met. In-gel fluorescence 
quantification is used as a measure of Anl incorporation by the L274GMars enzyme. At a fixed 
level of Met, changes in Anl concentration will directly translate into different incorporation 
levels of Anl that can be measured as a function of time.  
Notation: 
  E:  Concentration of L274GMars  
  A: Anl concentration 
  ESA:  Enzyme substrate complex for Anl 
ESM:  Enzyme substrate complex for Met 
PA:  Polypeptide containing an Anl residue 
PM:  Polypeptide containing a Met residue 
𝐾1
𝐴: K forward for Anl complex with L274GMars 
𝐾−1
𝐴 : K reverse for Anl complex with L274GMars 
𝐾2
𝐴: rate of product formation based on concentration of L274GMars and Anl 
𝐾1
𝑀: K forward for Met complex with L274GMars 
𝐾−1
𝑀 : K reverse for Met complex with L274GMars 
𝐾2
𝑀: rate of product formation based on concentration of L274GMars and Met 
 






→  𝐸𝑆𝐴  
𝐾2
𝐴
→  𝐸 + 𝑃𝐴           (1) 






→  𝐸𝑆𝑀  
𝐾2
𝑀
→  𝐸 + 𝑃𝑀   (2) 
 
At steady state:         𝐸𝑆𝐴
′ = 0 = 𝐸. 𝐴. 𝐾1
𝐴 − 𝐸𝑆𝐴( 𝐾−1
𝐴 + 𝐾2

























𝐸0 = 𝐸 + 𝐸𝑆𝐴 + 𝐸𝑆𝑀   𝐸 =
𝐸0.𝐾𝐴.𝐾𝑀
𝐾𝐴.𝐾𝑀+𝐴.𝐾𝑀+𝑀.𝐾𝐴
  (6) 
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𝑀𝑒𝑡    (7) 


















For a fixed time period “i”, the Anl concentration is a fixed amount and the total protein synthesis 
rate is also a constant amount C:  𝐶 = 𝑉𝐴𝑖 + 𝑉𝑀𝑖 
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) is selectivity, c is a constant and Met and Anl concentrations are known. Equation 
10 is used for a least-squares fit to kinetics of Anl incorporation at different Anl or Met 
concentrations to determine selectivity of L274G enzyme.  
The following Matlab functions was used to fit the data from Fig 4.3A in the main text, where the 













     
A=[0; 0.5; 1;  2; 4]; 
fl=[0.022871044;    0.516731636;    0.699062794; 0.752107911;   1] 
err=[0.002135075;   0.086032748;    0.127708537;    0.098922244;    0.183627695]; 
errorbar(A,fl,err,'ro'); 
  
% initial guess for paramters 
x0=[0.5 1] % This is the selectivity paratmer 









SStotal = (length(fl)-1) * var(fl); 
SSresid=sum(residual.^2); 







The following Matlab functions was used to fit the data from Fig 4.3B in the main text.  The data 
was first normalized so that at the Met concentration of 0.15mM, the Anl incorporation 
corresponds to that of Fig 4.3A.  Also, by definition of equation (10), at Met concentration of 
0mM, the value of constant C should be 1. Based on these results, we plotted the data as well as 












M=[0.15;    0.3;    0.75;   1.5]; 
fl=[0.7;    0.548851071;    0.263135683;    0.14119813]; 
err=[0.086722315;   0.112658654;    0.19100414; 0.11272512]; 
errorbar(M,fl,err,'ro'); 
  
% initial guess for parameters 
x0=[0.1 1] % This is the selectivity parameter 










SStotal = (length(fl)-1) * var(fl); 
SSresid=sum(residual.^2); 





Figure S4.12.  
The pMarC vector for expression of L274G Mars and mCherry proteins. The insertion 
cassette into the Nhe1/Xho1 restriction sites of the pcDNA3.1 plasmids is color coded 
corresponding to highlighted sequences. The pMars plasmid is the same construct as 
pMarsL274G, and below is the sequence for pMarsC which contains a T2A-Mcherry sequence 


































ORF frame 3 5568..6593



























































































































































Figure S4.13.  
The pMarlox vector for expression of L274G Mars and mCherry proteins. The insertion 
cassette into the Nhe1/Xho1 restriction sites of the pcDNA3.1 plasmids is color coded 
corresponding to highlighted sequences. The loxP sequences and transcriptional stop sequence 
































ORF frame 3 5870..6895








































































































































































Figure S4.14.  
Western blot for detection of Myc-tagged mCherry protein. Western blot using a Myc-tag-
Alexa Fluor 488 conjugate monoclonal antibody was used to probe for presence of mCherry in 
lystes of CHO cells transfected with pMarsC and pMars vectors. The pMarsC lane shows 
presence of a protein band at approximately 25 kDa corresponding to mCherry and no other 
bands at higher molecular weights indicating that mCherry is not fused to the AnlRS enzyme. The 
pMars vector lacks the mCherry sequence and as anticipated we do not observe a protein band 
corresponding to mCherry protein in the cell lysates.  This image corresponds to the western blot 
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Lineage-Specific Proteomic Analysis of Embryonic Stem Cell 




Advances in mass spectrometric instrumentation and methodologies have made proteomic 
analysis a valuable tool for biological discovery. A growing number of studies are using 
proteomics to investigate the mechanisms of pluripotency, differentiation, and lineage 
commitment of stem cells. These processes often involve the interactions of multiple cell types 
and occur in mixed populations. Therefore methods for proteomic analysis of specific cell types 
in heterogeneous cultures are needed. Here we introduce an approach, based on the cell-targeted 
metabolic incorporation of non-canonical amino acids, to enable lineage-specific proteomic 
analysis of stem cells in culture. We use this method to selectively label newly made proteins in 
subpopulations of mouse embryonic stem cells (ESCs) that are differentiating towards 
mesodermal and cardiac lineages that are tracked by brachyury and α-MHC promoters, 
respectively. This technique for lineage-specific proteomic labeling enables unbiased and 
comprehensive analysis of proteome changes during stem cell differentiation and cell-fate 






The field of stem cell research is quickly progressing towards understanding mechanisms of stem 
cell fate commitment and development of new therapies. Combined with recent advances in 
genome-editing
1
, stem cell research provides exciting opportunities for cell-based therapies and 
new models of human disease
2
. Transcriptomic and epigenetic studies have been used to uncover 
transcriptional profiles and chromatin states of stem cells, and proteomic analysis is being used to 
study posttranslational modifications of these cells
3
. Such efforts have generated dense and 




Advances in proteomics platforms have been complemented with progress in chemical 
approaches that enable the selective and temporal labeling and identification of proteins. Through 
the SILAC technique
5
, and more recently through the BONCAT
6
 method, amino acid labeling 
approaches are quickly becoming widely applicable for studies of proteome changes in cells. 
Whereas SILAC enables identification and quantitation of newly made proteins through 
incorporation of isotope-labeled amino acids, BONCAT utilizes incorporation of non-canonical 
amino acids into newly made proteins so that they can be chemically tagged, enriched and 





 of stem cells. A combined BONCAT-SILAC approach was recently used to 
quantitate protein dynamics of primary cells
11
 and to identify secreted proteins.
12,13
 BONCAT was 
used to successfully identify low abundance secreted proteins of mammalian cells from an 
abundance of other proteins in serum containing media. In these studies BONCAT was performed 
using the methionine surrogate non-canonical amino acid L-azidohomoalanine (Aha) which 
incorporates into newly synthesized proteins at met codons. However, Aha is metabolically 
incorporated into all cells and therefore labels the entire population of cells without cell-type 
specificity. Ideally one would like to have spatial (cell-targeted) and temporal (stage-specific) 
control of proteome labeling for study of stem cell biology. To solve this problem, here we utilize 
a mutant (L274G) mouse methionyl tRNA synthetase enzyme (MMetRS) that charges the non-
canonical amino acid L-azidonorleucine (Anl) in place of methionine. Only cells that express the 
MMetRS enzyme can incorporate Anl into newly made proteins, and therefore lineage-specific 
and temporally-defined proteomic labeling is achieved through controlled expression of this 
enzyme. We put the expression of MMetRS under the control of lineage-specific promoters that 
are activated during early stages of ESC differentiation and phenotype commitment. We focus on 
early mesodermal and cardiac differentiation of mouse ESCs because these processes can be 
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recapitulated in differentiating embryoid bodies (EBs), easily tracked using well-established 
markers
14




Results and Discussion 
We aimed to perform linage-specific proteomic labeling at two transition points towards cardiac 
differentiation, first at the transition between Oct4+ pluripotent cells to mesoderm lineage, and 
then during the further differentiation of mesoderm cells towards cardiac progenitors. 
For mesoderm lineage tracking, we used the promoter sequence of the Brachyury (T) gene to 
control MMetRS expression. Brachyury is a conserved transcription factor required for formation 
of mesoderm and notochord.
16
 Previous promoter mapping experiments have demonstrated that 
the -500 bp 5’ of the T gene, relative to ATG start codon, confers anterior mesoderm 
expression.
17
 The -430:-280 5’ sequence is required for T expression during early gastrulation, 
and the -280:-190 for late gastrulation. The sequence up to -350 is sufficient for expression in 
primitive streak, sequences up to -585 may function as enhancers whereas regulatory elements 
required for T expression in the notochord are not present until -2400 upstream of the gene
18
. We 
therefore used the limited promoter sequence of -645:-1 which supports transgene expression in 
early mesoderm cells excluding any that differentiate towards notochord. We made a reporter 
construct using this promoter sequence controlling the MMetRS expression and a constitutively 
active G418 resistance cassette for selection. This construct was electroporated into the G4 mouse 
ESC line to develop the BryMMetRS ES cell line expressing the MMetRS under the control of T 
promoter.  
Cardiac-specific promoters were used to control MMetRS expression for proteomic labeling 
during the transition from mesodermal and cardiac progenitors. Early cardiac differentiation is 
accompanied by upregulation of α-myosin heavy chain (α-MHC) protein, the transcription factor 
Nkx2.5, and downregulation of vascular endothelial growth factor receptor Flk1.
19
 We used the α-
MHC promoter to control MMetRS expression. The α-MHC gene encodes a cardiac muscle-
specific protein involved in active force generation. Previous work has shown that the α-MHC 
cardiac specific enhancer can be mapped to the -344:-156 upstream region of the gene and 
containing binding sites for MEF2, BF-2, SRF, ARF, MCBF and GATA-4 and possibly other 
transcription factors.
20
 The zinc finger transcription factor GATA-4, for example, is important to 
mesoderm induction and required for cardiac differentiation.
21
 In addition to this minimum 
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required 5’UTR sequence, additional upstream sequences maybe needed to obtain cardiac 
specificity. A recent study used a 5.5k bp fragment of the α-MHC promoter to control eGFP 
expression and track cardiac differentiation
22. We therefore put this 5’UTR sequence upsteam of 
the MMetRS transgene for cardiac lineage-specific proteomic labeling and developed the 
αMHCMMetRS ES cell line in a similar manner to the BryMMetRS cell line described above 
(Figure 5.1a). We used these two cell lines to probe for protein labeling during EB differentiation.  
Cell-targeted Anl labeled proteins can be chemoselectively tagged using 3+2 cycloaddition 
reaction between the azide side-chain of Anl terminal alkyne
23
 or strained alkyne probes.
24,25
 
Cells are fixed, permeabilized and reacted with probes for in situ detection of newly synthesized 
proteins using copper (I) catalyzed alkyne-azide cycloaddition (CuAAC) reaction with 
fluorescent probes. For proteomic analysis, total cellular lysates are reacted using copper-free 
cycloaddition with a strained cyclooctyne tag containing a dithionite-cleavable biotin moiety for 
binding to streptavidin and enrichment by affinity chromatography (Figure 5.1b). This probe 
reacts with Anl residues and enables selective enrichment of proteins from targeted cells and 
reduces sample complexity for mass spectrometric identification.  
To probe for lineage-specific incorporation of Anl we used an EB differentiation protocol. 
Hanging-drop EBs were initiated from αMHCMMetRS and BryMMetRS cell lines; after 48 
hours in suspension, the EBs were plated onto gelatinized tissue culture plates to allow for 
attachment and differentiation. Differentiation was enhanced by removal of leukemia inhibitor 
factor (LIF) ligand which signals through the Jak/Stat3 pathway to maintain mouse ESCs in an 
undifferentiated state
26
. Attached EBs were cultured for a total of 15 days and during this time 
ESCs differentiate towards a variety of lineages resulting in a mixed population of many different 
cell types. Previous reports show that Brachyury expression increases up to day 4 of 
differentiation and gradually decreases towards day 6 of differentiation in EBs
16. αMHC mRNA 
levels are detectable at day 5 of differentiation and continue to increase up to day 16
27
; protein 
expression is observed starting on day 6
28
 and the number of cells expressing αMHC in the EBs 
increases up to day 18
22
. We therefore pulse-labeled the EBs with Anl for a total of 10 hours on 
days 4 and 14 of differentiation to capture the transition points to mesoderm and cardiac lineage. 
On day 14 of differentiation we observed localized pulsating cell clusters associated with cardiac 
progenitors within differentiating EBs. Cells were fixed and reacted with alkyne-functionalized 
AlexaFluor 488 dye using CuAAC reaction. Clusters of αMHC+ cells were observable on day 14 
of differentiation (as determined by immunofluorescence detection with αMHC antibody), but not 
on days 0 and 4 (Figure 5.2a). AlexaFluor 488 labeling was restricted to αMHC+ cells showing 
207 
 
selective lineage-specific Anl incorporation. As expected, we did not observe any Anl 
incorporation in the parental G4 cell line which lacks the MMetRS construct (Figure 5.2b). Oct4 
labeling of these cells showed presence of pluripotent Oct4+ cells on day 0, a marked reduction 
of Oct4+ cells on day 4 and a lack of pluripotent cells by day 14 of differentiation. These results 
were in agreement with the timeline of differentiation of mouse ESCs.
27
 
Labeling of BryMMetRS cells with a Bry-specific antibody showed localized clusters of Bry+ 
cells on day 4 of differentiation. Co-localized labeling of the same cell clusters with AlexaFluor 
488 dye showed selective incorporation of Anl into mesoderm progenitors in this cell line (Figure 
5.2c). In comparing the pattern of labeling across the different cell lines, both the Bry and Oct4 
antibody labeling was nuclear and the αMHC labeling was cytoplasmic as would be expected for 
transcriptional factors and structural proteins, respectively. AlexaFluor 488 labeling was observed 
throughout the cells because Anl is metabolically incorporated into the proteome, whereas αMHC 
labeling is cytoplasmic (Figure 5.2d) and Bry labeling is nuclear (Figure 5.2e) in these cells.  
To determine the timeline of activation of labeling in the BryMMetRS cell line during hanging 
drop differentiation we plated day 2 hanging drop EBs of these cells onto gelatin coated plates 
and incubated the cells with Anl on each successive day of differentiation and reacted the cell 
lysates with Alkyne-TAMRA dye to probe for Anl incorporation into the proteome. We observed 
a marked increase in labeling of proteins on day 3 of differentiation, gradually increasing towards 
day 4 and starting to decrease on day 6 of differentiation (Figure 5.3). These results were in 
agreement with the timeline of Brachyury promoter activity in differentiating EBs and 
demonstrate promoter activated labeling of cellular proteomes during differentiation.
27
  
Taken together these results demonstrate that promoter-controlled expression of MMetRS can be 
used to obtain temporal and lineage-specific proteome labeling of differentiating mouse ESCs. 
The use of an EB differentiation protocol for this analysis highlights the selectivity of this protein 
labeling approach. Although we did not optimize differentiation towards specific lineages, the 
efficiency of differentiation towards cardiac and mesoderm cells can be increased by addition of 
exogenous factors such as retinoic acid and Bone morphogenic protein-4 (BMP4), respectively. 
 
Materials and Methods  
Embryonic Stem Cell Culture 
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Unless otherwise state, all cell culture reagents were obtained from Gibco (Invitrogen). Low 
passage G4 mouse ESCs were maintained at 37° C with 5% CO2 in mESC medium containing 
high-glucose DMEM supplemented with 15vol% ES-qualified fetal bovine serum, 2mM L-
glutamine, 100 µM β-mercaptoethanol, 1 mM sodium pyruvate, 0.1 mM nonessential amino 
acids, 50 µg/mL penicillin/streptomycin, and 500 pM mouse leukemia inhibitory factor. Media 
was changed every day, and cells were passaged every 3 days or at 50% confluence with 0.05% 
trypsin-EDTA and plated on 0.1% gel-coated tissue culture flasks. 
 
Differentiation Using Hanging Drop Embryoid Bodies (EBs) 
Hanging drop EBs were initiated with 600 cells in 24 µL of mouse ESC media lacking LIF. 
Hanging drop EBs were incubated for 48 hours in humidified chamber maintained at 37° C with 
5% CO2 and thereafter plated onto 0.1% gel-coated tissue culture plates to allow for surface 
attachment and differentiation of cells. 
 
Reporter Constructs for Development of αMHCMMetRS and BryMMetRS Cell Lines 
For PCR and cloning purposes, unless otherwise state, we used chemically competent E. coli 
MegaX DH10B (Zymo Research). Plasmid DNA was purified using a Miniprep kit (Qiagen), 
colony selection was performed on LB-agar plates with 100 µg/mL ampicillin. All plasmids were 
verified by sequencing (Laragen). The endogenous sequence of mammalian MetRS enzyme was 
obtained from a cDNA clone from American Type Culture Collection clone ID 6414029 (ATCC). 
Site-directed mutagenesis (Agilent) was used to introduce the L274G mutation into the MetRS 
sequence.  
 
The Brachyury promoter was obtained from Addgene plasmid 21222 and the αMHC promoter 
was obtained from Addgene plasmid 21229. A fusion PCR was used to connect the Bry promoter 
sequence to the MMetRS gene and the resulting construct was inserted between the BglII and 
Xho1 restriction sites of pCDNA3.1+ (Invitrogen) vector containing a gentamycin resistance 
cassette. This plasmid was used to construct a second plasmid in which the Bry promoter was 
removed and the αMHC promoter was inserted 5’ to the MMetRS. Sequences of these plasmids 
are included in Figure S5.1 and S5.2. 
 
Electroporation of Mouse ESCs and Development of ES Cell Lines 
Plasmids were amplified in E. coli MegaX DH10B and purified using endotoxin-free plasmid 
Maxi-kit (Qiagen). Linearized plasmids for Bry and αMHC promoter controlling MMetRS 
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expression were electroporated into the G4 mouse ES cell line. After electroporation, 
approximately 300,000 cells per plated on 0.1% gel-coated 150mm petri dishes to allow for 
individual colony growth. G418 was added to the media at 100µM final concentration, and the 
media was changed every day for a total of 8 days for selection. Approximately 60 individual 
colonies were picked from each electroporation and expanded to make hanging drop EBs. EB 
differentiation was followed for 4-16 days to identify colonies in which Anl incorporation 
matched expression pattern of Brachyury or αMHC proteins. The expression pattern of these 
proteins was determined by antibody labeling of cells and confocal fluorescence microscopy 
imaging of differentiating EBs. Successful clones were expanded to make stocks of 
αMHCMMetRS and BryMMetRS cell lines. 
 
Synthesis of Azidonorleucine and Metabolic Labeling of Cells 
Azidonorleucine synthesis was based on a previous protocol for azidohomoalanine synthesis, 
using Boc-lysine as the starting material.
29
 Briefly, 5.27 g (81.1 mmol) of sodium azide was 
treated with 2.7 mL (16 mmol) of distilled triflic anhydride in 13 mL of water for 2 h. The triflic 
azide product was extracted with 10 mL dichloromethane and added dropwise to a flask 
containing Boc-Lys-OH (2 g, 8.1 mmol), K2CO3 (1.68 g, 12.2 mmol) and CuSO4 (20 mg, 0.08 
mmol) in 26 mL of water and 250 mL of methanol. After 20 h at room temperature the product 
was extracted with ethyl acetate, redissolved in dichloromethane and purified by silica gel 
chromatography. After Boc deprotection with hydrochloric acid, the final product was purified by 
cation exchange chromatography. Anl was diluted from a stock of 100mM in deionized water, 
and it was added directly to the cell culture medium to a final concentration of 2mM. Cells were 
labeled for a total of 10 hours with Anl. After Anl pulse, cells were either fixed and 
permeabilized for imaging by fluorescence microscopy, or lysed with 4% SDS for analysis of 
proteins in cell lysates as described below. 
 
Labeling of Cell Lysate Proteins with Alkyne-TAMRA Dye and Detection by In-gel 
Fluorescence Imaging  
Cells were lysed as described above, and lysates were supplemented with 
Ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor (Roche) to reduce protease 
activity. Lysates were diluted with PBS to a final SDS concentration of 1% and centrifuged at 
14,000 rcf for 10 min to remove cellular debris. Concentration of protein in lysates was measured 
using a bicinchoninic protein quantification kit (BCA assay; Pierce). The same amount of protein 
was used for each time-point of cell differentiation.  CuAAC reaction of on lysates was 
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performed with the Click-IT TAMRA protein analysis kit (Invitrogen), wherein Anl residues 
were tagged with an alkyne-functionalized tetramethylrhodamine (TAMRA) dye. Proteins were 
precipitated with chloroform-methanol protein precipitation method and unreacted dye labeling 
components were removed by two additional washes with methanol. Proteins were 
electrophoresed using 12% Bis-Tris polyacrylamide gels (Invitrogen). TAMRA dye (λexcitation = 
555 nm and λemission = 580 nm) was excited at 532 nm and detected with a 580 band-pass 30 nm 
filter. In-gel fluorescence images were acquired on a Typhoon 9400 instrument (GE Healthcare). 
Non-specific detection of total cellular proteins in each lane of the gel was performed by labeling 
the gel with coomassie dye. 
 
Processing of EBs and Labeling of Anl-containing Cellular Proteins by Copper Catalyzed 
Alkyne-Azide Cycloaddition (CuAAC) 
For fluorescence confocal microscopy imaging the EBs were plated onto glass bottom 12 well 
plates (MatTek). After Anl labeling, cells were washed once with PBS, fixed with 3.7% 
formaldehyde for 15 minutes at room temperature and permeabilized for 10 minutes with 
methanol at 4°C. Thereafter the cells were incubated for 2 hours in PBS containing 0.25 vol% 
Triton X-100. CuAAC reaction and synthesis of requisite THPTA ligand were performed as 
described previously
29,30
. Briefly, the reaction was performed at room temperature in pH 7.4 PBS 
for 2 hours using a final concentration of 0.1mM copper sulfate, 0.5mM THPTA ligand, 5mM 
sodium ascorbate, 5mM aminoguanidine and 4 µM of alkyne functionalized AlexaFluor-488 dye. 
Cells were washed extensively with PBS with 0.25vol% Triton X-100 to remove the unreacted 
dye components and further processed as described below for antibody labeling and fluorescence 
confocal microscopy.  
 
Antibody Labeling and Imaging of Differentiating EBs by Fluorescence Confocal 
Microscopy 
Cells were fixed, permeablized and reacted with an alkyne-functionalized dye as described above. 
Thereafter, samples were incubated in 5 vol % FBS in PBS for 24 hours to block nonspecific 
binding. We used an anti-Brachyury goat IgG antibody (R&D Systems), an anti-αMHC mouse 
IgG antibody (Abcam) and an Oct4/POU5F1 mouse IgG antibody (BD Biosciences), all at 1:200 
dilutions. These primary antibodies were diluted in 5 vol % FBS in PBS containing 0.25vol% 
Triton X-100. Cells were incubated with the primary antibody solution for 24 hours at 4°C. We 
used a donkey anti-goat AlexaFluor-594 conjugate and an anti-mouse AlexaFluor-594 conjugate 
(both from Cell Signal Technologies), at 1:500 and 1:1000 dilutions, respectively. Secondary 
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antibodies were diluted in PBS with 0.25vol% Triton X-100. Cells were incubated with 
secondary antibody solutions for 10 hours at room temperature and thereafter washed with PBS. 
Cell nuclei were stained with 300nM DAPI in PBS for 30 minutes at room temperature and 
washed three times with PBS before imaging. Fluorescence confocal images were obtained on a 
Zeiss LSM 510 microscope.  
 
Tryptic Digestion and Sample Preparation for Mass Spectrometry 
Proteins were resuspended in 200µl Tris-HCl pH 8.5 and digested with 10µL of 0.1µg/µL of 
Lysyl endopeptidase(Wako) in 100mM Tris-HCl pH 8.5. Sample was incubated for 4 hrs at room 
temperature in the dark. Thereafter 20µL of 0.5µg/µL trypsin(Wako) in water was added and the 
sample was incubated in the dark overnight at room temperature. This solution was acidified to 
0.2% CF3COOH and desalted based on a previously published desalting protocol by Mann can 
coworkers
31
 using a 3ml MILI-SPE C18-SD extraction disk cartridge (3M) as follows: 1) 
Cartridge was first washed with 1ml of CH3OH and centrifuged at 1500 rcf for 1min. 2) Cartridge 
was washed once with 0.5ml of 0.1% CF3COOH, 70% CH3CN in water and centrifuged at 1500 
rcf for 1min. 3) The cartridge was washed with 0.1% CF3COOH in water and centrifuged at 1500 
rcf for 1 min. 4) Peptide sample was loaded to the cartridge and passed through three times, each 
time the cartridge was centrifuged at 150 rcf for 3min. 5) The cartridge was washed twice with 
0.5 ml of 0.1% CF3COOH in water and centrifuged at 150 rcf for 3 min. 6) To elute the desalted 
peptides, cartridge was washed with 0.5ml of CH3CN in water and centrifuged at 150 rcf for 3 
min, the eluent containing desalted peptides was retained. The desalted peptides were lyophilized 
and stored at 4°C before analysis by mass spectrometry.   
 
Mass Spectrometry 
Proteomic analyses was performed with a hybrid LTQ-Orbitrap (Thermo Fisher Scientific) 
equipped with a nanoelectrospray ion source connected to an EASY-nLC II instrument (Thermo 
Fisher Scientific). Fractionation of peptides was performed using a 15 cm reversed phase 
analytical column (75 μm ID) with 3 μm C18 beads (ReproSil-Pur C18-AQ) with a 60-minute 
gradient from 5% to 28% acetonitrile in 0.2% formic acid, over 50 minutes, followed by 10 
minutes at 80 % acetonitrile in 0.2% formic acid. The mass spectrometer was operated in data-
dependent mode. Survey full scan mass spectra were acquired with a resolution of 60,000 at 400 
m/z. The top ten most intense ions from the survey scan were isolated and, after the accumulation 
of 5000 ions, fragmented in the linear ion trap by collision induced dissociation. Precursor ion 
charge state screening was enabled and singly charged and unassigned charge states were 
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rejected. The dynamic exclusion list was enabled containing trypsin peptide sequences, with a 










Figure 5.1. Lineage-specific labeling, detection and identification of proteins during mouse 
embryonic stem cell differentiation. (A) Selective expression of MMetRS under the control of 
brachyury and αMHC promoters in ES cells.  The timeline of activity of each promoter as well as 
typical markers associated with each cell type are listed for each stage of differentiation. (B) 
Selective incorporation of methionine surrogate Anl enables detection and identification of newly 
synthesized proteins in targeted cell populations.  Anl labeled proteins are detected by azide-
alkyne cycloaddition with fluorescent dyes or enriched and identified by tandem MS. Inset shows 









Figure 5.2. Lineage-specific proteome labeling of subpopulations of cells in differentiating 
embryoid bodies (A) EBs from the αMHCMMetRS cell line were differentiated for 0,4, and 14 
days as indicated on the left of each image set. DAPI stains cell nuclei, Alkyne-488 indicates 
CuAAC labeling of Anl residues using alkyne-functionalized Alexa488 dye. Cardiac progenitor 
cells are labeled using an αMHC-specific antibody. (B) Differentiating EBs from the G4 cell line. 
Undifferentiated MESCs are labeled using an antibody for Oct4 protein. (C) Differentiating EBs 
from the BryMMetRS cell line. Mesoderm progenitors are labeled using a Bry-specific antibody. 
(D) Day 14 differentiating EBs from the αMHCMMetRS cell line showing cytoplasmic labeling 
of Anl residues and location of αMHC protein within cells. Arrows indicate interface of αMHC+ 
cells and differentiated cells of other lineages at the edge of an αMHC+ cell cluster. (E) Day 4 
differentiating EBs from the BryMMetRS cell line showing Anl incorporation throughout the 












Figure 5.3. Anl incorporation in the BryMMetRS cell line during differentiation. In-gel 
fluorescence image of TAMRA-alkyne tagged cell lysates from the BryMMetRS cell line. Day 2 
EBs were labeled with Anl on each day of differentiation indicated on the top of the image. α-




Figure S5.1.  
The pAMBryL274GMetRS vector for expression of L274G mouse MetRS under the control 





























ORF frame 3 5399..4863






















































































































Figure S5.2.  
The pAMAlphaMHCL274GMetRS vector for expression of L274G mouse MetRS under the 
































ORF frame 3 9418..10212
NeoR/KanR 9421..10209
































































































































































































Figure S5.3.  
Immunofluorescence detection of αMHC and Brachyury in undifferentiated mouse ESC 
lines. Each cell line, indicated on the left of images was labeled with either αMHC antibody or 
Brachyury antibody for detection of background levels of these proteins in undifferentiated cells. 












Figure S5.4.  
Confocal fluorescence imaging of EBs from αMHCMMetRS cell line. Differentiating 
αMHCMMetRS cells on day 4 of differentiation were fixed, permeablized, and labeled with 
alkyne functionalized Alexa 488 dye and labeled with either the αMHC or the Brachyury 
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The technologies and methods introduced in this thesis provide versatile tools for the 
comprehensive and unbiased detection and identification of newly synthesized proteins in 
complex multicellular systems. Time-resolved, genetically encoded and spatially defined non-
canonical amino acid incorporation enables the identification of proteins involved in cell-cell 
interactions and the proteins made during specific cell states.  
Future advances in mass spectrometers and chemical biology techniques will enhance our ability 
to probe the inner workings of the cell. For example, the cell-selective labeling of newly 
synthesized proteins will continue to provide a unique approach towards identifying proteins 
made by specific subpopulations of genomically homogenous cells. Without labeling, proteins of 
these cells are indistinguishable in mass spectrometric analyses. Even if the instrumentation 
advances obviate the need for affinity enrichment, the labeling that is afforded by non-canonical 
amino acid incorporation is indispensable for accurate identification of proteins made by specific 
cell types. For example, analyzing proteins that are secreted by subpopulations of cells during 
hematopoietic stem cell differentiation may provide insight into methods to expand and control 
the differentiation of these cells. Applying the same approaches to neurobiology will provide a 
detailed map of the brain proteome and the dynamics of protein synthesis during learning and 
memory formation. These applications demonstrate exciting possibilities and future directions. 
The labeling strategies introduced here can be readily combined with various quantitative 
proteomics methods and analytical techniques to probe posttranslational modifications. These 
combined approaches will increase the scope of problems that can be investigated by mass 
spectrometry. Improvements in bioorthogonal chemistries will help to increasingly move towards 
in vivo labeling techniques that enable the tagging and analysis of proteins in their native states. 
In addition to the intended use of these tools for basic research, it is anticipated that these 
technologies will help develop diagnostic methods and new therapies for a variety of diseases 
including brain disorders, age-related illnesses and cancer. In the distant future, it is hoped that 
these technologies will help decrease the gap between humans and intelligent machines, perhaps 











The azide−alkyne cycloaddition provides a powerful tool for bio-orthogonal labeling of proteins, 
nucleic acids, glycans, and lipids. In some labeling experiments, e.g., in proteomic studies 
involving affinity purification and mass spectrometry, it is convenient to use cleavable probes that 
allow release of labeled biomolecules under mild conditions. Five cleavable biotin probes are 
described for use in labeling of proteins and other biomolecules via azide−alkyne cycloaddition. 
Subsequent to conjugation with metabolically labeled protein, these probes are subject to 
cleavage with either 50 mM Na2S2O4, 2% HOCH2CH2SH, 10% HCO2H, 95% CF3CO2H, or 
irradiation at 365 nm. Most strikingly, a probe constructed around a dialkoxydiphenylsilane 
(DADPS) linker was found to be cleaved efficiently when treated with 10% HCO2H for 0.5 h. A 
model green fluorescent protein was used to demonstrate that the DADPS probe undergoes highly 
selective conjugation and leaves a small (143 Da) mass tag on the labeled protein after cleavage. 
These features make the DADPS probe especially attractive for use in biomolecular labeling and 
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Cell-based sensing represents a new paradigm for performing direct and accurate detection of 
cell- or tissue-specific responses by incorporating living cells or tissues as an integral part of a 
sensor. Here we report a new magnetic cell-based sensing platform by combining magnetic 
sensors implemented in the complementary metal-oxide-semiconductor (CMOS) integrated 
microelectronics process with cardiac progenitor cells that are differentiated directly on-chip. We 
show that the pulsatile movements of on-chip cardiac progenitor cells can be monitored in a real-
time manner. Our work provides a new low-cost approach to enable high-throughput screening 
systems as used in drug development and hand-held devices for point-of-care (PoC) biomedical 




Figure AB. Magnetic cell-based sensor. (a) Magnetic particles result in an increased effective 
inductance Leff in the LC resonator, which causes a downshift in the resonant frequency. This 
frequency shift can be detected by the CMOS circuits and serves as the readout for the sensing 
unit. (b) The normalized transducer gain (sensitivity to magnetic particles) of the CMOS 
magnetic sensor is plotted with respect to the sensor inductor geometry. (c) A spontaneous 
cardiac cell beating. Inset at top shows the cell potential changes (in milli-volts) during the 
periodic beating motion. SR = sarcoplasmic reticulum. (d) Autonomous beating of the cardiac 
progenitor cells leads to displacements of the magnetic particles and is detected by the CMOS 
magnetic sensor as periodic shifts in resonant frequency. (e) The sensor chip contains 64 (8 × 8) 
independent sensing sites as a sensor array. A zoom-in view shows the individual sensing site. (f) 
The sensor module fits in a petri dish. The module includes a PDMS reservoir to hold the cardiac 
progenitor cells and the medium. (g) An image of the PDMS sample reservoir shows a cell cluster 
on the CMOS sensor surface. (h) Diagram for the CMOS magnetic sensor chip microphotograph, 
chip system architecture, and the measurement setup. 
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Colony-Forming Cells in the Adult Mouse Pancreas are 
Expandable in Matrigel and Form Endocrine/Acinar 
Colonies in Laminin Hydrogel 
 
Abstract 
The study of hematopoietic colony-forming units using semisolid culture media has greatly 
advanced the knowledge of hematopoiesis. Here we report that similar methods can be used to 
study pancreatic colony-forming units. We have developed two pancreatic colony assays that 
enable quantitative and functional analyses of progenitor-like cells isolated from dissociated adult 
(2-4 mo old) murine pancreas. We find that a methylcellulose-based semisolid medium 
containing Matrigel allows growth of duct-like "Ring/Dense" colonies from a rare (∼1%) 
population of total pancreatic single cells. With the addition of roof plate-specific spondin 1, a 
wingless-int agonist, Ring/Dense colony-forming cells can be expanded more than 100,000-fold 
when serially dissociated and replated in the presence of Matrigel. When cells grown in Matrigel 
are then transferred to a Matrigel-free semisolid medium with a unique laminin-based hydrogel, 
some cells grow and differentiate into another type of colony, which we name 
"Endocrine/Acinar." These Endocrine/Acinar colonies are comprised mostly of endocrine- and 
acinar-like cells, as ascertained by RNA expression analysis, immunohistochemistry, and electron 
microscopy. Most Endocrine/Acinar colonies contain beta-like cells that secrete insulin/C-peptide 
in response to D-glucose and theophylline. These results demonstrate robust self-renewal and 
differentiation of adult Ring/Dense colony-forming units in vitro and suggest an approach to 
producing beta-like cells for cell replacement of type 1 diabetes. The methods described, which 
include microfluidic expression analysis of single cells and colonies, should also advance study of 
pancreas development and pancreatic progenitor cells. 









 cells isolated from dissociated adult murine pancreata. (A) A Ring 
colony starts as a “Small Bright” colony and grows into a Ring colony. (B) Flow cytometry 
analysis of CD133 and Sox9/EGFP expression of total dissociated adult pancreata. Regions (R) 
drawn indicate sorting windows. (C) PCFUs–Ring are most enriched in the CD133+Sox9/EGFP+ 
R3 window. (D) Single-colony microfluidic qRT-PCR analysis demonstrates that Small Bright 
and Ring colonies express high levels of ductal markers and low but detectable levels of 
endocrine and acinar cell markers. Each column is from a single colony. (E) Whole-mount and 
frozen section immunostaining demonstrated protein expression of ductal (Sox9, Mucin1, and 
Spp1), acinar (Amylase), or endocrine (C-Peptide) markers. 
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Synthesis of Bioactive Protein Hydrogels by Genetically 
Encoded SpyTag-SpyCatcher Chemistry 
 
Abstract 
Protein-based hydrogels have emerged as promising alternatives to synthetic hydrogels for 
biomedical applications, owing to the precise control of structure and function enabled by protein 
engineering. Nevertheless, strategies for assembling 3D molecular networks that carry the 
biological information encoded in full-length proteins remain underdeveloped. Here we present a 
robust protein gelation strategy based on a pair of genetically encoded reactive partners, SpyTag 
and SpyCatcher, that spontaneously form covalent isopeptide linkages under physiological 
conditions. The resulting "network of Spies" may be designed to include cell-adhesion ligands, 
matrix metalloproteinase-1 cleavage sites, and full-length globular proteins [mCherry and 
leukemia inhibitory factor (LIF)]. The LIF network was used to encapsulate mouse embryonic 
stem cells; the encapsulated cells remained pluripotent in the absence of added LIF. These results 
illustrate a versatile strategy for the creation of information-rich biomaterials. 





Figure AD. Spy network hydrogels. (A) Genetic constructs for the four protein precursors 
(AAA, AA′A, AA, and BB). The reactive groups are Asp-20, Asp-117, Asp-214, Lys-57, and 
Lys-337. AA′A is an Asp-117–to–Ala mutant of AAA, which enables only noncovalent 
molecular recognition between SpyTag and SpyCatcher at the A′ site. Construct BB contains an 
internal integrin-binding RGD sequence to facilitate cell adhesion and an MMP-1 cleavage site at 
the C-terminus to allow matrix remodeling by encapsulated cells. (B–D) Schematic illustration of 
the products formed by mixing protein precursors. AAA+BB leads to the formation of a 
covalently cross-linked gel, whereas AA′A+BB and AA+BB cannot form covalent molecular 
networks. 
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Colony-Forming Progenitor Cells in the Postnatal Mouse 
Liver and Pancreas Give Rise to Morphologically Distinct 
Insulin-Expressing Colonies in 3D Cultures 
 
Abstract 
In our previous studies, colony-forming progenitor cells isolated from murine embryonic stem 
cell-derived cultures were differentiated into morphologically distinct insulin-expressing 
colonies. These colonies were small and not light-reflective when observed by phase-contrast 
microscopy (therefore termed "Dark" colonies). A single progenitor cell capable of giving rise to 
a Dark colony was termed a Dark colony-forming unit (CFU-Dark). The goal of the current study 
was to test whether endogenous pancreas, and its developmentally related liver, harbored CFU-
Dark. Here we show that dissociated single cells from liver and pancreas of one-week-old mice 
give rise to Dark colonies in methylcellulose-based semisolid culture media containing either 
Matrigel or laminin hydrogel (an artificial extracellular matrix protein). CFU-Dark comprise 
approximately 0.1% and 0.03% of the postnatal hepatic and pancreatic cells, respectively. Adult 
liver also contains CFU-Dark, but at a much lower frequency (~0.003%). Microfluidic qRT-PCR, 
immunostaining, and electron microscopy analyses of individually handpicked colonies reveal the 
expression of insulin in many, but not all, Dark colonies. Most pancreatic insulin-positive Dark 
colonies also express glucagon, whereas liver colonies do not. Liver CFU-Dark require Matrigel, 
but not laminin hydrogel, to become insulin-positive. In contrast, laminin hydrogel is sufficient to 
support the development of pancreatic Dark colonies that express insulin. Postnatal liver CFU-
Dark display a cell surface marker CD133⁺CD49(flow)CD107b(low) phenotype, while pancreatic 
CFU-Dark are CD133⁻. Together, these results demonstrate that specific progenitor cells in the 
postnatal liver and pancreas are capable of developing into insulin-expressing colonies, but they 
differ in frequency, marker expression, and matrix protein requirements for growth. 
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The artificial extracellular matrix proteins developed for this work are reported in Appendix G.  
 
Figure AE. “Dark” colonies are formed from dissociated one-week-old murine liver or 
pancreas in our 3D colony assays. (A) Schematic of an in vitro methylcellulose-based colony 
assay for progenitor cells. Two different colony assays were used in this report; one contained 
Matrigel and the other contained laminin hydrogel. (B-E) Morphologically distinct colonies are 
identified when observed under a phase-contrast light microscope one week after plating. (B) A 
photomicrograph of a Dark colony developed from dissociated murine ES cell-derived day-16 
cultures, confirming our prior finding. A Dark colony grown in Matrigel (C) or laminin hydrogel 
(D) from dissociated postnatal liver. (E) A Dark colony grown in laminin hydrogel from 
dissociated postnatal pancreas. mESC, mouse embryonic stem cells. 
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Cells with Surface Expression of CD133highCD71low are 




Adult pancreatic stem and progenitor cells are potential sources of insulin-producing beta-like 
cells for cell replacement therapy of type 1 diabetes. In previous studies, we identified colony-
forming progenitor cells in the murine adult pancreas that are capable of robust self-renewal and 
multi-lineage differentiation in vitro. However, one roadblock to effective study of these 
progenitors is that they are a minor population in the pancreas (up to 1% in 2-4 month-old mice). 
We report here that adult pancreatic progenitors express specific cell surface markers that allow 




 cells, but not 
other cell subpopulations in the adult pancreas, are the most enriched (up to 30-fold) for colony-



















 cells secreted C-peptide in response to 
D-glucose in vitro, and when placed under the renal capsules of diabetic mice for five weeks they 













 cells contained progenitors, suggesting 
functional heterogeneity of adult ducts. We conclude that adult pancreatic progenitors are 
distinguishable by cell surface markers and can self-renew and differentiate into multiple lineages 
of cells. This study establishes that adult pancreatic progenitors can be purified using live-cell 
sorting, which will enable in-depth understanding of these cells.  













 and respond to D-glucose in vitro. Whole-mount 




 cells co-expressed 
Glucagon (A) but not CK19 (B) or Amylase (C). C-peptide is a surrogate marker for de novo 
synthesized insulin. (D) Transmission electron microscopy of a cell in an Endocrine/Acinar 
colony that contained two types of granules. Red and green arrows indicate insulin-like and non-
insulin granules, respectively. (E) Endocrine/Acinar colonies were pooled and subjected to 
sequential in vitro incubation with designated levels of D-glucose and/or theophylline, a cAMP 
potentiator. 
This work was submitted as follows:  
Jin, L.; Gao, D.; Feng, T.; Rawson, J.; Luo, A.; Chai, J.; Wedeken, L.; Ghazalli, N.; Hsu, J.; LeBon, J.; 




  APPENDIX G 
 
Artificial Extracellular Matrix Proteins with Laminin-Derived 
Sequences Enhance Survival and Differentiation of 




Information-rich and well-defined materials that recapitulate the essential functions of the 
extracellular matrix (ECM) are of interest as substrates for studies of cellular behavior and as 
scaffolds for use in regenerative medicine. For example, matrix-derived peptide sequences can be 
used to enhance survival of and insulin release from pancreatic beta cells encapsulated in poly 
(ethylene glycol) (PEG) hydrogels. The application of such strategies to progenitor populations 
has not been explored. Here we report the use of artificial ECM (aECM) proteins based on elastin 








This manuscript is included because it provides information about the protein-based materials 
used in appendices C, E and F. 
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 Well-defined materials that recapitulate the essential functions of the extracellular matrix (ECM) 
are of interest as substrates for studies of cellular behavior and as scaffolds for use in regenerative 
medicine.
1-3
 For example, Anseth and coworkers have shown that matrix-derived peptide 
sequences can be used to enhance survival of and insulin release from pancreatic beta cells 
encapsulated in poly(ethylene glycol) (PEG) hydrogels.
4
 To our knowledge, the application of 
such strategies to progenitor populations has not been explored. Here we report the use of 
artificial ECM (aECM) proteins based on elastin and laminin to enhance survival and 
differentiation of beta cell progenitors in culture.  
A variety of extracellular matrix proteins, including laminin, collagen type IV, fibronectin, 
heparin sulfate proteoglycans and nidogen/entactin, are present in the microenvironments of 
pancreatic cells.
5
 In the endocrine pancreas, insulin-expressing beta cells use VEGF-A to recruit 
endothelial cells, which form capillaries with a vascular basement membrane adjacent to the beta 
cells.
6
 Among the vascular basement membrane proteins, laminins were found to induce insulin 







 This effect was dependent on β1-integrin receptor binding as determined by a 
blocking antibody assay.
6
 Both the survival and glucose-stimulated insulin secretion of isolated 
adult rat islets may be enhanced by culturing the cells on laminin.
7,8
 
These reports prompted us to explore the response of pancreatic cells to elastin-based aECM 
proteins that include three copies of the laminin-derived IKVAV sequence (designated 19mer) 
(Figure G1a). The elastin-based sequences dominate the physical properties of the protein and 
facilitate its purification by thermal cycling through the lower critical solution temperature 
(LCST). The 19 amino acid residues that include the IKVAV sequence were obtained from the α-
chain of laminin. To investigate the specificity of the cell response to the IKVAV sequence, we 
designed two additional proteins (Figure G1a). The first includes a scrambled version of the 
IKVAV sequence (designated 19scr). As a control for effects of differential cell adhesion, we 
designed a second protein that contains a fibronectin-derived RGD peptide sequence (designated 
RGD). The aECM proteins were expressed in E. coli strain BL21 (DE3) pLysS by using an 
inducible pET28 expression vector (Supplementary Figure GS.1 and GS.2). After three rounds of 
thermal cycling, we obtained each aECM protein in pure form, as shown by gel electrophoresis 
(Figure G1c). The molecular weight of each protein was verified by MALDI-TOF mass 
spectrometry (Figure G1d). The LCST was approximately 27°C in phosphate buffered saline at a 
protein concentration of 10 mg/ml (Figure G1e).  
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To test the effects of aECM proteins, we chose to study postnatal pancreas—a rich source of 
progenitor cells
9,10
 in addition to differentiated cells. Dissociated cells were harvested from 
pancreas and plated in 3-dimensional cultures containing semi-solid media that permit the 
survival, proliferation and/or differentiation of single cells.
11
 We compared the effects of these 
materials to those of Matrigel
TM
 which is a commercial source of crude ECM components.
12-15
  
Cells were grown in the presence of either Matrigel (5%), 19mer or 19scr (100 µg/ml each) 
proteins for 7 days, and gene expression of various marker genes was analyzed by quantitative 
(Q) RT-PCR. The level of gene expression was first analyzed relative to an internal control, the 
housekeeping gene β-actin. Subsequently, gene expression levels from cells supported by aECM 
proteins were further normalized to those supported by Matrigel. Compared to Matrigel, both the 
19mer and 19scr proteins enhanced expression of endocrine (glucagon
+
 alpha cells and insulin
+
 
beta cells), neuronal (β3-tubulin), endothelial (CD31) and mesenchymal (vimentin) cell markers 
(Figure G2a and b). Compared to 19scr, the 19mer protein enhanced the levels of insulins 1 and 2 
(Figure G1a), suggesting a specific effect of the IKVAV sequence to support the survival of 
single beta cells or the differentiation of their progenitors.  
We next investigated the dose-dependent response of dissociated pancreatic cells to the 19mer 
protein. There was a positive correlation between the concentration of 19mer protein and 
expression of amylase 2A (an acinar cell marker), CD31, glucagon, insulins 1 and 2, and 
vimentin (Figure G2c). In contrast, the level of ductal cell marker, CK7, was lower in cells 
supported by the 19mer protein compared to Matrigel. Taken together, these findings indicate that 
in short-term cultures and in contrast to Matrigel, the 19mer protein enhances survival or 
differentiation away from ductal cells, and that the IKVAV sequence specifically increases 
insulin expression.  
We next investigated the long-term effect of the 19mer protein by using 25 day cultures. QRT-
PCR analysis showed increased levels of insulins 1 and 2 and glucagon above those characteristic 
of freshly isolated adult pancreatic cells (Figure G2d). Consistent with the short-term culture 
results and compared to Matrigel, the ductal cell marker CK7 was down-regulated, The 
expression of the delta cell marker somatostatin (SST) was retained and the exocrine marker 
amylase 2a was minimally up-regulated by the 19mer protein (Figure G2e).  Taken together, 
these results indicate that, in long-term culture, the 19mer protein preferentially supports the 
survival of alpha and beta cells and to lesser extent acinar cells but in contrast to Matrigel, the 
19mer protein does not support ductal cells. 
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To investigate the effects of aECM proteins specifically on progenitor cells, we analyzed single 
cell-derived colonies, whose lineage composition and number would indicate their lineage 
potential and survival, respectively. Single cells harvested from postnatal pancreas were plated in 
our clonogenic assay in the presence of various aECM proteins. After 7 days in culture, we 
observed light-reflective colonies with diameters ranging from 20 to 60 μm (Figure G3a). In the 
control culture containing Matrigel, cystic colonies typical of ductal cell morphology
12-15
 were 
observed. Such ductal colonies have been extensively characterized in prior studies, including 
ours; they are formed  in cultures initiated with purified adult human 
12,13
 or mouse 
14,15
 ductal 
cells in the presence of Matrigel.  
To analyze lineage composition, individual 8-day-old colonies that showed morphologies 
consistent with those in Figure G3a were handpicked and subjected to microfluidic QRT-PCR 
analysis (Figure G3b). All values were normalized to β-actin and compared to those obtained 
from freshly isolated postnatal pancreas cells. We found that among the single colonies supported 
by the 19mer protein, 2 out of 6 expressed insulin 1 or 2, and none expressed ductal (CK7, 
mucin1, and HNF1b) or acinar (amylase 2a) cell markers. In contrast, 19scr- and RGD-supported 
colonies did not express insulins 1 or 2, but 4 out of 6 colonies from each group expressed at least 
one of the three ductal markers. These results demonstrate that the 19mer protein specifically 
supports differentiation of beta cell progenitors. Alternatively, the 19mer protein may divert 
lineage commitment to beta cells from a bi-potential progenitor that could otherwise differentiate 
toward both ductal and beta cell lineages. We did not detect expression of glucagon in any of the 
6 colonies supported by the 19mer protein, which may suggest a lower prevalence of alpha- than 
beta-cell progenitors in postnatal pancreas.  
To examine protein expression and to ensure glucagon-expressing colonies could be observed, we 
used whole-mount immunostaining and imaged colonies by confocal fluorescence microscopy. 
C-peptide was used as a surrogate marker for de novo synthesized insulin to distinguish it from 
exogenous recombinant insulin,
16
 which was present in our culture media. We found colonies 
positively stained for either glucagon or C-peptide (Figure G3c). The staining was specific; 
incubation with isotype control antibody did not yield a positive signal. The staining patterns of 
glucagon or C-peptide were cytoplasmic, consistent with the expected locations of these proteins 
as secretory hormones. Together, these results indicate that the 19mer protein supports 
differentiation of both alpha and beta cell progenitors. Comparison of colony-forming frequency 
among cultures containing various aECM proteins revealed that the 19mer protein best supports 
the overall survival of progenitor cells (Figure G3d).  
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In summary, we have developed an elastin-based aECM protein bearing a laminin-derived 
IKVAV sequence that supports survival and differentiation of beta cell progenitors in culture. The 
observed effects may be due to better survival or selection for beta versus ductal cell lineages. 
Appropriately designed aECM proteins may eventually enable expansion and differentiation of 





Materials and Methods  
Expression of aECM proteins 
Cloning was performed in E. coli strain DH10B (Invitrogen, Carlsbad, CA). Bacteria 
transformation was accomplished with Z-competent E. coli transformation kits (Zymo Research, 
Irvine, CA). Restriction enzymes were obtained from New England Biolabs (Ipswich, MA). 
Ligations were performed with T4 DNA ligase (Roche, Indianapolis, IN). Plasmids were isolated 
with QIAprep kits (Qiagen, Valenica, CA). Final plasmid sequences were verified by restriction 
digestion and sequencing (Laragen, Culver City, CA). DNA sequences encoding various aECM 
proteins were ligated into pET28 (Novagen, Madison, WI) and induced under control of a 
bacteriophage T7 promoter. Expressions were performed in E. coli strain BL21 (DE3) pLysS 
(Novagen). Overnight cultures were used to inoculate Terrific Broth (TB) medium supplemented 
with 50 μg/ml kanamycin and 100 μg/ml chloramphenicol (Sigma, St. Louis, MO). Cells were 
grown to optical density at 600 nm (OD600) of 5 in a 10 L BioFlow 3000 fermenter (New 
Brunswick Scientific, Edison, NJ) with oxygen and pH control as previously described
17,18
. 
Induction was initiated at OD600 = 5 by addition of 2.5 mM isopropyl-1-β-D-
thiogalactopyranoside (IPTG). After 3h the OD600 was 10-15. 
 
Purification of aECM proteins 
Bacteria cells were pelleted by centrifugation (10,000 g, 15 min, 4°C) and lysed in TEN buffer 
(10 mM Tris-HCL, 1 mM EDTA, 0.1 M NaCl, pH 8) supplemented with 50 μg/ml 
phenylmethylsulfonyl flouride (Sigma) and 10 μg/ml each of ribonuclease A and 
deoxyribonuclease 1 (Sigma). Cells were lysed by a freeze-thaw cycle followed by sonication at 
4°C. Lysates were centrifuged (35,000 g, 2 h, 4°C), and the soluble fraction was adjusted to pH 9 
in 1 M NaCl. Each thermal cycle consisted of a temperature shift to 37°C, followed by 
centrifugation (35,000g, 2 h), resolubilization of the pellet in pH 9 water at 4°C, and 
centrifugation (35,000g, 2 h). After three thermal cycles, aECM proteins were dialyzed in water 
at 4°C and the product lyophilized. A solution of 0.25 mg/ml of protein was subjected to 
electrophoresis on a Novex 12% Bis-Tris polyacrylamide gel (Invitrogen), labeled with colloidal 
blue dye (Invitrogen) and imaged on a Typhoon 9400 molecular imager (GE Healthcare). 
 
MALDI-TOF mass spectrometry 
Matrix assisted laser desorption ionization mass spectrometry (MALDI-MS) was performed on a 
Voyager DE-Pro MALDI TOF-MS (Applied Biosystems, Beverly, MA).  Protein solutions at 30 
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mg/ml were added to matrix solution consisting of 10 mg/ml sinapinic acid in 0.07% 
trifluoroacetic acid and 30% acetonitrile. A matrix to protein ratio of 20:1 was used.  
 
LCST measurement 
Lower critical solution temperature measurements were performed at a protein concentration of 
10 mg/ml in phosphate buffered saline (pH 7.4). Absorbance at 300 nm was measured on a 
DU7400 diode array UV-visible spectrophotomer (Beckman Coulter, Indianapolis, IN). 
 
Pancreas dissociation 
Pancreata were dissected from 8-day-old C57BL/6 mice, and dissociated with 4 mg/ml 
collagenase B (Roche, Indianapolis, IN) and 1000 U/ml deoxyribonuclease I (Calbiochem, 
Gibbstown, NJ) at 37°C for 20 min. Cells were washed twice with Dulbecco’s PBS (Mediatech, 
Manassas, VA) containing 0.1% bovine serum albumin (Sigma) and filtered through a 40 μm 
mesh to yield single cell suspensions. All mice were maintained under specific pathogen-free 
conditions, and animal experiments were conducted according to the Institutional Animal Care 
and Use Committee at the City of Hope. 
 
Mouse cell culture 
The culture assay was reported previously
11
. Briefly, cells were dissociated as described above 
and resuspended in cold culture medium containing DMEM/F12 (Mediatech), 1% 1500 
centipoise methylcellulose (Sinetsu Chemical, Tokyo, Japan), 50% conditioned medium from 
pancreatic-like cells differentiated from embryonic stem cells, 5% fetal bovine serum (Tissue 
Culture Biologicals, Seal Beach, CA), 10 mM nicotinamide (Sigma), 0.1 nM exendin-4 and 10 
ng/ml human recombinant activin-β (R&D Systems, Minneapolis, MN). Unless specified 
otherwise, aECM proteins were added at 100 μg/ml. Matrigel (BD Biosciences, Bedford, MA) 
was added at 5% V/V. Cells were placed in 24-well Ultra-Low attachment plates (Corning 
Incorporated, Corning, NY) at 1x10
4
 cells/well and incubated at 37°C with 5% CO2 air. 
Quadruplicate wells were routinely plated and analyzed.  
 
RNA isolation, RT-PCR and quantitative PCR analysis 
Total RNA was extracted by using RNeasy Micro Kits (Qiagen). Reverse transcription was 
performed using QuantiTect Reverse Transcription Kits (Qiagen). The cDNAs of interest were 
amplified with Taqman probes (Applied Biosystems) and reaction buffer PerfeCTa FastMix 
(Quanta Biosciences, Gaithersburg, MD) on an ABI 7900HT Fast Real-time PCR System 
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(Applied Biosystems). All samples were tested in duplicate and β-actin was used as an internal 
control to calculate relative (∆CT) gene expression among samples in the same PCR run. Values 
in Figure G2 were further normalized to that obtained from freshly isolated postnatal pancreatic 
cells (panel d) or from Matrigel-treated cells (rest of panels).  
 
Microfluidic QRT-PCR analysis on single handpicked colonies 
Individual colonies were handpicked and analyzed using the BioMark™ 48.48 Dynamic Array 
System (Fluidigm, South San Francisco, CA) according to the manufacturer’s protocol. Threshold 
cycle (CT) was determined from fluorescence intensity by the BioMark PCR Analysis software. 
∆CT was calculated relative to β-actin, similar to the QRT-PCR analysis.    
 
Colony counts 
Colonies were scored visually on an inverted optical microscope as described previously.  
 
Whole-mount immunofluorescent staining and confocal microscopy 
Colonies were handpicked, pooled, placed in round-bottom 96-well plates, and fixed with 4% 
paraformaldehyde (Pierce, Rockford, IL) in PBS for 30 min. After washing twice with PBS, cells 
were permeabilized with 0.1% Triton-X100 (Pierce) for 10 min and then washed again with PBS. 
Non-specific binding sites were first blocked by incubation overnight with Protein Block Serum-
Free solution (Dako, Carpinteria, CA) at 4°C, followed by staining with primary antibody (rabbit 
anti-human Glucagon or C-peptide serum [Dako]) at 1:75 dilution in blocking solution for 24 h at 
4°C. Rabbit IgG was used as an isotype control. After washing, Cy5-conjugated goat anti-rabbit 
antibody (Jackson Immunology Research Labs, West Grove, PA) (1:100) was added and 
incubated at room temperature for 4 h. After washing, colonies were resuspended in 50 μg/ml 
DPPI in PBS for 30 min prior to imaging on a glass-bottom petri dish (MatTek, Ashland, MA). 
Confocal imaging was performed on a LSM510 Meta NLO microscope (Zeiss) with 2-photon 












Figure G1. Artificial extracellular matrix (aECM) proteins.  (A) Amino acid sequences of the 
aECM proteins generated in this report. (B) Schematic representation of laminin protein 
comprised of three chains (αβγ), showing the location of the IKVAV sequence. (C) 
Polyacrylamide gel stained with Colloidal Blue demonstrates the purity of aECM proteins. Arrow 
indicates protein dimers. (D) MALDI-TOF mass spectra of aECM proteins. Signal at 
approximately 18 kDa is assigned to the doubly charged protein and the peak at approximately 73 
kDa is assigned to the protein dimer. (E) Absorbance at 300 nm was measured as a function of 






Figure G2. Opposing effects of aECM proteins versus Matrigel in pancreatic cell culture. 
Artificial ECM protein with laminin-derived sequences (19mer) preferentially supported the 
survival of pancreatic endocrine and acinar cells, but not ductal cells. Single cells procured from 
postnatal pancreas were plated into semi-solid media containing Matrigel, 19mer or 19scr. Seven 
(A-C) or 25 (D-E) days post-plating, total cells were collected and gene expression analyzed by 
QRT-PCR. Gene expression levels were normalized to those supported by Matrigel (A-C and E) 
or to freshly isolated day-8 pancreatic cells (D). Cells in panels d and e were grown in the 
presence of 100 µg/ml 19mer. Error bars represent standard deviation. *This number is different 
from 19scr at P<0.05. **This number is different from 10 µg/ml 19mer at P<0.05. ***This 






Figure G3. Pancreatic progenitor cells survive and differentiate in aECM proteins. 
Differentiation of beta-cell progenitor cells is best supported by aECM protein with laminin-
derived sequences (19mer). (A) Photomicrographs of single cell-derived colonies (7-day-old) 
grown in the presence of designated aECM proteins. (B) Microfluidic QRT-PCR analysis of 
individually handpicked 8-day-old colonies grown on designated aECM proteins. Expression is 
relative to the internal control β-actin. Each black bar represents expression level of 1 colony 
(n=6 from each group). Red bars represent the expression levels from positive control postnatal 
pancreatic cells. (C) Whole-mount immunofluorescent staining of handpicked 8-day-old colonies 
grown in 19mer. Nuclei are stained with DAPI in blue. (D) Survival of pancreatic progenitor cells 
is enhanced by 19mer, as indicated by the higher number of single cell-derived colonies. Data 








Figure GS.1.  
Scheme of an inducible expression system used for the production of aECM proteins in 
bacteria. The E-coli expression strain, BL21 (DE3) pLysS, contains a gene for bacteriaphage T7 
polymerase under the control of the UV5p promoter. In the absence of the inducer IPTG, the 
endogenous T7 polymerase is inhibited by the T7 lysozyme expressed by an episomal plasmid, 
pLysS, in the bacteria. After addition, IPTG binds to UV5p promoter and activates production of 
T7 polymerase, which subsequently triggers the expression of aECM gene, such as the 19mer 





Figure GS.2.  
Efficient purification of aECM proteins using cold-hot temperature cycles. In purification 
method 1 (upper panel), the nickel-nitrilotriacetic acid (Ni-NTA) resin affinity chromatography 
was used to enrich 19scr and 19mer proteins, because of their N-terminal polyhistidine-tag that 
can bind to the Ni-NTA resin. In purification method 2 (lower panel), temperature cycling based 
on the lower critical solution temperature (LCST) of the 19scr and 19mer proteins was also 
effective in purifying these proteins. Dotted lines show the position of the 19scr and 19mer 
proteins on polyacryamide gels stained with Coomassie Blue. Since temperature cycling is more 
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